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Abstract
The cholesterol-dependent cytolyslns (CDCs) are a group of toxins produced by 
several genera of Gram-positive bacteria, that bind to and form large oligomeric 
pores in target cell membranes that contain cholesterol. In addition to cell lysis, a 
great number of other biological functions have been described for many members 
of the group, including induction of cytokine release and complement activation. 
Some of the CDCs have been shown to be critical virulence factors of their 
producing organisms and immunisation with a number of the CDCs has been 
shown to be protective against disease caused by those producing organisms. 
The CDCs are also being used in a diverse array of applications that utilise their 
pore-forming and toxic properties, including anti-cancer therapy, anti-viral therapy 
and cell biology.
Pneumolysin (PLY) is a member of the CDCs produced by S. pneumoniae and is
an important virulence factor and vaccine candidate. A deletion mutant of PLY,
A6PLY, has been described (Kirkham et a!., 2006b), and this mutant is capable of
cell binding but incapable of pore formation. Enhanced green fluorescent protein
(eGFP) tagged forms of PLY and A6PLY were produced and the tagged toxins
had similar haemolytic and cytotoxic effects to the parent toxins. Toxin binding to
host cells was visualised by epifluorescence microscopy and laser scanning
confocal fluorescence microscopy. Binding of the tagged toxins to erythrocytes
could also be measured by flow cytometry and an increase in the quantity of
bound toxin could be detected in a dose-dependent manner over a large range of
toxin concentrations. Rod-like structures were observed on membranes treated
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with A6eGFPPLY and these were further studied by SEM. These rod-like 
structures may be responsible for the strong aggregation effect observed upon 
A6PLY treatment of erythrocytes.
Intermedilysin (ILY) is a member of the CDCs produced by S. intermedius. It is 
unique within the group in that it exhibits human-specific cytolysis and initial 
studies suggested that this is due to binding of a different cellular receptor to other 
toxins of the family and that this receptor was a protein (Nagamune et al, 1996).
eGFP-tagged forms of ILY and A6ILY were produced to allow tracking of the 
localisation of ILY and for use in development of a quantitative binding assay. It 
was confirmed that these proteins could be easily visualised by fluorescence 
microscopy and that binding could be detected by flow cytometry. A two-hybrid 
screen was also used to screen for proteins from a human brain cDNA library that 
were capable of interaction with ILY in order to identify candidate protein receptors 
for ILY, however no likely receptor candidates were identified.
In order to determine which region is responsible for the human specificity of 
intermedilysin, a bank of chimeras between ILY and PLY was created. The 
chimeric toxins were expressed and purified and the specificity of the mutants was 
determined by haemolytic assay on human and rabbit erythrocytes. The specificity 
of the chimeric toxin was determined by the origin of the C-terminal 53/56 
residues, indicating that the latter part of domain 4 is responsible for the human 
specificity of intermedilysin.
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To further resolve the region involved in human specificity or cholesterol-binding, a 
series of small substitution mutants was created. These revealed that the 
promiscuous cell binding activity of the other CDCs was conferred by residues in 
the undecapeptide loop as this property could be transferred to ILY by introduction 
of the typical undecapeptide sequence. Surface-plasmon resonance analysis of 
substitutions of PLY was used to detect any mutants possessing reduced binding 
affinity. However, problems with aggregation of purified proteins prevented 
quantitative data from being collected.
Anth rolys in O (ALO) is a toxin produced by Bacillus anthracis, the causative agent 
of anthrax. It is a member of the cholesterol-dependent cytolysin (CDC) group of 
toxins, many of which are potential vaccine candidates that protect against their 
producing organisms.
Pore formation by ALO was studied by transmission electron microscopy and 
pores were found to be consistent with those formed by other members of this 
toxin family. A novel genetic toxoid of anthrolysin O, A6mAL0, was constructed 
and characterised and was able to bind to cells but was incapable of pore- 
formation or haemolysis. The capacity of the haemolytic and non-haemolytic forms 
of ALO to protect against challenge with the toxin or B. anthracis was determined. 
Immunisation with both active and non-haemolytic forms of ALO elicited protection 
against lethal i.v. challenge with ALO but neither was protective against B. 
anthracis in a murine i.p. challenge model. Immunisation with another CDC, 
pneumolysin, did not confer cross-protection against challenge with ALO.
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Histopathological investigation following lethal i.v. challenge with ALO revealed 
acute pathology in the lungs with occlusion of alveolar vessels by fibrin deposits.
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Abbreviations
°C Degrees Celsius
|Xl Microiitre
[lM Micromolar
|xm Micrometre
5FOA 5-Fluoroorotic Acid
A Absorbance
AEG Anion exchange chromatography
ALO Anthrolysin O
ALY Alveolysin
APS Ammonium Persulphate
AUG Analytical Ultracentrifugation
BSA Bovine Serum Albumin
GDG Cholesterol-Dependent Cytolysin
cds Coding sequence
cDNA complementary deoxyribonucleic acid
GIAP Calf Intestinal Alkaline Phosphatase
GLY Cereolysin
GSF Cerebral Spinal Fluid
DAPI 4',6-Diamidino-2-phenylindole
DHA Docosahexaenoic acid
DMEM Dulbecco's Modified Eagle’s Medium
DNA Deoxyribonucleic acid
DTT Dithiothreitol
EDTA Ethylene Diamine Tetra Acetic Acid
EF Edema (Oedema) Factor
eGFP Enhanced Green Fluorescent Protein
ELISA Enzyme-Linked Immunosorbent Assay
EGM Erythrocyte Medium
FAGS Fluorescence Activated Cell Sorting
FBS Foetal Bovine Serum
FITG Fluorescein isothiocyanate
FIAsH Fluorescein Arsenical Hairpin
FPLG Fast Protein Liquid Chromatography
FRET Fluorescence resonance energy transfer
HIG Hydrophobic interaction chromatography
His-Tag Poly-Histidine Tag
MRP Horse Radish Peroxidase
i.p. intraperitoneal
i.v. intravenous
IgG Immunoglobulin G
ILO Ivanolysin O
ILY Intermedilysin
IPTG lsopropyl-(3-D-Thiogalactopyranoside
kb Kilobase(s)
LAL Limulus Amebocyte Lysate
LB broth Luria Bertani Broth
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LF
LLO
LPS
LSO
M
MTT
NBD
orf
PA
PBS
PCR
PFO
PLO
PLY
Rpm
SDS-PAGE
SEM
SLO
smhPAF
TB
TEM
TLO
TLR
TLY
YPAD
Lethal Factor 
Listeriolysin O 
Lipopolysaccharide 
Seeligeriolysin O 
Molar
3-{4,5-Dimethylthiazol-2“yl]-2,5-dipheny[tetrazoliumbroinide
A/,A/-dimethyl-A/-(iodoacetyl)-A/-(7~nitrobenz-2-oxa-1,3-
diazolyl)ethylene-diamine
Open Reading Frame
Protective Antigen
Phosphate Buffered Saline
Polymerase Chain Reaction
Perfringolysin O
Pyolysin
Pneumolysin
Revolutions per minute
Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis 
Scanning Electron Microscopy 
Streptolysin O
Streptococcus mitis-derived human platelet aggregation 
factor
Terrific Broth
Transmission Electron Microscopy 
Thuringiolysin O 
Toll-like receptor 
Tetanolysin 0
Yeast extract-peptone-adenine-dextrose medium
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Chapter 1 : An introduction to the 
cholesterol-dependent cytolyslns
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The cholesterol-dependent cytolyslns (CDCs) are a group of toxins produced by 
particular members from seven genera of Gram-positive bacteria. At least 25 
members are currently known (Table 1.1) and the family continues to grow with 
the discovery of novel members through traditional screening processes (Ohkuni 
et al., 1997) and the completion of bacterial genome sequencing projects (Read et 
al., 2003).
Table 1.1: Known members of the CDC family.
Genus Species CDC produced Abbreviation Genbank Accession
Arcanobacterium pyogenes Pyolysin PLO AB027461
Bacillus anthracis Anthrolysin 0 ALO AE017034 (from genome BA3355)
Bacillus cereus Cereolysin GLY AY818309
Bacillus thuringiensis Thuringiolysin 0 TLO AE017355 (from genome { BT9727_3096)
Brevibacillus laterosporus Laterosporolysin LSL
Paenibacillus alvei Alveolysin ALY M62709
Clostridium bifermentans Bifermentolysin BFL
Clostridium chauvoei Chauveolysin CVL
Clostridium bofulinum Botulinolysin ELY
Clostridium histolyticum Hlstolyticolysin HLO
Clostridium novyi (type A) Novyilysin NVL
Clostridium perfringens Perfringolysin 0 PFO M36704
Clostridium septicum Septicolysin O SPL
Clostridium sordellii Sordellilysin SDL ■I'
Clostridium tetani Tetanolysin 0 TLY AE015927 (from genome ! CTC01888) i
Listeria ivanovi Ivanolysin 0 ILO X60461
Listeria monocytogenes Listeriolysin 0 LLO M24199 j
Listeria seeiigeri Seeligeriolysin 0 LSO X60462 1
Streptococcus canis Streptolysin 0 SLO 1
Streptococcus equisimilis Streptolysin 0 SLO i
Streptococcus intermedius Intermedilysin ILY AB029317 1
Streptococcus pneumoniae Pneumolysin PLY X52474 1
Streptococcus pyogenes Streptolysin 0 SLO Ml 8638 1
Streptococcus suis Suilysin 
Streptococcus mitis-
SLY AF043556 |
Streptococcus mitis derived human platelet 
aggregation factor
smhPAF AB051299 i
The group was formerly referred to as the thiol-activated cytolysins (TACYs) since 
these toxins were observed to lose their haemolytic activity through oxidation of a 
thiol-group, and regain activity upon addition of reducing agents such as
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dithiothreitol or p-mercaptoethanol (Iwamoto et al., 1987; Johnson, 1972; Van 
Epps & Andersen, 1971). This effect was originally thought to indicate reduction of 
intra-molecular di-sulphide bonds, however gene sequencing showed that many 
members had only a single cysteine residue that occurred within the conserved 
‘undecapeptide’ region of the molecule (Kehoe et al., 1987; Mengaud et al., 1987; 
Tweten, 1988; Walker ef a/., 1987).
Highly purified preparations of CDCs do not demonstrate thiol-activation (Alouf, 
1980; Boulnois et al., 1991) and substitution of the cysteine residue with alanine 
leads to only a small reduction in haemolytic activity of PLY, PFO and LLO 
indicating that the thiol group is not essential for the activity of the toxins (Michel et 
al., 1990; Pinkney et al., 1989; Saunders et al., 1989). It is thought that the effect 
may be attributed to association of the cysteine residue with cysteine-containing 
impurities causing steric hindrance to critical residues contained within this region 
(Pinkney et al., 1989).
Structure of the CDCs 
Primary Structure
Gene sequences of the CDCs published to date range from 1416 to 1998 base 
pairs in length, corresponding to mature proteins with predicted molecular weights 
of 51 -  70kDa. The most variable region between the CDCs is the N-terminal end, 
where both SLO and smhPAF possess an additional domain, although these 
domains are dissimilar between the two proteins.
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All CDCs sequenced to date, with the exception of PLY, carry a putative N- 
terminal secretion signal that targets the protein for secretion from the bacterium. 
PLY does not carry a secretion signal (Walker et al., 1987), and it is thought to be 
released from the cell through autolysin (LytA) mediated degradation of the cell 
wall (Benton et al., 1997; Paton et al., 1993). The toxin has also been shown to be 
released from some strains during log-phase growth and in an autolysin- 
independent manner suggesting that in some cases PLY may be released by an 
as yet undefined mechanism (Balachandran etal., 2001).
A 1v e o 1y s  i n ( 4 6 0 ) ECTGLAWEWWR
A n t h r o 1y s  i n 0 ( 4 7 1 ) ECTGLAWEWWR
C e r e o 1 y s i n 0 ( 4 6 8 ) ECTGLAWEWWR
T h u r  i ng  i o 1y s  i n 0 ( 4 7 1 ) ECTGLAWEWWR
P e r f r  i n g o 1y s 1n 0 ( 4 5 8 ) ECTGLAWEWWR
S t r e p t o 1y s  i n 0 ( 5 3 2 ) ECTGLAWEWWR
T e t a n o 1y s i n ( 4 8 4 ) ECTGLAWEWWR
I v a n o I y s  i n 0 ( 4 8 2 ) ECTGLAWEWWR
L i s t e r  1o i y s  i n 0 ( 4 8 3 ) ECTGLAWEWWR
P n e u m o 1y s  i n ( 4 2 7 ) ECTGLAWEWWR
Su i 1y s I n ( 4 5 5 ) ECTGLAWEWWR
Se e  1 1g e r  i o 1y s  i n 0 ( 4 8 4 ) ECTGLFWEWWR
P y o 1y s  i n ( 4 9 1  ) EATGLAWDPVAL
smhPAF ( 6 6 6 ) EKTGL\WEPWR
I n t e r m e d  i 1y s i n ( 4 8 5 ) GATGLAWEPWR
Figure 1.1: Alignment of undecapeptide sequences of the CDCs
Alignment of available sequences of the CDCs using the ClustalW algorithm 
(Appendix 1) indicates amino acid sequence similarity ranging from 40-97% and 
there are a number of regions of sequence that are highly conserved between the 
CDCs (Appendix 1, Figure 1.1 and Figure 1.2).
In addition to sequence variation between members of the CDCs, there can also 
be sequence variation between alleles of a single CDC. A number of alleles of 
pneumolysin have been described in clinical isolates of Streptococcus 
pneumoniae, including some alleles in S. pneumoniae ST306 that were non- 
haemolytic (Kirkham et al., 2006a).
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Sequence variability was 
calculated from an amino acid 
sequence alignment
(ClustalW) of ALY, ALO, GLY, 
PFO, SLO, TLY, ILO, LLO, 
PLO, ILY and PLY using the 
AA_Frequency excel macro 
from
htto://www.biochem.unizh.ch/a 
ntibodv/Macros/Macros/AA Fr 
equencv.html.
The frequency of an amino 
acid at a particular position is 
calculated as the number of 
times the amino acid occurs at 
that position divided by the 
number of sequences in the 
alignment. The sequence 
variability is defined as the 
number of different amino 
acids in a given position 
divided by the frequency of the 
most abundant amino acid in 
that position (Kabat et al., 
1977).
Values potentially range from 1 
(no variability) to 400 (Highest 
variability -  i.e. all 20 amino 
acids occurring with equal 
frequency) but in this 11 
sequence comparison the 
maximum possible sequence 
variability is 121. Amino acids 
that did not align with a 
corresponding residue in the 
structure of PFO were 
excluded.
Sequence variability was 
mapped onto the crystal 
structure of perfringolysin O 
(Rossjohn at al., 1997) using 
the colours shown in the table 
below and rendered with 
WebLab Viewer Lite 5.0 
(Accelrys Software,
Cambridge, UK).
Sequence Variability Colour
1
1-3
3-10
>10
Red
Orange
Green
Blue
Figure 1.2: 3D sequence variability map of the CDCs
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The variation between different alleles of a CDC can equal the variation found 
between CDCs from different bacterial species: for example alignment of 
anthrolysin O and cereolysin produces a similarity score of 97%, equal to the 
similarity score calculated between different PLY alleles produced by S. 
pneumoniae (sequences obtained from Dr. Johanna Jefferies and Mr. Calum 
Johnson, University of Glasgow, unpublished results). This is perhaps not 
surprising when you take into account the difficulty in defining species limits and in 
particular the indistinct boundary between B. anthracis and 6. cereus (Hoffmaster 
et al., 2004).
The most prominent and well-studied highly conserved region is the 
‘undecapeptide’ motif consisted of 11 contiguous amino acid residues. The 
undecapeptide region is completely conserved in all CDCs sequenced to date with 
the exception of ILY, PLO, LSO and smhPAF, which have variation in up to 4 of 
the 11 amino acid residues ( Figure i.i).
The cysteine residue within the undecapeptide region has been shown to be non- 
criticai to activity, since substitution of this residue in PLY with alanine, C428A did 
not affect the haemolytic activity of the protein, but this residue is in an important 
region of PLY, since mutations C428G and C428S reduced the activity of the toxin 
(Saunders et a i, 1989).
A number of other conserved regions occur in the alignment and these map to 
residues throughout the crystal structure of PFO. Conserved residues mostly 
oppose other conserved residues within p-sheets and highly variable residues
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occur opposite other highly variable residues, possibly indicating the occurrence of 
co-ordinated or compensatory mutations (Figure 1.2).
-Alveolysin (0.1376)
 Anthrolysin O (0.0249)
— Cereolysin O (0.0163)
— Thuringiolysin O (0.0210)
■Perfringolysin O (0.1368) 
 Streptolysin O (0.2086)
— Tetanolysin (0.2236) 
-Ivanolysin 0  (0.1073)
 Listeriolysin 0  (0.0924)
— Seeligeriolysin 0  (0.0887) 
 Pyolysin (0.3057)
■Intermedilysin (0.2557)
— Pneumolysin (0.2125) 
•Suilysin (0.2475)
Figure 1.3: Guide tree indicating relationship between the CDCs built using the Neighbour 
Joining method (NJ) of Saitou and Nei {Saitou & Nei, 1987). Values in parenthesis indicate 
calculated distance values.
Tertiary Structure
X-ray crystal structures of two members of the cholesterol-dependent cytolysins, 
ILY and PFO, have been solved (Polekhina et a i, 2005; Rossjohn et a i, 1997). 
Although ILY and PFO have two of the most dissimilar sequences when compared 
on a dendrogram of the CDCs (Figure 1.3), their tertiary structures are very similar 
(Polekhina et a i, 2005). Both PFO and ILY have an elongated shape and are 
composed of four domains (Figure 1.4). The molecules are rich in p-sheet in all 
domains, but particularly domains 2 and 4 which contain no a-helices.
The most distinct differences between the PFO and ILY structures occur within
domain 4. The curved undecapeptide loop of PFO is in a straightened
conformation in ILY and a hairpin loop centred on E418 at the opposing end of
domain 4 of PFO is folded over in ILY (Polekhina et a i, 2005). The angle formed
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between domain 4 and domains 1-3 in the crystal structure of ILY is more 
pronounced than that of PFO giving this molecule an overall bent shape. However, 
this angle is different for each of the two monomers within the crystal cell of ILY 
suggesting that this junction may be flexible and the apparent differences may be 
an artefact of crystallisation
Figure 1.4: Crystal structures of ILY (Polekhina et al., 2005) (left) and PFO (Rossjohn et al., 
1997) (centre). A schematic diagram (right) indicates the layout of the four domains of the 
CDCs.
Quaternary Structure
It has been shown using analytical ultracentrifugation (AUC) and small-angle X-ray
scattering combined with ab-initio modelling that PFO forms anti-parallel dimers in
solution (Solovyova et al., 2004). PFO also occurs as an anti-parallel dimer in the
crystal cell in all of the crystal forms solved to date (Gilbert, 2005). In contrast, PLY
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did not form dimers in solution (Solovyova et al., 2004) and this toxin has been 
shown to be capable of oligomerisation in solution (Gilbert at a!., 1998; Gilbert et 
a!., 1999; Solovyova et a!., 2004). Solovyova et a! suggest that formation of dimers 
is a method of preventing untimely pore formation prior to membrane contact and 
that the different oligomerisation states of the two toxins may reflect the different 
mechanisms of release from the bacteria (Solovyova et a!., 2004). PFO is secreted 
across the plasma membrane and this may require a dimeric structure to allow 
transport across the membrane, whereas PLY appears to remain in the cytoplasm 
until cell lysis in at least some strains of S. pneumoniae.
Mode of Action of the CDCs
The mechanism of pore formation by the CDCs remains largely controversial 
despite years of study. It is now generally agreed that the mode of action involves 
binding of the monomeric toxin to the host cell membrane followed by 
oligomerisation and insertion to form a pore, however many of the finer points 
remain unclear.
Target Cell Binding
The first event in the mode of action is binding of the CDC monomer to the target
cell membrane. With the exception of one member of the group -  ILY -  the CDCs
are able to bind to cells from a wide range of animal species. ILY is specific for
human cells -  it was shown to be fully active on human erythrocytes and retained
1% activity on erythrocytes from chimpanzees and cynomolgus monkeys, but it
was inactive on erythrocytes from all of the other mammalian species tested
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(Nagamune et al., 1996). ILY binds to human CD59, a cell surface protein that 
protects the host from complement-mediated lysis by the membrane-attack 
complex, but was found to be incapable of binding to rabbit CD59 (Giddings et al., 
2004). Binding is thought to involve an a-helical region contained within residues 
40-66, the region responsible for CD59 binding to C8a and C9 complement 
proteins, since exchange of residues 42-58 between human and rabbit CD59 
expressed in SV-T2 cells also transferred susceptibility to lysis by ILY.
For the other CDCs, a number of lines of evidence suggest that cholesterol is the 
binding receptor. Cholesterol inhibition of CDC haemolysis has been realised for a 
long time (Johnson, 1972). It has also been demonstrated that CDCs are capable 
of binding to artificial membranes containing cholesterol (Ohno-lwashita et al., 
1991) and that chemical modification of cholesterol inhibits cytolysis by 
streptolysin O (Prigent & Alouf, 1976).
Since it is clear that for members of the family other than ILY, binding to 
cholesterol is sufficient to allow toxin binding and insertion into model lipid bilayers, 
it is commonly stated that cholesterol acts as the cell binding receptor for these 
CDCs.
Flowever, studies on LLO have shown that pre-incubation of the toxin with
cholesterol inhibited haemolysis but did not inhibit LLO from binding to erythrocyte
membranes, eukaryotic cells or artificial membranes, suggesting that another cell
binding site may exist on LLO (Jacobs et al., 1998). Toxin fragments composed of
either domains 1-3 or domain 4 of LLO were both independently capable of
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binding to cells, judged both by immunoblot of erythrocyte membranes and 
immunohistochemistry of epithelial cells incubated with D123 LLO or D4 LLO 
(Dubail et al., 2001). The authors suggest that this indicates that more than one 
binding site exists for these toxins. It is therefore possible that in the work by 
Jacobs et ai (Jacobs et al., 1998), the LLO pre-incubated with cholesterol bound to 
cells by the binding site on domain 1-3 and that this was a non-productive binding 
event for pore formation.
Giddings et al, 2003 used a combination of FRET to detect oligomerisation and 
labelling of transmembrane (3-hairpin 1 with the NBD fluorophores to detect 
membrane insertion (Giddings et al., 2003). They demonstrated that cholesterol 
depletion of erythrocyte membranes did not prevent binding and oligomerisation of 
PLY, PFO or ILY but prevented insertion of the toxins into the membrane. Like the 
LLO data discussed above, this suggests that the role of cholesterol is not in the 
initial binding step but it is involved in insertion of the pore into the membrane, 
perhaps being required for a second binding step, to enable conformational 
change or to maintain membrane fluidity.
Further evidence was provided by Billington et al, who showed that a number of 
mutants in the undecapeptide region of PLO which greatly reduced haemolytic and 
cholesterol binding activities retained erythrocyte membrane binding activity 
(Billington et al., 2002). PLO is also more active on erythrocytes from some 
species (e.g. rabbit) than others (e.g. bovine) (Funk et al., 1996), suggesting that 
toxin action may involve more than just a cholesterol-containing membrane.
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Given these observations, it seems plausible that although cholesterol is sufficient 
to act as a receptor for membrane binding and insertion of the CDCs in artificial 
systems, another receptor may be involved in whole-cell systems.
Oligomerisation and Pore Formation
Following binding to the cell membrane, toxin monomers are thought to come 
together through transverse movement in the cell membrane and oligomerise to 
form a prepore complex. Shepard et al showed by SDS-agarose gel 
electrophoresis that PFO predominantly occurred as a single size of oligomer on 
liposomal membranes, although small amounts of lower molecular weight 
oligomers were detected by immunoblot analysis (Shepard et al., 2000). Following 
incubation of PFO with cholesterol-containing liposomes for 90 minutes at 4°C, 
nearly 80% of the PFO was found to have oligomerised to the typical 
oligomerisation mass. However, insertion of the oligomers into the membrane 
appeared to be limited, as only a 5-28% change in fluorescence of NBD-labelled 
residues within the transmembrane helices was detected (Shepard et al., 2000).
Hotze et al used a di-sulphide trapped mutant of PFO, to separate the
processes of oligomerisation and membrane insertion (Hotze et al., 2001). Using 
FRET to monitor toxin oligomerisation and PFO containing residues of the 
transmembrane hairpin labelled with NBD to indicate membrane insertion, the 
authors showed that oligomerisation proceeded to form large ring-shaped 
oligomers in non-reducing conditions but upon reduction of the di-sulphide bond 
the transmembrane hairpin was able to insert into the membrane.
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These lines of evidence indicate that oligomerisation can occur without insertion of 
the toxin into the membrane.
Monomer-monomer interactions are thought to initially involve domain 4 since PLY 
derivatised with TMB at C428 in domain 4 was rendered incapable of self 
association (Gilbert et al., 1998) and domain 4 of SLO was found to interact 
reversibiy with the whole toxin to inhibit pore formation (Weis & Palmer, 2001). 
However, in the prepore state, contact between subunits occurs between domain 
1 and domain 3 (Ramachandran et al., 2002; Tilley et al., 2005; Weis & Palmer,
2001). A hidden (3-strand that forms the monomer-monomer interface is reported 
to be exposed upon cell binding (Ramachandran et al., 2004). In this work, 
crosslinking of the p4 and p5 strands by introduction of a disulphide bridge 
inhibited toxin oligomerisation and pore formation but upon addition of a reducing 
agent, oligomerisation and pore formation were able to proceed.
The size of the CDC oligomers appears to be variable (Olofsson et al., 1993; 
Sekiya et al., 1993) and the number of molecules per oligomer have been reported 
as 40-50 (Morgan etal., 1995), -33 (Gilbert etal., 1999), 34-36 (Czajkowsky et al., 
2004) or 31 (prepore) and 38-44 (pore) (Tilley et al., 2005). The conformation of 
toxin monomers in the prepore complex is thought to be similar to that of the x-ray 
crystallographic structure (Czajkowsky et al., 2004; Tilley et al., 2005).
The next step involves a conformational change of the oligomer to insert into the
membrane. One predominant model, the prepore model (Rossjohn et al., 1997;
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Tweten et al., 2001), requires that oligomerisation into ring structures must be 
complete prior to membrane insertion.
It is thought that insertion of the oligomers to form a pore is a co-ordinated process 
suggesting that conversion involves monomer-monomer interactions (Hotze et al.,
2002). Hotze et al showed that a mutant of PFO, Y181A was not able to insert its 
transmembrane hairpins but these hairpins were inserted when PFO was added to 
create mixed oligomers. Insertion of the transmembrane helices was found to be 
an ‘all or nothing’ process and it was therefore suggested that monomer-monomer 
interactions drive the insertion of the transmembrane hairpins.
Prepore to pore conversion involves a huge conformational change of the toxin 
subunits that form the oligomeric ring. Domain 3 inserts into the membrane by 
conversion of six helices to p-hairpins (Heuck et al., 2000; Ramachandran et al., 
2004; Ramachandran etal., 2005; Shepard etal., 1998).
Prepore to pore conversion is accompanied by a ‘vertical collapse’ of the prepore 
structure, with most height loss due to a shortening of domain 2. This has now 
been illustrated by a number of techniques. Czajkowsky et al used atomic force 
microscopy to visualise a change in height of the di-sulphide trapped PFO 
mutant upon reduction of the disulphide bond allowing insertion of the 
transmembrane helices (Czajkowsky et al., 2004). Tilley et al used cryo-electron 
microscopy and image processing to determine the structures of prepore and pore 
configurations of PLY and showed a large conformational change and shortening 
of domain 2 upon membrane insertion (Tilley et al., 2005) (Figure 1.5).
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R am ach a nd ra n  e t al used F R E T  to  d e te c t re -a rran ge m e n t o f P F O  d om a in s  upon 
m em brane  inse rtion  w h e re b y  parts  o f d om a in  3 e n te r the  m em brane , d om a in  1 
m oves c lose r to  the  m em brane , d om a in  4 rem a ins  in a p p ro x im a te ly  the  sam e 
pos ition  p e rp e n d icu la r to  the  m em bran e  and, by in fe rence , d om a in  2 und e rgo es  a 
sh o rten ing  o r re -con figu ra tio n .
Binding to  
M em bran e
O ligom erisation to 
form  prepore com plex
Insertion of 0 3  loops  
to create  pore
Figure 1.5: Schematic diagram of the prepore model as suggested by Rossjohn et al 1997 
and Tweten et al 2001. Vertical collapse of the prepore to form a pore is incorporated based 
upon findings by Czajkowsky et al 2004 and Tilley et al 2005. Toxin monomers are coloured 
green and the host cell membrane is represented in grey.
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Problems with the prepore model
The prepore model described above (Figure 1.5) is the currently prevailing model 
in most texts, however it has a number of discrepancies with research findings.
In addition to ring-shaped structures, arc structures are frequently observed by 
electron microscopy on membranes treated with CDC toxins (Bhakdi et al., 1985; 
Morgan et al., 1994; Sekiya et al., 1996; Sekiya et a i, 1998) but the role of arcs in 
pore formation remains largely unresolved. It has been shown by the use of an 
oligomerisation-deficient, arc-forming mutant of SLO, SLO T250C, that arcs were 
capable of forming small pores allowing passage of NaCI and calcein but not large 
dextran molecules (Palmer etal., 1998).
A study on PLY-induced channels in artificial bilayers showed that a range of 
different sizes of PLY-induced channels were present based on conductance 
measurements (Korchev et al., 1992). The smallest channels exhibited cation 
selectivity whereas the larger channels were not ion selective. Small and medium 
sized channels were subject to closure by divalent cations to a greater degree 
than larger channels (Korchev et al., 1992). The existence of a number of sizes of 
pore would be in accordance with the idea that in addition to fully circular pores, 
smaller arc-mediated pores may be present. Their gated nature could be a result 
of the bounding of part of the pore by an edge of lipid, as interpreted from TEM 
images of streptolysin O (Bhakdi et al., 1985; Palmer et al., 1998).
Page 30
As mentioned earlier, Czajkowsky et al used atomic force microscopy to visualise 
a change in height of ring structures resulting from insertion into the membrane 
(Czajkowsky et al., 2004). However in the images of pore complexes of PFO 
inserted into the lipid bilayer that accompany the work, ring and arc structures 
occur in approximately equal numbers. On these images and on a graph of cross- 
sectional relief, the arc structures are of similar relief to the ring structures, i.e. they 
appear to protrude from the membrane by approximately 73A and not 113À like 
the prepore structures. The presence of arcs is mentioned in the figure legend but 
no other mention or discussion of their relevance is made in this work (discussed 
in Gilbert, 2005).
Another study used a form of PFO that has an introduced disulphide bond within 
domain 3 which prevents insertion until the disulphide bond is reduced, termed 
dsPFO (Dang et al., 2005). This work was performed on cholesterol-lipid bilayers 
and both pores and arcs are present in the negative-staining TEM images 
presented. Inserted ring structures observed in samples treated with DTT possess 
an inner ring of density that is absent on those in the prepore state (DTT 
untreated). However, the arcs present in the DTT treated sample also appear to 
possess a corresponding area of density, in contrast to the untreated sample. The 
presence of arcs is not acknowledged within the text and their potential 
significance appears to have been overlooked.
The observation of different sizes of arc-like structures gave rise to the model of 
Palmer et al, 1998 whereby oligomerisation and pore formation are simultaneous 
and semi-circular arcs form a pore lined by a free-edge of lipid membrane that
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grows sequentially until a complete circular pore is formed (Palmer et al., 1998). 
This model does not account for the observation of un-inserted arcs and prepore 
complexes (Czajkowsky et al., 2004; Shepard et al., 2000; Tilley et al., 2005) and 
is in direct conflict with the prepore model.
A hybrid model
Given the inconsistencies above, there is evidence for alteration of prepore model 
presented above (Gilbert, 2005). A hybrid model, as previously proposed by 
Gilbert (Gilbert, 2002), is capable of fitting the discrepancies that cast doubt on the 
prepore model. In this combined model, toxin monomers bind to the target 
membrane and commence oligomerisation. Oligomeric structures can be triggered 
to insert their transmembrane loops either when fully formed as a ring structure or 
in the form of a semi-circular arc. The result is a mixture of inserted arc and ring 
structures, which is consistent with the results provided in the work by Czajkowsky 
et al and Dang et al (Czajkowsky et al., 2004; Dang et al., 2005). This model also 
allows for the formation of the double arc structures that are commonly observed 
by electron microscopy of treated membranes (Bhakdi & Tranum-Jensen, 1985).
Despite the great amount of work that has been done to elucidate the mechanism 
of action of the CDCs, even the combined hybrid model requires further 
experimental support. It is still to be shown whether arcs are able to insert as a co­
ordinated process as shown in the hybrid model and whether the pores formed by 
arcs are responsible for the cation-gated pores that have been observed at low
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tox in  co nce n tra tion s . A n o th e r h ig h ly  ac tive  a rea  is inves tiga tion  o f the  ro le  o f the  
C D C s in v iru len ce  o f th e ir  p ro du c ing  o rg a n ism s  in in fec tio ns  and in fec tion  m ode ls .
...........
Figure 1.6: A hybrid model of pore-formation by the CDCs based on that proposed by 
Gilbert 2002. Vertical collapse of toxin structure upon membrane insertion is incorporated 
into this model according to the work of Tilley et al (Tilley et al., 2005), Crajkowsky et al 
(Crajkowsky et al, 2004) and Dang et al (Dang et al., 2005).
Role of the CDCs in Virulence
A  n um be r o f m em be rs  o f th e  C D C  fa m ily  have  been im p lica ted  in the  v iru len ce  o f 
th e ir p roduc ing  o rgan ism s.
D e le tion  o f the  ply g ene  o f Streptococcus pneumoniae led to  reduced  v iru le n ce  in 
a m urine  i.p. cha llen ge  m ode l o f in fec tion . The  m ed ian  su rv iva l tim e  fo r m ice  
in jected  w ith  the  P LY  kn ocko u t s tra in  w as  13.8 days, co m pared  w ith  0 .9  days  fo r 
the  w ild -type  D 39  s tra in  (B e rry  et al., 1999). A n o th e r s tu dy  found  th a t a P LY  
kn ocko u t s tra in  caused  ch ro n ic  bac te ra e m ia  lasting  seve ra l days  w he re a s  the  
w ild -type  D 39 s tra in  caused  acu te  se ps is  lead ing  to  dea th  w ith in  24 to  38 hou rs  
p os t-in fec tion  (B en ton  etal., 1995).
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LLO has been shown to be essential for the virulence of Listeria monocytogenes 
as Tn917 transposon insertion mutants of the hly gene encoding LLO were 
avirulent but full virulence was returned upon gene complementation (Cossart et 
a!., 1989). Similarly, insertional inactivation of the p/o gene of Arcanobacterium 
pyogenes lead to reduced virulence in murine models of infection (Jost et al., 
1999).
Whereas the reduction in virulence of S. pneumoniae resulting from inactivation of 
PLY is substantial, loss of PFO from C. perfringens has only a minor effect on the 
overall virulence of the organism (Awad et al., 2001), indicating the CDCs can 
have a range of importance to their producing organisms. However, experimental 
evidence suggests that the role and importance of the toxin can vary depending on 
the infection model used. For example, a PLY knockout strain, PLN-A, was found 
to cause chronic bacteraemia rather than acute sepsis in a mouse model of 
bronchopneumonia (Benton et al., 1995), the knockout strain was ten times less 
virulent than the wild-type in a mouse model of lobar pneumonia (Rubins et al., 
1995) but in a chinchilla model of otitis media, toxin positive and negative S. 
pneumoniae produced similar amounts of inflammation (Sato etal., 1996).
Biological effects of the CDCs
The cholesterol-dependent cytolysins were initially described as haemolysins, but 
for many their biological effects are now recognised to be much more complex and 
diverse than solely cytolytic activity. A great number of other biological effects in 
addition to pore formation have been described in a wide array of CDCs however
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for many of these, the degree of contribution to pathogenesis of the producing 
organism has not been well defined.
Complement activation
PLY and SLO have both been shown to activate complement (Bhakdi & Tranum- 
Jensen, 1985; Paton et al., 1984). Activation of complement by PLY occurred in 
the absence of specific antibodies and introduction of a D385N mutation to PLY 
reduced non-specific antibody binding and abolished complement activation 
(Mitchell et al., 1991). It has been suggested that activation occurs via a 13- 
sandwich region of domain 4 similar to that of the Fc region of IgG (Rossjohn et 
al., 1998).
A strain of S. pneumoniae expressing a PLY mutant deficient in complement 
activation, D385N, had reduced virulence in a murine pneumonia model 
(Alexander et al., 1998). Another S. pneumoniae mutant expressing D385N PLY 
showed greater clearance from the blood and reduced mortality compared with 
wild-type S. pneumoniae following i.v. injection in cirrhotic rats (Alcantara et al., 
1999). This group also demonstrated complement depletion during S. pneumoniae 
infection of cirrhotic and control rats that was directly attributed to the complement 
activating activity of PLY (Alcantara et al., 2001). An S. pneumoniae mutant 
carrying the D385N mutation of PLY that reduces complement activation activity 
was found to have lower virulence in a rabbit model of corneal infection, although it 
was less attenuated than a PLY knockout strain indicating that complement
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activation may play a role in the activity of the protein during ocular infection 
(Johnson et al., 1995).
Phagosomal escape and intra cellular growth
LLO is a major virulence factor that is responsible for the escape of L. 
monocytogenes from phagosomes to the cytosolic space within macrophages 
(Cossart et al., 1989; Portnoy et al., 1988). LLO, in conjunction with two other 
proteins, phosphatidylinositol-specific phospholipase 0  (PI-PLC) and 
phosphatidylcholine phospholipase 0  (PG-PLC) lead to a escape of the bacterium 
through the phagosomal membrane (Gamilli et al., 1993; Gedde et al., 2000; 
Portnoy et al., 1992).
LLO has an acidic pH optimum to enable disruption of the phagosomal membrane 
at low endosomal pH but prevent damage to the host cell plasma membrane. LLO 
also contains a 26 amino acid region rich in proline, glutamate, serine and 
threonine which is similar to PEST sequence motifs that target eukaryotic proteins 
for degradation. This motif is critical to the virulence of L. monocytogenes and was 
first thought to target the toxin for degradation thereby preventing damage to the 
host cell (Decatur & Portnoy, 2000; Lety et al., 2001). However mutational studies 
have cast doubt that the PEST-like sequence is acting to promote degradation as 
previously thought (Lety et al., 2002). Recent results showed that mutation of the 
PEST sequence did not change intracellular half-life but did lead to higher LLO 
levels, suggesting that the sequence may have a role in translational control of the 
toxin in the host cell cytosol (Schnupf et al., 2006aa; Schnupf et al., 2006bb).
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Introduction of LLO to the soil-resident bacterium B. subtilis enabled escape of the 
bacterium from the phagosome and growth within macrophages (Bielecki et a/., 
1990).
Another bacterium that employs escape from within the phagosome as a virulence 
mechanism is B. anthracis. During inhalation anthrax, B. anthracis spores are 
phagocytosed by alveolar macrophages which transport the bacterium across the 
alveolar barrier upon migration to the lymph nodes (Guidi-Rontani et al., 1999). 
The spores then germinate within the phagolysosome of the macrophage, and 
escape from the macrophage allowing the bacterium to proliferate within the 
bloodstream.
Given the similar requirement of B. anthracis to L. monocytogenes to escape from 
the phagosome of macrophages, it is possible that ALO plays a role in the 
disruption of the phagosomal and/or plasma membranes. Recombinant strains of 
L  monocytogenes expressing anthrolysin O were capable of escape from the 
phagocytic vacuole but unlike LLO also damaged the plasma membrane of the cell 
(Wei et a!., 2005), highlighting the essential role of the low pH optimum of LLO in 
selectively damaging the endosomal membrane without cell lysis (Glomski et al., 
2002; Schuerch etal., 2005).
SLO has been shown to allow group A Streptococci to evade uptake and killing 
within pharyngeal epithelial cells by preventing internalisation into lysosomes. On
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the other hand, SLO-negative mutants were readily taken up and killed within the 
lysosomes of epithelial cells (Hakansson etal., 2005).
Cytolysin-mediated translocation
SLO has been shown to be capable of translocating a small effector molecule, S. 
pyogenes NAD-glycohydrolase (SPN) across the host membrane (Madden et al., 
2001). This process has been likened to a Gram-positive version of the well- 
described type-1 II secretion systems of gram-negative bacteria. SPN produces the 
secondary messenger cyclic-ADP-ribose that contributes to the cytotoxic effect of 
S. pyogenes on HaCaT kératinocytes (Madden etal., 2001). SPN has been shown 
to enhance the cytotoxic activity of Group-A Streptococcal lysate in combination 
with SLO and leading to depletion of NAD+, ATP and cell death (Michos et al., 
2006).
Translocation of SPN is dependent on a 66 amino acid domain of SLO not present 
in other CDCs but addition of this domain to PFO was insufficient to confer SPN- 
translocating ability on it (Meehl & Caparon, 2004). None of the other CDCs 
sequenced to date has such a large N-terminal extension with the exception of 
smhPAF, although no translocational activity has been attributed to this domain 
and its function remains unknown.
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Cytokines and inflammatory mediators
CDCs have been demonstrated to potentiate release of a number of cytokines and 
are very potent inflammatory mediators. A selection of the broad range of 
inflammatory mediators produced by cells upon exposure to CDCs in vitro is 
shown in Table 1.2. C-terminal truncations of PLY which are not capable of cell 
binding or pore formation are still capable of inducing interferon y and TNF-a, 
indicating that cell binding may not be required for these effects (Baba et al., 
2001).
Table 1.2: Table sh ow ing  som e o f the  c y to k in e  and in flam m ato ry  m ed ia to rs  induced  by 
CDCs
CDC
PLY
ALO
SLO
PLY
PLY
PLY
PLY
LSO
LLO
LLO
LLO
LLO
SLO
SLO
Cell Type
Epithelial cells 
(D562cells & 
A549 cells)
Primary Murine 
Spleen Cells
Human
Monocytes
Murine
Macrophages
Human
neutrophils
Primary Murine 
Spleen Cells
Murine peritoneal 
macrophage
Murine Spleen 
Cells
Human umbilical 
vein endothelial 
cells (HUVECs) 
Caco-2 cells 
Human 
monocytes
Human 
Keratlnocytes 
(HaCat) and 
Endothelial cells
C ytok ine  o r m ed ia to r induced
Activation of p38 MAPK leading to 
release of IL-8
y-lnterferon and nitric oxide Induced by 
PLY and two C-terminal truncations, 
PLY426 and PLY437
TNF-a and IL-1(3 
Nitric Oxide
IL-8 but not TNF-a
Y-lnterferon induced by LSO and a 
truncated derivative, LSO 483
IL-1
Y-interferon and IL-12
Activation of NF-kappaB and IL-8 
secretion
IL-6 production
TNF-a and IL-1p production
NF-kappaB activation and release of IL-6 
and IL-8
Reference
(Ratner et a!., 2006)
(Baba et al., 2002)
(Houldsworth et al., 
1994)
(Braun etal., 1999) 
(Cockeran et al., 2002)
(Ito etal., 2003)
(Yoshikawa et al., 
1993) 
(Nishibori etal., 1996) 
(Nomura et al., 2002)
(Kayal et al., 1999)
(Tsuchiya et al., 2005)
(Hackett & Stevens, 
1992)
(Walev et al., 2002)
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The results of such experiments vary greatly by cell-lines used, many of which 
may not be relevant as toxin exposure may not occur to all cell types in the body 
during infections. The situation is further complicated by cascade effects of 
activation when multiple cell types are present. For example, it has been shown 
that co-cultures of U937 and NK cells produce interferon-yon stimulation with PLY 
but this is not observed on individual cultures of either cell type (Kerr et al., 2005).
The induction of pro-inflammatory mediators such as IL-1p, IL-6 and TNF-a is 
thought to have a role in inflammation in vivo. PLY production by S. pneumoniae 
has been linked to inflammation and histological examination of rats indicated that 
adminstration of PLY directly to the lung can cause pulmonary inflammation 
effects on the lung similar to those observed in infection with S. pneumoniae 
(Feldman et al., 1991).
Recent work has shown that in mice some of these effects can be caused by a 
direct interaction of CDCs with Toll-like receptor 4 (TLR-4).
Activation of TLR-4
Toll-like receptors are transmembrane proteins that recognise conserved microbial 
structures as part of the innate immune system (Kawai & Akira, 2005).
A number of components of Gram-positive bacteria have been shown to activate
TLRs including peptidoglycan and teichoic acid, mainly through TLR2
(Schwandner et al., 1999). The responses generated by these components are
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generally weaker than the responses produced by activation of TLR-4 by LPS from 
Gram-negative bacteria. It has now been shown that a number of CDCs, including 
PLY, ALO, PFO, LLO and SLO (Malley et a i, 2003; Park et al., 2004) are also 
capable of activation of TLR-4.
In the study by Malley and colleagues, they found that signalling through TLR-4 
was responsible for the stimulation of IL-6 and TNF-a in macrophages by PLY, 
and that mice with a mutation in TLR-4 that reduced activation by PLY were more 
susceptible to intranasal infection by S. pneumoniae (Malley et al., 2003). They 
also showed that mice with a mis-sense mutation that makes TLR-4 
hyporesponsive to stimulation by PLY and LPS were more susceptible to lethal 
infection after intra-nasal colonisation with S. pneumoniae. It was therefore 
suggested that interaction between PLY and TLR-4 is important in preventing 
pneumococcal colonisation from progressing to invasive pneumococcal disease 
(Malley et al., 2003).
Activation of TLR-4 by ALO in combination with another toxin from B. anthracis, 
lethal toxin (LT), can induce apoptosis of macrophages and it is suggested that 
ALO is required for the induction of macrophage apoptosis by B. anthracis (Park et 
al., 2004). The ability to activate TLR-4 was also shared by PFO, SLO and LLO 
(Park et al., 2004).
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Protective vaccination with the CDCs
immunisation with some members of the cholesterol-dependent cytolysin family, or 
genetic toxoids or peptides derived from them, can be protective against disease 
caused by the producing organisms.
Paton et al first demonstrated that PLY can protect against infection with S. 
pneumoniae (Paton et al., 1983) and this has been subsequently confirmed by a 
number of studies. Immunisation of mice with a partial toxoid of PLY containing a 
single mutation causing greatly reduced haemolytic activity, W433F, protected 
mice against i.p. or i.n. challenge with a number of strains of S. pneumoniae 
(Alexander et al., 1994). Recently it has been shown that i.p. immunisation with 
wild-type PLY or a novel non-toxic genetic toxoid, A6PLY, increases the survival of 
mice after i.p. challenge with S. pneumoniae (Kirkham et al., 2006b).
Immunisation of mice with PLO or genetically-toxoided PLO showed complete 
protection against i.p. challenge with A. pyogenes (Billington et al., 2001; Jost et 
al., 2003). Vaccination of mice with SLY has also been demonstrated to protect 
against its producing organism, Streptococcus suis (Jacobs etal., 1994).
Vaccination with CDCs can also produce a response that is protective against an
intracellular bacterium. A number of studies have demonstrated that immunisation
with LLO can produce a response protective against Listeria monocytogenes.
Vaccination with L. monocytogenes strains producing LLO causes protective
immunity whereas LLO-negative or LLO-attenuated mutants fail to protect against
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L  monocytogenes infection (Berche et al., 1987; Michel et al., 1990). Cytotoxic T- 
lymphocytes (CTLs) specific for LLO are generated by immunisation, particularly 
directed toward the class I MHC-restricted epitope LLOgi_gg (Pamer et al., 1991) 
and these lymphocytes are protective against L. monocytogenes in vivo (Harty & 
Bevan, 1992).
Intramuscular DNA vaccination with a plasmid containing the coding sequence for 
LLO W492A , a mutant of LLO with 100-1000 fold reduced haemolytic activity, was 
also effective at producing a protective response against L. monocytogenes 
(Cornell et al., 1999). Prime-boost DNA gene gun vaccination with a plasmid 
containing the hly gene for LLO is also capable of protection against listeriosis 
(Fensterle etal., 1999).
The efficacy of particular formulations of antigen and routes of administration may 
vary between CDCs and with the type of infection. While vaccination with a 
purified pneumolysin toxoid protected against lethal intraperitoneal challenge with 
S. pneumoniae, DNA vaccination with the same toxoid did not provide protection 
(Ferreira etal., 2006).
Other Applications of the CDCs
The cholesterol-dependent cytolysins are finding uses in a number of applications. 
The most common application of the CDCs is the use of SLO as a cell 
permeabilisation reagent in cell biology, although other CDCs including TLY have 
also been used in this way (Bhakdi etal., 1993).
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The human-specific cell-binding domain of ILY has been shown to be capable of 
use as an adaptor molecule to bind substances conjugated to the N-terminus of 
domain 4 to human cells. An initial trial of this technology proposes use of domain 
4 of ILY as a cell-targeting molecule in cancer immunotherapy (Nagamune et al., 
2004b). This ‘proof of principle’ demonstrated that domain 4 of intermedilysin 
linked to Fab of an anti-carcinoembryonic antigen monoclonal antibody was 
capable of delivering erythrocytes to carcinoembryonic cancer cells in vitro, 
although the potential for cancer therapy in a clinical setting is not elaborated 
upon.
The cytotoxic activity of the CDCs may also prove therapeutically useful when 
specifically targeted to kill problematic cells. One approach being investigated is 
using ALO in anti-viral therapy against HIV (Yuntao, 2004). Delivery of a lentiviral 
vector for HIV-1 Tat and Rev promoter driven expression of ALO to cells may limit 
the toxicity of ALO to selectively kill HIV-1-infected cells.
Another approach, pioneered by Yang et al, utilises SLO as a ‘suicide gene’ in 
cancer therapy. This group created an adenovirus and injected the virus directly 
into human cervical cancer cell-derived tumours grown in a nude mouse model. 
The average size of the tumours reduced to 26.3% of that of a PBS control group 
after 21 days, demonstrating that tools derived from CDCs could prove useful in 
cancer therapy (Yang etal., 2006).
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Aims of this project
The aims of this work were:
□ Construction of a fluorescently-tagged form of pneumolysin to enable detection 
and visualisation of toxin localisation.
o Determination of the protein receptor for intermedilysin and analysis of the 
region of intermedilysin responsible for this interaction through mutational 
studies.
□ Cloning of anthrolysin O and creation of a genetic toxoid for immunisation 
studies. Investigation of the potential of ALO and detoxified derivatives for 
immunisation against anthrax.
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Chapter 2: Materials and Methods
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Materials
Primers
All primers used in these experiments are shown in appendix 2. Primers were 
obtained from Sigma-Genosys Ltd, UK. All primers were ordered desalted with no 
further purification steps.
Plasmid Constructs
The pET33b(+) plasmid was obtained from Novagen Inc, pQE9mlLY was a kind 
gift from H. Nagamune, University of Tokushima and pNF320 was from N. Freitag 
of Wayne State University School of Medicine, Detroit, Michigan, USA.
Bacterial Strains
Chemically competent E. coli strains TOP10 and DFI5a were purchased from 
Invitrogen, and chemically-competent E. coli strains XL-1-blue and BL21(DE3) 
were purchased from Stratagene. B. anthracis ST I was from the strain library at 
DSTL, Porton Down, UK and all B. anthracis experimental work was performed by 
DSTL staff at the facility.
Blood
Human blood was obtained from the Scottish Blood Transfusion Service. Horse 
and sheep blood were obtained from E&O laboratories and rabbit blood was from 
the Central Research Facility, University of Glasgow.
Solutions, Buffers and Growth Media
The composition of solutions, buffers and growth media, and protocols for their 
production are given in appendix 3.
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DNA modifying enzymes
T4 DNA Ligase and Calf Intestinal Alkaline Phosphatase (CIAP) was obtained 
from Promega. All restriction enzymes were obtained from Promega except for 
Pcil, which was obtained from New England Biolabs.
Methods
Construction of pET33bEGFPPLY
The GFP coding sequence was amplified from pNF320 (Freitag et al, 1999) by 
PGR using primers 20G and 20H. The PGR product was cut with Nhel and Bglll, 
ligated into Nhel/BamHI digested pET33bPLY and transformed into TOP 10 E. coii. 
Mutations F64L and S65T (Gormack at al, 1996) were introduced into the GFP cds 
to make eGFP by site-directed mutagenesis (Quikchange SDM Kit, Stratagene) 
with primers 24W and 24X.
Construction of pET33bDei6EGFPPLY
pET33bDel6EGFPPLY was created by site directed mutagenesis (Quikchange 
SDM Kit, Stratagene) of pET33bEGFPPLY using primers 23B and 23G to 
introduce the A6 mutation (Deletion of A146 and R147, (Kirkham et a!., 2006b)) 
within the p/y coding sequence.
Construction of pET33bEGFP
The coding sequence for eGFP was amplified by PGR from pET33bEGFPPLY 
using primers 20G and 45L. The resulting product was cut with Nhel and Sac/, gel 
purified and ligated Into Nhel/SacI cut, GIAP-treated pET33b. The ligation reaction 
was transformed into XL-1 E. coll (Stratagene).
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Construction of TOPO-ALO
A 2433bp genomic segment containing the anthrolysin O coding sequence and 
flanking regions was amplified by PGR from B. anthracis Ames strain genomic 
DNA using primers 32G and 32H. The resulting PGR product was cloned into 
pGR2.1-T0P0 and transformed into TOP10 Escherichia coli using the TOPO-TA 
cloning kit (Invitrogen) according to the manufacturer’s recommended protocol. 
This cloning step was performed by Prof. Richard Titball, DSTL, Porton Down, UK.
Construction of pET33b-mALO
The coding sequence of mature ALO (mALO), encoding residues E35-H512 of 
whole ALO, was amplified by PGR from TOPO-ALO using primers 43X and 41 P. 
The amplified product was digested with BamHi and Sad, gel purified, ligated into 
BamHi/Saci cut, calf-intestinal alkaline phosphatase-treated pET33b and 
transformed into chemically-competent XL-1 E. coii (Stratagene, Amsterdam 
Zuidoost, Netherlands).
Construction of pET33b-A6mALO
The A6 mutation (Kirkham et ai., 2006b), which corresponds to deletion of 
residues A190 R191 of whole ALO or A156 R157 of mALO, was introduced to 
pET33bmALO by site-directed mutagenesis (SDM) (Stratagene Quikchange XL 
kit) using primers 42S and 42T.
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Construction of pET33bmlLY
The mILY cds was amplified by PGR from pQE9mlLY using primers 26W and 26X. 
The amplified fragment was gel purified, digested with BamHI and Sad  and ligated 
with a BamHI/Sad digested, GIAP-treated pET33b purified plasmid. The ligation 
reaction was transformed into XL-1 blue E. coli.
Construction of pET33bEGFPmlLY
The eGFP and mILY coding sequences were amplified by PGR using primer sets 
31T vs 31V and 31U vs 26X respectively. The PGR products were purified and an 
overlap PGR was performed to join the two products using primers 31T vs 26X.
The resulting PGR product was digested with Spel and Sad and ligated with 
Nhel/SacI digested pET33b plasmid. The ligation mixture was transformed into 
TOP10 E. co//and plated on LB agar containing kanamycin.
Construction of pET33bEGFPslLY
The eGFP cds was amplified from pET33bEGFPPLY using 31T vs 36D and the 
sILY fragment was amplified from pET33blLY using primers 26X vs 36G. PGR 
products were gel purified and an overlap PGR reaction was performed using 
primers 31T and 26X to join the two products. The resulting PGR product was 
digested with Spel and Sad, gel purified and ligated into Nhel/SacI cut, GIAP- 
treated pET33b and the ligation reaction was transformed into TOP 10 E. coii. The 
sequence of the cds and flanking regions of the plasmid were confirmed by DNA 
sequencing.
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Construction of pET33bDel6EGFPslLY
The A6 mutation (deletion of residues equivalent to A204 and R205 of ILY 
precursor) was introduced to pETSSbEGFPslLY using primers 31W vs 31X) by 
SDM (Stratagene Quikchange XL SDM kit). The sequence over the mutated 
region was checked by DNA sequencing and confirmed to be correct.
Construction of vectors for expression of chimeric toxins between PLY and 
ILY
Fragments of ILY and PLY were amplified by PGR using the primer sets shown in 
Table 2.1. Each pair of amplified fragments was gel purified and joined by overlap 
PGR using the overlap primers shown on the right hand side of Table 2.1. The 
resulting product was gel purified, digested with BamHi and Sac! and ligated into 
BamHI/SacI cut, GIAP-treated pET33b. Ligations were transformed into TOP10 E. 
co//and plated on LB containing kanamycin.
Chimera 6’ primer set (template)
3' primer set 
(template)
Overlap Primer 
set
A 26F vs 9Y (PLY) 26G vs 26X (ILY) 9Y vs 26X
B 26D vs 26W(ILY) 26E vs 9Z (PLY) 26W vs 9Z
C 26J vs 9Y (PLY) 26G vs 26X (ILY) 9Y vs 26X
D 261 vs 26W(ILY) 26H vs 9Z (PLY) 26W vs 9Z
E 26N vs 9Y (PLY) 26K vs 26X (ILY) 9Y vs 26X
F 26LVS 26W(ILY) 26M vs 9Z (PLY) 26W vs 9Z
G 26R VS 9Y (PLY) 260 vs 26X (ILY) 9Y vs 26X
H 26P vs 26W(ILY) 26Q vs 9Z (PLY) 26W vs 9Z
Table 2.1: P rim ers used fo r  a m p lifica tio n  o f PLY and ILY frag m en ts  in c o n s tru c tio n  o f 
ch im e ric  to x in s
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pDest32-D4ILY Yeast-2-hybrid bait vector
The D41LY coding sequence was amplified from pQE9mlLY using primers 40T 
and 40U. These primers were designed to add Gateway Att-B1 and Att-B2 sites to 
the ends of the coding sequence.
A one-tube gateway cloning reaction was performed according to the Invitrogen 
Pro-Quest manual to clone the D4ILY PCR product into pDEST32 (DNA binding 
domain fusion vector) via pDONR221. The reaction was transformed into DH5a E. 
coli and plated on LB agar containing gentamycin.
Gateway cloning
Gateway cloning was performed according to the Gateway Cloning Manual 
provided by Invitrogen. All reagents for gateway cloning were obtained from 
Invitrogen.
Gateway Cloning is a technology for cloning of DNA sequences which relies on 
site-specific recombination rather than traditional restriction and ligation cloning 
techniques (Figure 2.1). This provides a rapid and highly efficient method of 
moving DNA sequences into and between cloning and expression vector systems 
that ensures reading frame and ORF orientation are maintained.
The Gateway system is based on a modification of the bacteriophage lambda site- 
specific recombination system. Gateway components are modified from those of 
bacteriophage lambda to increase specificity and efficiency (Bushman et a!., 
1985). A BP (attB-attP) reaction clones an attB-flanked PGR product or coding
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sequence from a Gateway expression clone into a Gateway entry clone. This entry 
clone can then be combined with a Gateway destination vector in an LR reaction 
(attL-attR) to produce a Gateway expression clone containing the gene of interest 
(Figure 2.1).
• BP Reaction: Facilitates recombination of an /?ffB substrate {(?/fB-PCR product 
or a linearized lUtB expression clone) w ith  an lUfP substrate (donor \ ector) to 
create an rtffL-containing entry clone (see diagram below). Tlais reaction is 
catalyzed by BP Clonase™ enzyme mix.
a»B airB
aWB-tlanked PCR 
product or attB 
expression done
BP Oonase
donor
vector
a « R __________ aHRI I M i  I
by-product
• LR Reaction: Facilitates recombination of an tUtL substrate (entry clone) w ith  
an nttR substrate (destination vector) to create an ,7ffB-containing expression 
clone (see diagram below). This reaction is catalyzed by LR Clonase” ' enzyme 
mix.
affL aSL attR a#R
LR Clonase
destination
vector
expression
done
by-product
Figure 2.1: Overview of the Gateway Cloning system. Diagram taken from the Invitrogen 
Gateway Manual.
DNA sequencing
DNA sequencing was provided by the Molecular Biology Support Service, 
University of Glasgow. Sequence analysis was performed using the Contig 
Express component of Vector NTI Software version 9 or 10 (Invitrogen).
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Protein Expression
Recombinant E. coli containing the expression plasmids were grown to mid-log 
phase in terrific broth (Tartof & Hobbs, 1987) containing an antibiotic appropriate 
to maintain plasmid selection. IPTG was added to a final concentration of ImM to 
induce expression and cultures were incubated shaking at 30°C or 37°C for 3, 6 or 
18 hours. Bacteria were harvested from the broth by centrifugation at 13000 x G 
for 3 minutes. Bacterial pellets were resuspended in PBS containing Dnase I 
(Sigma) and Benzamidine (Sigma) and cells were disrupted by sonication or using 
a One-Shot Cell Disrupter (Constant Systems). Cell lysates were centrifuged at 
18000 X G and 4°C for 30 minutes and the supernatant was passed through a 
0.2jiM syringe filter to remove remaining cell debris.
Nickel-affinity purification of His-Tagged proteins
His-tagged proteins were purified from crude cell extracts by FPLC on a Nickel- 
charged NTA column (Qiagen Superflow resin) with elution on a 0-300mM 
continuous imidazole gradient in PBS. Purified proteins were dialysed at least 
three times against a greater than 50-fold volume of PBS and concentrated using 
Amicon Ultra Centrifugal Concentration columns with 10 or 30kDA molecular 
weight cut-off membranes.
Hydrophobic interaction chromatography
Hydrophobic interaction chromatography of PLY and eGFPPLY was performed as 
described (Kirkham et ai., 2006b) using a Bio-Cad 700E chromatography 
workstation.
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SwellGel Tab purification
Purification of poly-histidine tagged proteins using SwellGel Ni-NTA tabs (Pierce 
Biotechnology, Rockford, IL, US) was performed according to the ‘batch 
purification’ protocol provided by the manufacturer.
Anion Exchange Chromatography
Following nickel-affinity purification or hydrophobic interaction chromatography, 
proteins were dialysed into PBS and then further purified by passage through an 
anion exchange (HQ) column on a BioCad 700E Workstation (Applied Biosystems 
Ltd, Warrington, UK). In this purification step, DNA and contaminants were 
retained on the column and purified proteins were present in the flow through. 
Eluted proteins were immediately dialysed into PBS and concentrated using 
Amicon Ultra centrifugal concentrators (Millipore, Watford, UK).
UV Absorbance Scanning
Absorbance scans from 220-320nm were performed on purified proteins using a 
Unicam UV2 spectrophotometer.
LAL assay
Endotoxin levels were measured in protein samples using the Limulus 
Amoebocyte Lysate (LAL) Kinetic-QCL kit from BioWhittaker. LPS causes the 
conversion of a proenzyme in the LAL lysate into the active form and the rate of 
activation is proportional to the amount of LPS present. This enzyme then cleaves 
p-nitroaniline (pNA) from Ac-lle-Ala-Arg-pNA increasing the absorbance of the 
solution at 405nM. LPS concentration is calculated by comparison to a standard 
curve generated from known standards.
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Bradford Assay
Bradford assays were performed according to the technique of Bradford (Bradford, 
1976). Known standards of BSA (Sigma) were made up in PBS covering a range 
of concentrations from 23-1500 jag/ml. lOyl of standard, blank (PBS) or protein 
sample were added to a flat-bottomed 96-well plate (Nunc) and 200jil Bradford 
reagent (Sigma) was added to each well. The absorbance at 570nM was read on 
a plate reader (Dynex Revelation) and protein concentrations were interpolated on 
graphs of standard curves generated using Graphpad Prism software.
Western Blotting
Western Blotting was performed by routine methods as originally described 
(Burnette, 1981; Renart et al., 1979). Optimal antibody concentrations varied 
according to the reaction and are described in the appropriate results section.
Epi-fluorescence microscopy of eGFP-tagged toxins
The following protocol was devised to visualise eGFP-tagged toxin binding to 
human erythrocytes. Fresh human blood was washed three times by resuspension 
in PBS followed by centrifugation at 900 x G for 5 minutes. After the final wash, the 
human erythrocyte suspension was diluted to 4% v/v in PBS. 250yl of 1.4|aM 
eGFP-tagged toxin solution in PBS was added to 250yl 4% hRBC solution to give 
500jil of 700nM eGFP-tagged toxin in a 2% hRBC solution and the suspension 
was incubated at 37°C for 30 minutes.
10 |il of reaction solution was applied to the surface of a glass microscope slide 
and a glass coverslip was gently applied. Slides were viewed immediately by
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fluorescence microscopy using a Zeiss Axioskop 20 Fluorescence Microscope 
fitted with a #09 FITC filter set (Excitation 488nM, Emission 530nM bandpass). 
Images were captured using a Coolsnap CCD camera (Photometries) and 
Openlab software (Improvision).
The protocols for the epifluorescence microscopy work described in Beurg et al, 
2005 are described in that work (Beurg et al., 2005).
Laser Scanning Confocai Fluorescence microscopy
Tissue culture cells were grown to 30-50% confluence on 8-well chamber slides 
(Nunc ref. 154534). The growth medium was removed from each well and 
replaced with 300|iil pre-warmed growth medium containing toxin at test 
concentration, or PBS for control wells. Slides were incubated at 37°C, 5% CO2 
and 100% humidity for 30 minutes. The growth medium was removed from each 
well and cells were washed with 300(xl pre-warmed growth medium. Cells were 
fixed by addition of 300yl 3.8% w/v paraformaldehyde in growth medium, 
corrected to pH 7 and pre-warmed to 37°G, for 20 minutes at room temperature. 
Fixed cells were washed with PBS. Where appropriate, cells were also stained by 
addition of 6 .6 |iM (200units/mL) rhodamine-phalloidin (Invitrogen) in PBS for 20 
minutes and/or 0.1jig/ml DAP I (Sigma Chemicals) in PBS for 1 minute, both at 
room temperature. Cells were rinsed three times in PBS, slide chambers were 
removed using the tool provided and cells were mounted using Pro-long Gold anti­
fade reagent (Invitrogen) according to the manufacturer’s instructions.
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Scanning Electron Microscopy
Toxin solutions were centrifuged for 5 minutes at 17000 x G to remove any large 
aggregates of protein. 250jal of 1.4mM toxin in erythrocyte medium (ECM) was 
added to 250p.l 0.4% human erythrocyte solution in ECM and each reaction was 
incubated at 37°C for 10 minutes. 500|il 5% Glutaraldehyde in ECM was added to 
each tube and incubated for 1 hour at room temperature. Erythrocytes were then 
washed three times in ECM by centrifugation at 17000 x G for 1 minute and 
resuspended in lOOyl ECM. 20jil erythrocyte suspension was applied to a poly­
lysine coated 10mm glass coverslip and incubated at room temperature for 20 
minutes. Coverslips were rinsed three times with ECM solution and fixed with 1% 
OSO4 for 1 hour. After rinsing in dH20 three times for 10 minutes, samples were 
dehydrated by passage through an ethanol series. Samples were processed using 
a critical point drier then coated twice with gold/paladium using a Polaron SC515 
diode sputter coater. Sample dehydration and gold coating was done my Margaret 
Mullen.
Coverslips were mounted on aluminium studs using double-sided tape and viewed 
on a Jeol JSM 6400 Scanning Electron Microscope.
Transmission Electron Microscopy
Fresh human blood was washed three times in PBS by centrifugation for 3 
minutes at 100 x G in a microcentrifuge. Washed erythrocytes were diluted to 2% 
v/v with PBS. Toxins were diluted to a concentration of 20|ig/ml in 200|il PBS and 
added to 1000p,l 2% human erythrocyte solution. Samples were incubated for 5 
minutes at 37°C and washed three times in 0.5M Tris 150mM NaCI pH7.4.
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Formvar/Carbon-coated 200 mesh copper grids were glow discharged and 
specimens in distilled water were dried from suspension onto the support film. A 
droplet of 1% aqueous methylamine vanadate (Nanovan; Nanoprobes , Stony 
Brook, NY, USA) or 10% uranyl formate (appendix 3) stain was applied and 
allowed to dry. Specimens were imaged with a LEO 912AB energy filtering 
transmission electron microscope at 120kV. Contrast enhanced, zero-loss 
electron energy filtered images were recorded with a 14 bit /2K Prosean CCD 
camera. Scale bars were derived from calibration against the lattice plane 
spacings of a catalase crystal grid (Agar Scientific Ltd, Stansted, UK).
Detection of eGFP-tagged toxin binding by FACS
Human blood was washed three times by centrifugation at 3000 x G for 1 minute 
and resuspension in PBS. The pellet was resuspended in PBS to give a 4% 
erythrocyte solution. 250p.l 4% v/v human blood solution in PBS was added to 
250)0.1 toxin at 2 times final concentration in PBS and the solution was incubated at 
37°C for 10 minutes before being placed on ice. Erythrocytes were either pelleted 
at 10000 X G for 3 minutes then resuspended in 3mL PBS or diluted to 3mL with 
PBS.
Cell suspensions were analysed by flow cytometry using a Becton-Dickinson 
FACScalibur flow cytometer and Cell-Quest software recording forward scatter, 
side scatter and FL-1 channels (Excitation 488nM, Emission 530nM). Flow 
cytometry charts were generated using WinMDI v2.8 (http://facs.Scripps.edu) and 
axis labels were added manually using Adobe Photoshop CS software.
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The experimental work and data analysis for the flow cytometry binding assay 
published with Dr. R Anderson’s group at the University of Pretoria, South Africa is 
described in that work (FickI et al., 2005).
Transformation of Yeast -  Simple Low-Efficiency Transformation
This protocol is based on that described by Grey and Brendel (Grey & Brendel, 
1992).
Yeast strain MAV203 was grown to large single colonies on YPAD agar by 
incubation at 28°C for 3 days. One colony of approximately 20p,L volume was 
picked using a sterile toothpick. The pellet was resuspended and washed three 
times by centrifugation at 17000 x G in Im L of sterile 20mM HEPES buffer 
containing 1M Sorbitol. After the final centrifugation, the pellet was resuspended in 
250|il sterile buffer containing 20mM HEPES and 1M Sorbitol. 0.5jig plasmid DNA 
in 5|tI sterile distilled water was added to 40jil yeast suspension and the solution 
was transferred to a pre-cooled 0.2cm gap electroporation cuvette. The sample 
was electroporated using BioRad Genepuiser electroporation apparatus set to 
1.6kV, 25|iF and 200Q, 0.2mL 1M sorbitol was added and the sample was plated 
immediately on selective SC agar media.
Transformation of Yeast -  Library Transformation (60x)
MAV203 yeast containing the DB-X plasmid were inoculated into 25mL SC-leu 
medium and incubated at 30°C overnight. The number of cells were counted with 
a haemocytometer and 1.5x10® cells were pelleted by centrifugation at 3000 x G
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for 5 minutes at room temperature. Cells were resuspended in 300mL pre-warmed 
YPAD broth, transferred to a sterile culture flask and incubated at 30°C shaking at 
200 rpm until the cell titre reached 2x10^ cells/mL. Cells were harvested by 
centrifugation at 3000 x G for 5 minutes at room temperature then the cell pellet 
was washed by resuspension in 150mL sterile distilled water followed by 
centrifugation at 3000 x G for 5 minutes. The pellet was resuspended in 6mL of 
sterile lOOmM Lithium Acetate, transferred to a sterile 15mL centrifuge tube and 
incubated for 15 minutes at 30°C. Cells were pelleted again by centrifugation at 
3000 X G for 5 minutes and the supernatant was removed.
The following reagents were added, in order, to a separate tube and mixed 
thoroughly by vortexing: 14.4 mL 50% PEG, 2.16mL 1.0 M Lithium Acetate, 3.0mL 
0.5 mL Single-Stranded Carrier DNA, 50pg plasmid cDNA library in 2.04mL 
distilled water. The transformation mix was added to the cell pellet and vortexed 
vigorously until the cell pellet was resuspended. The transformation mix was 
incubated at 30°C for 30 minutes then heat-shocked at 42°C for 50 minutes, with 
inversion for 15 seconds every 5 minutes. Cells were pelleted by centrifugation at 
3000 X G for 5 minutes then resuspended in 40mL sterile distilled water and 
spread onto 200 SC-leu-trp-ura plates. The number of transformants screened 
was calculated by spreading dilutions of the mixture onto four SC-leu-trp plates.
Yeast-2-hybrid screen
With the aim of finding candidates which may be the protein receptor for ILY, a 
yeast-2-hybrid assay was used to determine proteins from a human cDNA library 
were able to interact with ILY.
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The yeast-2-hybrid system is a yeast-based assay to identify protein:protein 
interactions (Figure 2.2). Two yeast plasmid vectors are constructed: one fuses a 
‘bait’ protein (X) to the DNA-binding domain (DB) of the GAL-4 transcription factor 
and the other fuses a library of ‘prey’ proteins (Y) to the activation domain (AD) of 
GAL-4 transcription factor. Interaction of the DB-X and AD-Y proteins leads to 
reconstitution of an active transcription factor and transcription of genes under the 
control of GAL4 promoters. After transformation with the plasmids, the yeast are 
screened for multiple reporter genes and transcription of these genes suggests an 
interaction between the prey and bait proteins. The potential interacting proteins 
can then be confirmed by other means such as co-immunoprecipitation, surface 
plasmon resonance or knockout experiments in model biological systems.
For this study, a yeast-2-hybrid system was used to screen for proteins from a 
human brain cDNA library that are capable of interaction with domain 4 of 
intermedilysin.
A yeast-2-hybrid screen was performed with pDest32-D4ILY against a human 
foetal brain cDNA library (Invitrogen 11396-018) using the Invitrogen Pro-Quest 
Yeast-2-hybrid system.
The pDest32-D4ILY plasmid was transformed into MAV203 yeast using the plate 
transformation method. The presence of the plasmid in a resulting clone was 
confirmed by PCR using primers 42P and 42R.
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M A V 203  ye as t con ta in ing  the  p D e s t3 2 -D 4 IL Y  ba it ve c to r w e re  g row n  up and a 60x 
lib ra ry -e ffic ie ncy  ye as t tran s fo rm a tio n  w as pe rfo rm ed  to  in tro du ce  a hum an  bra in  
cD N A  G a l4 -A D -fus io n  lib ra ry . C e lls  w e re  p la ted  on to  S C -leu -trp -h is+ 25 m M  3AT. 
P la tes w ere  incuba ted  a t 28°C  fo r 3 days.
Nucleus p
URA3
Figure 2.2: Schematic diagram of the Yeast-2-hybrld system. Interaction of the bait protein 
(X) fused to the Gal4 DNA-blndIng domain (DB) with the prey protein (Y) fused to the Gal4 
activation domain (AD) causes reconstitution of an active transcription factor. This leads to 
expression of the ura3, his3 and lacZ reporter genes. Initial Screens select colonies capable 
of growth on histldlne-deflclent agar medium and these clones are further characterised for 
growth on uracll-deflclent medium, p-galactosldase activity using X-GAL and Inhibition of 
growth on 5FOA-contalnlng medium.
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Trypsin treatment of erythrocytes
An assay was developed to determine the effect of trypsin treatment of 
erythrocytes on susceptibility to lysis by ILY and PLY.
A 5mg/ml solution of trypsin in PBS (Sigma T-1426) and solutions of trypsin 
inhibitor containing 10mg/mL chicken egg-white trypsin inhibitor (Sigma T-4385) 
and 1% w/v BSA in PBS were made up. Human blood was washed three times by 
centrifugation at 3000 x G for 1 minute and resuspension in PBS. The pellet was 
resuspended in PBS to give a 2% v/v erythrocyte solution.
Six 15mL centrifuge tubes were set up, each containing 2.5mL 2% human 
erythrocyte solution. 0.25mL trypsin solution was added to five tubes and 0.5mL 
PBS was added to the other tube (no trypsin control). 0.25mL trypsin inhibitor 
solution was added to the five tubes containing trypsin either immediately or after 
1 hour, 2 hours, 4 hours or 8 hours.
The erythrocytes in each tube were pelleted by centrifugation at 3000 x G for 5 
minutes and resuspended in 2.5mL PBS. The colour of the supernatants was 
monitored to ensure no haemolysis had occurred at this stage. Erythrocytes were 
used in a standard quantitative haemolytic assay as described in this chapter to 
determine their susceptibility to lysis by PLY or ILY. Lysis of erythrocytes causes 
release of haemoglobin into the supernatant in the assay well causing an increase 
in absorbance at 540nM.
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Cell culture
BHK 013 cells (ATCC ref. CRL-1632) and Detroit 563 cells (ATCG ref. CCL-138) 
were maintained by standard cell culture techniques. Detroit 562 cells were grown 
in RPMI medium (Sigma) without phenol red, and for BHK 013 cells the growth 
medium used was DMEM (Sigma) without phenol red. Both media were 
supplemented with 2mM glutamine (Sigma) and 10% foetal bovine serum (Sigma). 
1x Trypsin-EDTA solution (Oambrex) was used to detach the cells for cell 
passage.
L929 fibroblast cytotoxicity assay
The L929 fibroblast cytotoxicity was performed as described by Mosmann 
(Mosmann, 1983). The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay is based on the ability of the mitochondrial dehydrogenase 
enzyme of viable cells to cleave the tétrazolium rings of pale yellow MTT forming 
dark blue formazan crystals which are impermeable to cell membranes, thus 
resulting in accumulation within healthy cells. Addition of a detergent to the cells 
results in the liberation of the crystals, which are then dissolved. The number of 
surviving cells is directly proportional to the level of the formazan product created 
and this colour can be quantified using a simple colorimetric assay read on a 
multiwell spectrophotometer (ELISA reader).
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Haemolysis Assay
Haemolysis assays were performed using human blood (Scottish Blood 
Transfusion Service) and horse blood (E&O laboratories, Bonnybridge, Scotland) 
by a modification of the technique described by Walker et al., 1987 (Walker et al., 
1987). Following the incubation step, plates were centrifuged at 1000 x G using a 
Sigma 4K15 bench top centrifuge, and 50|u.i supernatant from each well was 
transferred to a new plate. The absorbance at 540nm was measured using a 
Dynex Revelation microplate reader and the A540 for percentage lysis was 
calculated by expression of each absorbance reading as a percentage of the A 5 4 0  
for a positive control well containing erythrocytes lysed by addition of O.Img/mL 
PLY.
Data were imported into Graphpad Prism 4 (GraphPad Software Inc.) and an XY 
scatterplot of Logio toxin concentration against percentage haemolysis was 
produced. A variable slope sigmoidal response curve was plotted using the 
analysis component of the software and the concentration of toxin that would 
cause 50% lysis was calculated by interpolation using the fitted line on the graph. 
The specific activity was then determined by taking the reciprocal of the 
concentration that would cause 50% lysis (in mg/mL). 1 haemolytic unit is the 
amount of toxin that produces 50% lysis of a well containing 1% erythrocyte 
solution and specific activity is expressed in HU/mg.
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Anthrolysin O binding assay
Human erythrocyte ghost membranes were produced by washing of 1mL of 
human blood in 5mM sodium phosphate buffer three times by centrifugation at 
17000 X G for 1 minute followed by resuspension in Im L PBS. 200|iL of human 
erythrocyte ghost membrane solution was mixed with 50|uL toxin at 20jag mL'^ and 
the reaction was incubated at 37°C for 10 minutes. Ghost membranes were 
pelleted by centrifugation at 17000 x G and washed three times in PBS. Pellets 
were resuspended in SDS-PAGE buffer (without p-mercaptoethanol), incubated at 
70°C for 10 minutes and run on a 10% SDS-PAGE gel. An immunoblot was 
performed by standard techniques using pooled mouse anti-mALO anti-serum 
from the ALO vaccination experiments of this work as the primary antibody and an 
anti-mouse IgG HRP-linked secondary antibody (Amersham Biosciences).
Determination of anti-ALO and anti-PLY IgG levels by ELISA
ELISA plates were coated with lOOjiL of 2.5jig/mL mALO or PLY in 50mM 
bicarbonate coating buffer (pH9.6) per well and incubated for 18h at 4°C. Plates 
were washed five times with PBS containing 0.01% Tween 20 (PBS-T) then 200jiL 
1% bovine serum albumen (Sigma) in coating buffer was applied to each well and 
plates were incubated for 3 hours at 37°C. Plates were washed five times with 
PBS-T then 1:5 serial dilutions of control or test serum in assay buffer (coating 
buffer containing 1% bovine serum albumin + 0.25% Tween 20) were made across 
the plate with a final volume of 100|iL.
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Following incubation for 2 hours at 37“C, plates were washed five times in PBS-T. 
IO O illL  of 1:2000 dilution of anti-mouse IgG HRP-linked antibody from sheep 
(Amersham Biosciences) in assay buffer was added to each well and plates were 
incubated at 37°C for 1 hour. Plates were washed five times in PBS-T and 
100|aL/well TMB substrate solution was added (KPL, Maryland, USA). After 
development, reactions were stopped by addition of 50jil 0.4M H2SO4 to each well.
The absorbance at 450nm was measured using an ELX808 Ultra microplate 
reader (Bio-Tek Instruments Inc, Winooski, VT, USA) and titres were calculated 
using Kineticalc v2.7 software (Bio-Tek Instruments Inc, Winooski, VT, USA). 
Absorbance readings were corrected for background by subtraction of values 
obtained from wells containing pooled serum from naïve animals and the A450 was 
plotted against dilution for each serum sample. Titres were calculated as the 
dilution of serum calculated by interpolation to give an A450 value of 0.3, which was 
within the linear part of the curve. Serum from each mouse was tested in duplicate 
and the mean value for each mouse was calculated.
Determination of lethal dose of Anthrolysin O and histopathology
This work was performed as part of a collaboration with DSTL, Porton Down, UK. 
Five groups of 8-12 week old female A/J mice were injected intravenously (i.v.) 
with single doses of 0.1 |ig (n=7), 0.5jig (n=7), Ijig  (n=7), 2|iig (n=7) or 5jag (n=3) 
mALO protein in IOOp.1 PBS. Survival of each group of mice was monitored.
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Tissues (spleen, heart, kidney, liver and lung) were harvested from 2 mice that 
died immediately after injection with I jig  mALO and from a naïve mouse. Organs 
were fixed with 10% neutral-buffered formalin (Sigma) and embedded in paraffin. 
Sections were stained with haematoxylin and eosin and Martius Yellow-Brilliant 
Crystal Scarlet-Soluble Blue (MSB) (Lendrum et al., 1962).
Immunisation studies with mALO, A6mALO and PLY
This work was performed as part of a collaboration with DSTL, Porton Down, UK. 
For each challenge study, five groups of 8 female A/J mice were immunised via 
the intra-peritoneal (i.p.) route with 10)jig mALO, A6mAL0, or PLY in 100|il PBS 
containing 25% v/v alhydrogel (2%) adjuvant (Superfos Biosector a/s, Vedback, 
Denmark). Control groups were administered the adjuvant alone, or left untreated. 
For the B. anthracis challenge experiment, a sixth group was immunised with 
recombinant protective antigen (rPA; obtained from DSTL). Immunisations were 
performed on day 0, day 14 and day 28. Mice were bled on day 40 for 
determination of anti-mALO and anti-PLY IgG titres.
Animals were challenged on day 49 by i.v. administration of 5jig mALO in lOOjul 
PBS for the anthrolysin O challenge study or inoculated with 10^ B. anthracis ST I 
spores (obtained from DSTL) via the i.p. route (previously calculated to be 
approximately equivalent to 100 MLD (Beedham et al., 2001)) and survival was 
monitored.
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All in vivo experiments were performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986.
Surface Plasmon Resonance
Surface plasmon resonance (SPR) was performed using a Biacore 3000 (Biacore 
AB, Uppsala, Sweden. CM5 sensor chips were coated with thiol-coupled CD59. 
The binding assay was developed and performed by Dr. Tim Hughes, UWCM, 
Wales.
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Chapter 3: Production and 
characterisation of eGFP-tagged
pneumolysin
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Summary
Pneumolysin is a toxin produced by virtually all clinical isolates of Streptococcus 
pneumoniae (Paton et a!., 1993) and is a member of the cholesterol-dependent 
cytolysins. PLY has been shown to be a key virulence factor (Berry et a/., 1999; 
Rubins et a!., 1995; Wellmer et al., 2002) and the toxin has a range of biological 
effects including pore formation, complement activation and induction of cytokine 
production in vitro and in vivo. A deletion mutant of PLY, A6PLY, has been 
described (Kirkham et al., 2006b), and this mutant is capable of cell binding but 
incapable of pore formation.
The aim of this study was to produce an enhanced green fluorescent protein 
(eGFP) labelled form of PLY that could be detected quantitatively and in real time. 
It was hoped that this would allow direct visualisation of the localisation of the toxin 
as an aid to studies of cellular tropism, potential internalisation into host cells, and 
the binding capabilities of toxin mutants.
PLY and A6PLY were fused to the C-terminus of eGFP to produce eGFPPLY and 
A6eGFPPLY. Both fluorescently labelled proteins were shown to have similar 
haemolytic and cytotoxic properties to their parent toxins as measured by 
quantitative haemolytic assay and MTT-cytotoxicity assay on L929 fibroblasts.
Fluorescence microscopy of eGFPPLY and A6eGFPPLY treated erythrocytes and 
Detroit 562 cells showed the toxins bound to the plasma membranes.
Page 72
eGFPPLY and A6eGFPPLY binding of erythrocytes could be measured by flow 
cytometry and the fluorescence of cells was found to increase with the 
concentration of toxin added over a 100-fold range from 0.7nM up to 70nM.
Finally, rod-like structures were observed on membranes treated with A6eGFPPLY 
and these were further studied by SEM. These structures were found to be caused 
only by the A6 mutant of PLY as they were present on cells treated with 
AGeGFPPLY and A6PLY but not those treated with PLY or eGFPPLY.
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Results
Construction of eGFPPLY, AGeGFPPLY and eGFP expression vectors
Plasmid vectors were constructed containing the coding sequence for eGFP alone 
(pET33bEGFP), as an N-terminat fusion to PLY (pET33bEGFPPLY) or as an N- 
terminal fusion to A6PLY (pET33bA6EGFPPLY). The pET33b expression vector 
(Novagen) was selected to allow high-level inducible expression with the addition 
of a poly-histidine tag to facilitate protein purification. Initial cloning was confirmed 
by PGR using primers for the T7 promoter and T7 terminator sequences flanking 
the multiple cloning site (primer references 7F and 7G).
The construction of all plasmids was checked by DNA sequencing. The sequence 
was confirmed to be as expected with no mutations present. Plasmid maps of 
pET33bEGFPPLY and pET33bDel6EGFPPLY plasmids are shown in Figure 3.1. 
Constructs were transformed into BL21(DE3) E. co//for protein expression.
Page 74
f1 ori T7 term
KanR
pBR322 ori
pET33bEGFPPLY
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Lad
f1 ori T7 term
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N term His Tag 
17 promoter
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Lad
Figure 3.1: Schematic diagrams of pET33bEGFPPLY and pET33bDel6EGFPPLY plasmids
Page 75
Expression of eGFP-tagged PLY, AGeGFPPLY and eGFP proteins
Recombinant eGFPPLY, AGeGFPPLY and eGFP were expressed in E. coli and 
purified by nickel-affinity chromatography or hydrophobic interaction 
chromatography (HIC), then further purified by anion exchange chromatography 
(AEG). Protein preparations were estimated by Goomassie-blue-stained SDS- 
PAGE to be greater than 98% pure and protein concentrations were determined 
by Bradford assay.
All experiments used nickel-affinity chromatography / AEG purified toxins, except 
for the MTT cytotoxicity assay, which used FIIG / AEG purified toxins. This 
alternative purification strategy was used to allow comparison with PLY and 
AG PLY proteins which had previously been purified by this method.
The levels of lipopolysaccharide (LPS) in the HIG and AEG eGFPPLY and 
AGeGFPPLY preparations were measured by LAL endotoxin assay. The LPS 
concentration was calculated to be 93IU/mg for eGFPPLY and 308IU/mg for 
AGeGFPPLY.
Comparison of haemolytic activity of eGFPPLY and AGeGFPPLY to PLY and 
AGPLY
A quantative haemolysis assay was performed to compare the activities of PLY, 
eGFPPLY and AGeGFPPLY on human erythrocytes (Figure 3.2). Toxin 
concentration was calculated using molarity to enable a comparison in terms of the
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number of toxin molecules present that was not influenced by the much higher 
molecular weight of the eGFP-tagged toxins.
PLY and eGFPPLY were both similarly haemolytic on human erythrocytes with 
calculated specific haemolytic activities of 1x10® HU/M. AGeGFPPLY was not 
haemolytic even up to a concentration of 4mM.
Haemolytic activity of eGFPPLY, AGeGFPPLY, PLY 
and AGPLY on human erythrocytes
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Figure 3.2: Comparison of the haemolytic activity of eGFPPLY, AGeGFPPLY, PLY and AGPLY 
on human erythrocytes.
Transmission Electron Microscopy of eGFPPLY and AGeGFPPLY
In order to compare pores formed by eGFPPLY to those formed by wild-type PLY, 
erythrocyte membranes were treated with eGFPPLY or PLY and examined by 
negative staining TEM. Membranes treated with AGeGFPPLY were also examined
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to  d e te rm ine  w h e th e r any  o lig o m e ric  s truc tu res  w ere  v is ib le  on the  m em branes . 
E lectron  m ic ro g rap hs  a re  show n  in F igu re  3.3.
Figure 3.3: Transmission electron micrographs of human erythrocyte ghost membranes 
treated with A: wtPLY B: eGFPPLY C: AGeGFPPLY D: No toxin. Samples were stained with 
Nanovan negative staining reagent. Magnification x25000, white horizontal scale bar 
represents 200nm.
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Full rings, arcs and double arcs were present on membranes treated with PLY. All 
of these structures were also observed on membranes treated with eGFPPLY and 
were similar to those formed by PLY. No rings or arcs were observed on 
membranes treated with AGeGFPPLY.
Comparison of cytotoxicity of eGFPPLY, AGeGFPPLY, PLY and AGPLY to 
L929 fibroblast cells
An L929 fibroblast cytotoxicity assay was performed by Lea-ann Kirkham using 
eGFPPLY, AGeGFPPLY, PLY, AGPLY and eGFP purified proteins to determine 
whether addition of the eGFP tag affected the cytotoxicity of the parent toxin. High 
A540 indicates viability of the cells as the active mitochondria are capable of 
conversion of MTT into a purple product whereas loss of viability is indicated by a 
low A540 where the MTT solution remains yellow.
Both PLY and eGFPPLY caused a loss of viability to L929 fibroblasts and their 
toxicities were found to be similar. AGeGFPPLY, AGPLY and eGFP were not toxic 
to L929 fibroblast cells at the concentrations tested (Figure 3.4).
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L929 fibroblast cytotoxicity assay on eGFP tagged toxins
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Figure 3.4: Cytotoxicity of eGFP-tagged toxins to L929 fibroblast cells. L929 fibroblasts were 
treated with a range of concentrations of PLY, AGPLY, eGFP, eGFPPLY or AGPLY and the 
cell viability was measured by MTT assay.
Visualisation of eGFPPLY and AGeGFPPLY binding to erythrocytes by 
fluorescence microscopy
In order to determine whether eGFPPLY and AGeGFPPLY were capable of cell 
binding, erythrocytes treated with each of two toxins were visualised by 
fluorescence microscopy. Slides of treated erythrocytes were viewed using a Zeiss 
Axioskop 20 fluorescence microscope fitted with Zeiss FITC filter set 09, which 
provides excitation of 450-490nM with a 520nM high-pass emission filter.
Erythrocytes treated with eGFPPLY and AGeGFPPLY were fluorescent whereas
no fluorescence was observed on samples treated with eGFP (Figure 3.5). For
both eGFPPLY and AGeGFPPLY-treated erythrocytes, fluorescence appeared to
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loca lise  to  the  p lasm a m em bran e  o f the  e ry th rocy tes . T he  m orph o lo gy  o f 
e ry th rocy te s  trea ted  w ith  the  w ild -typ e  o r A6 fo rm s o f the  to x in s  w ere  d iffe ren t: 
e ry th rocy te s  trea ted  w ith  e G F P P L Y  w e re  fla ttened  g ho s t m em bran e s  w he re a s  
e ry th rocy te s  trea ted  w ith  A G eG FP PLY m a in ta ined  th e ir rounded  b i-concave  shape  
and w ere  no t lysed , as revea led  by the  red co lo u r obse rved  on b righ tfie ld  im ages 
o f th ese  ce lls  (im ages no t show n).
Figure 3.5: Human erythrocytes treated with A: 
eGFPPLY, B: AGeGFPPLY and C: no toxin. 
Samples were viewed by epifluorescence 
microscopy using a FITC filter set (Excitation 
488nM, Emission 530nM bandpass) at 100x 
under oil immersion.
S m a ll foc i o f flu o re sce n ce  w ere  obse rve d  on e ry th rocy te s  trea te d  w ith  eG F P P LY . 
V e ry  p ronounced  foc i w e re  o bse rve d  on e ry th rocy te s  trea ted  w ith  A G eG FP PLY 
and th ese  w ere  m uch m ore  d is tin c t than  th ose  obse rved  fo r eG F P P LY .
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O w ing  to  th e  sh a llow  dep th  o f fie ld  ob ta ined  w hen  v iew ing  sa m p le s  w ith  the  100x 
o il- im m ers ion  lens, it w as  p oss ib le  to  lim it the  foca l p lane  to  the  u pp e r m em brane  
o f the  e ry th rocy te s  (F igu re  3 .6). T h is  revea led  th a t the  pun c ta te  loca lisa tion  
obse rved  w hen  the  foca l p lane  w as  se t to  v iew  the  cen tre  o f the  e ry th rocy te s  in the  
Z -p lan e  w as a c ross -sec tio n  o f flu o re sce n t rod -like  s truc tu res  on the  ce ll 
m em brane  (F igu re  3 .6).
Figure 3.6: AGeGFPPLY treated human erythrocytes viewed by epifluorescence microscopy. 
Figure A shows the cells viewed with the focal plane set to the Z-centre of the erythrocytes 
whereas figure B shows the same cells with the focal plane set to view the upper surface of the 
erythrocytes. Samples were viewed by epifluorescence microscopy using a FITC filter set 
(Excitation 488nM, Emission 530nM bandpass) at 100x under oil immersion.
Use of eGFPPLY to study binding to cochlear hair cells of the rat
In co lla bo ra tion  w ith  Dr. D id ie r D u lo n ’s g ro up  a t the  U n ive rs ity  o f B o rdeaux  , w e 
used tagged  tox in  to  s tu dy  the  b ind ing  o f eG F P P LY  to  rat co ch le a r ha ir ce lls  by 
e p ifluo resce nce  m ic ro scop y  (B eurg  et al., 2005). T he  to x ic ity  o f e G F P P L Y  w as  
e va lua ted  in an o rgan  o f co rti (O C ) e xp la n t cu ltu re  m ode l and w as  found  to  be 
s im ila r to  th a t o f P LY  (B eurg  at a!., 2005).
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Figure 3.7: Binding of PLY in cochlear HC cultures
The eGFPPLY (5 ng //I" ) was pressure puffed for 2 s on isolated rat HCs. An example of an 
IHC (A) and OHC (D) is shown in brightfield. Fluorescent images {B,E) were obtained 10 s 
after the puff of PLY on the same cell (A,D). The eGFPPLY labelling was localized in the 
plasma membrane of IHCs and OHCs. Graphs (C,F) show the time course of the 
incorporation of eGFPPLY in the HC plasma membrane. The fluorescence intensity was 
quantified by integration of a small zone shown by the rectangular box shown on the 
brightfield images. Fluorescence (F -  FD) is corrected from background fluorescence (FO). 
G, binding of eGFPPLY in OC cultures (representative of four explants) treated 24 h with 1 
ng pl-1 of the conjugated-toxin. A more sustained labelling in OHCs’ hair bundles compared 
to IHCs’ (arrowhead) could be observed. Note a high disorganization of the IHC stereocilia 
when remaining. H,l, immunolocalisation of PLY in control (H) and PLY (/) (1 ng pl-1, 24 h) - 
treated OC cultures (representative of three explants). Surface preparation of the OC 
showed a staining of stereocilia and plasma membrane of IHCs and OHCs, while no 
labelling was observed in control cultures. Scale bars 10 //m. Figure taken from Beurg et al, 
2005.
e G F P P L Y  w as d is tribu ted  h o m o g e n o u s ly  in the  p lasm a m em bran e  o f fresh ly  
d issoc ia ted  inn e r h a ir ce lls  (IH C s) and o u te r ha ir ce lls  (O H C s) and w as  res tric ted  
to  the  m em brane  su rfa ce  w ith  no flu o re sce n ce  de tec ted  in the  ce ll cy toso l (F igu re  
3 .7). No s ig n ifica n t d iffe ren ce  in the  flu o resce nce  in ten s ity  o f e G F P P L Y -trea te d
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IHCs and OHCs was observed. Epifluorescence microscopy of eGFPPLY-treated 
OC explants revealed that eGFPPLY labelled the hair bundles of both IHCs and 
OHCs with the staining being more pronounced in the OHCs (Figure 3.7).
Raised extracellular calcium was found to reduce the binding of eGFPPLY to IHCs 
and OHCs (Figure 3.8). eGFPPLY was pressure puffed for 5 seconds on isolated 
rat IHCs or OHCs in the presence of OmM, 1mM or 10mM calcium and 
epifluorescence micrographs were recorded. Fluorescence of a membrane portion 
was plotted on a histogram from a number of repeat samples for each condition. 
The amount of eGFPPLY bound with external 10mM CaCE was drastically 
reduced from that bound at OmM and 1mM CaCE (Figure 3.8). To eliminate the 
possibility that the observed effect was due to a reduction of the fluorescence of 
eGFPPLY with increased calcium concentration, these results were confirmed by 
examining the binding of PLY in cultures OC in the presence of 1.8mM or 10mM 
calcium using PLY-specific antibody (Beurg etal., 2005).
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Figure 3.8: Elevation of extracellular calcium prevents binding of eGFPPLY to HCs
A, the eGFPPLY (5 ng /yl-i) was pressure puffed for 5 s on Isolated rat IHC and OHC shown 
In (a). Fluorescent Images before (b) and after the puff of PLY In 10 mM (c) or ImM (control) 
CaCl2 (oO In the same IHC and OHC. In the presence of 10 mMCaCb, eGFPPLY Is not seen In 
the HC membrane while a strong signal Is present In control conditions. 8, histogram 
represents the Intensity of eGFPPLY fluorescence bound to the HC plasma membrane as a 
function of external calcium concentration. eGFPPLY (5 ng //l-i) was pressure puffed for 5 s 
on Isolated rat HC. Fluorescence Intensity was measured In a fixed-size area of the plasma 
membrane, Illustrated by the box In the HC scheme. Fluorescence Intensity corresponds to 
F -  Fq. The asterisk Indicates a significant different data (unpaired t test, P < 0.001). Results 
are obtained over the number of Indicated cells. C, top Images show the Immunolocalisation 
of PLY In PLY (1 ng //l-i, 24 h) -treated OC cultures (n -  4) In the presence of control (left 
panel) (DMEM 1.8 muCaCb) or high external calcium concentration (right panel) (10 mu). 
Bottom Images show binding of eGFPPLY In OC cultures treated 24 h with 1 ng ^l-i In the 
presence of control or high external calcium concentration (representative of four explants 
for each condition). Surface preparation of the OC showed a staining of stereocilia and 
plasma membrane of IHCs and OHCs in control condition, while no labelling was observed 
In high calcium. Error bars show standard error. Scale bars lO^vm. Figure taken from Beurg 
et al 2005.
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Visualisation of eGFPPLY and AGeGFPPLY binding by confocai fluorescence 
microscopy
The binding and localisation of eGFPPLY and AGeGFPPLY on Detroit 562 human 
nasopharyngeal cells was visualised by laser scanning confocai fluorescence 
microscopy. Cells were also treated with an equimolar concentration of eGFP as a 
negative control to ensure that binding localisation was due to the toxin component 
of the fusion proteins. Micrographs of cells treated with 700nM eGFPPLY, 700nM 
AGeGFPPLY or 700nM eGFP are shown in 
Figure 3.9, Figure 3.10 and
Figure 3.11 respectively. eGFP localisation was visible on the green channel, actin 
localisation was Indicated with rhodamine-phalloidin staining on the red channel 
and cell nuclei were visualised on the blue channel by DAP I staining.
eGFPPLY and AGeGFPPLY could both be observed bound to Detroit 5G2 cells but 
no fluorescence was observed on cells treated with eGFP. Both eGFPPLY and 
AGeGFPPLY localised to the plasma membrane of the treated cells and no 
internalisation of the toxins was visualised, however the morphology of the treated 
cells was vastly different. Cells treated with AGeGFPPLY remained spread out on 
the slide surface and the overall cell or actin cytoskeletal morphology did not differ 
from that of untreated cells or those treated with eGFP. The actin in these cells 
covered the entire area within the cell. However, cells treated with eGFPPLY were 
rounded up from the slide surface with a marked change in the actin cytoskeleton, 
whereby the actin was found to be condensed around the nuclei.
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Figure 3.9: Laser Scanning Confocai Microscopy of Detroit 562 cells treated with 700nM 
eGFPPLY. All images captured with 63x objective lens under oil immersion.
A) Red Channel (Ex. 543nm Em. BP 561-625nm) shows localisation of rhodamine-phalloidin 
stain for actin.
B) Blue Channel (Ex. 405nm Em. BP 420-480nm) shows localisation of DAPI nuclear DNA 
stain.
C) Green channel (Ex. 488nm Em. BP 505-530nm) shows localisation of eGFPPLY.
D) Combined image of all three channels.
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Figure 3.10: Laser Scanning Confocai Microscopy of Detroit 562 cells treated with 700nM 
A6eGFPPLY. All images captured with 63x objective lens under oil immersion.
A) Red Channel (Ex. 543nm Em. BP 561-625nm) shows localisation of rhodamine-phalloidin 
stain for actin.
B) Blue Channel (Ex. 405nm Em. BP 420-480nm) shows localisation of DAPI nuclear DNA 
stain.
C) Green channel (Ex. 488nm Em. BP 505-530nm) shows localisation of A6eGFPPLY.
D) Combined image of all three channels.
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Figure 3.11: Laser Scanning Confocai Microscopy of Detroit 562 cells treated with 700nM 
eGFP. All images captured with 63x objective lens under oil immersion.
A) Red Channel (Ex. 543nm Em. BP 561-625nm) shows localisation of rhodamine-phalloidin 
stain for actin.
B) Blue Channel (Ex. 405nm Em. BP 420-480nm) shows localisation of DAPI nuclear DNA 
stain.
C) Green channel (Ex. 488nm Em. BP 505-530nm) shows localisation of eGFP.
D) Combined image of all three channels.
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Scanning Electron Microscopy of eGFPPLY and AGeGFPPLY
Rod-like structures were previously observed on erythrocytes treated with 
AGeGFPPLY under examination by fluorescence microscopy. From the 
fluorescence microscopy work, it was not possible to ascertain whether the 
structures were a characteristic of the AG mutant of PLY or whether this was due 
to the addition of the eGFP domain. In order to determine this and to visualise the 
structures in more detail, human erythrocytes treated with PLY, AGPLY, eGFPPLY 
and AGeGFPPLY were examined by scanning electron microscopy (Figure 3.12).
Untreated erythrocytes had a bi-concave appearance with smooth membranes. 
Rod-like structures were observed on the surface of cells treated with AGPLY or 
AGeGFPPLY. Examination of micrographs revealed that some of the strands 
spanned between adjacent erythrocytes. The bi-concave shape of the erythrocytes 
appear to have been distorted but the overall size of the cells was similar to 
untreated erythrocytes. No such structures were observed on erythrocytes treated 
with PLY or eGFPPLY, although these ‘ghost erythrocyte’ cells differed from the 
untreated cell by losing their smooth bi-concave shape, having many folds in their 
membranes and being of larger size.
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Figure 3.12: Scanning electron micrographs 
of erythrocytes treated with:
A) 700nM eGFPPLY
B) 700nM AGeGFPPLY
C) 700nMPLY
D) 700nMA6PLY
E) No toxin.
Magnification x 8000.
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Detection of eGFPPLY and AGeGFPPLY binding to erythrocytes by flow 
cytometry
The potential use of eGFPPLY and AGeGFPPLY in a flow-cytometry based binding 
assay was investigated. Suspensions of human erythrocytes in PBS were treated 
with a range of concentrations of eGFPPLY, AGeGFPPLY or eGFP between 
0.7nM and 70nM and incubated for 10 minutes at 37°C. Cell fluorescence was 
measured by flow-cytometry using the FL-1 fluorescence channel (Ex 488nM, Em 
530nM).
Erythrocytes treated with eGFPPLY and AGeGFPPLY showed a concentration- 
dependent increase in fluorescence (Figure 3.13) indicating that both eGFPPLY 
and AGeGFPPLY bound to erythrocytes in a dose-dependent manner.
No increase in fluorescence of erythrocytes treated with equimolar concentrations 
of eGFP was observed, confirming that the binding was due to the toxin 
component of the fusion proteins and not a non-specific binding by the eGFP 
component.
The range of fluorescence intensities per detection event was greater for 
eGFPPLY than AGeGFPPLY, with the result that tighter peaks were obtained for 
each of the concentrations of AGeGFPPLY used than for eGFPPLY. The mean 
fluorescence at each concentration of toxin was greater for eGFPPLY than
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AGeGFPPLY, possibly as a result of absorption of part of the fluorescence signal 
by the haemoglobin within the unlysed cells.
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Figure 3.13: Histograms of fluorescence (Ex 488nM, Em 530nM) of cells treated with 
eGFPPLY (left), AGeGFPPLY (centre) and eGFP (right). Flow cytometry data was plotted 
using WinMDI (http://facs.scripps.edu).
Application of the eGFPPLY binding assay
The eGFPPLY flow cytometry binding assay was used to study the antagonistic 
effects of docosahexaenoic acid (DMA) on binding of eGFPPLY to neutrophils, an 
omega-3 poly-unsaturated fatty acid (FickI et al., 2005). This work was done in 
collaboration with Dr. R. Anderson’s group at the University of Pretoria, South 
Africa. The results showed that the addition of 5 or 10 pg/mL DMA reduced binding 
of eGFPPLY to the neutrophils by 18% (±5%) and 45% (±7%) respectively (Figure 
3.14). It is likely that this is, at least in part, responsible for the antagonism of PLY- 
induced IL-8 release, influx of extracellular calcium and activation of NFkB that 
was also observed in this work (FickI at a/., 2005).
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Figure 3.14: Effects of docosahexaenoic acid (DHA, 5 and 10 mg/ml) on the binding of the 
eGFPPLY protein (500 ng/ml) to neutrophils. The cells were treated with DHA for 5 min at 
37°C followed by addition of the construct and flow cytometric analysis of cell-associated 
toxin. The results shown are those of a single representative experiment with three in the 
series. Figure taken from FickI et al, 2005.
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Discussion
Rationale for using eGFP as a fusion partner
Green fluorescent protein is a protein produced by Aequorea aequoria, a 
bioluminescent jellyfish with a wide geographical distribution. During the course of 
studies of aequorin, the light-emitting protein of A. aequoria, Dr. Osamu 
Shimomura discovered that purified aequorin produced blue light, not the green- 
light produced by live specimens, and discovered a protein which exhibited green 
fluorescence under UV light (Chalfie & Kain, 1998; Shimomura et aL, 1962). This 
protein, later to be named green fluorescent protein (GPP), is excited by the blue 
luminescence of aequorin and emits the green light observed in specimens of A. 
aequoria (Morise etal., 1974).
Following cloning and expression of GPP (Chalfie et al., 1994; Prasher et al., 
1992), interest in GPP increased enormously and a number of modifications have 
subsequently been made to alter it’s excitation and emission spectra, stability and 
solubility. One such variant, enhanced green fluorescent protein (eGPP), is a 
widely used fusion partner for studies of protein expression and localisation.
A number of different versions of eGPP exist -  the variant used in this study is 
GPPmutI discovered by Cormack and Valdivia (Cormack et al., 1996) and is a 
mutant of GPP containing two mutations - P64L and S65T. These mutations 
increase the excitation at 488nM enabling compatibility with flow cytometers and 
microscopes that utilise argon lasers or FITC filter sets (Cormack et al., 1996). 
This version of eGPP was picked in preference to the variant of eGPP marketed by
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Clontech as this produces the same amino acid sequence but has been 
‘humanised’ by alteration of codon usage in the eGFP cds and this can lead to 
reduced expression in bacterial systems (Dr. Georgina Donovan, Clontech 
Laboratories Inc, personal communication). In fact the S65T mutant has been 
sho\A/n to fold as well as wild-type GPP in bacterial systems and 10-fold less in 
mammalian cells (Sacchetti etal., 2001).
Since eGPP is a protein, it offers the advantage that it can be linked to PLY by 
expression as a genetic fusion and does not require chemical conjugation as 
would be required for chemical fluorophores. This may allow the toxin to be 
expressed within S. pneumoniae, allowing study of toxin production and 
localisation within model infection systems.
eGPP is fluorescent without the addition of exogenous substrates or co-factors 
(Inouye & Tsuji, 1994) and therefore it facilitates easier experimental design than 
some other tracking systems where external substrates are required such as 
fluorescein arsenical hairpin (PIAsH) tags (Adams et a!., 2002; Griffin et al., 1998), 
which may also have problems of penetration of the substrate to the site of toxin 
localisation. Such systems would indicate toxin localisation only where that region 
is also accessible to the substrate.
Yet another alternative approach to tagging of pneumolysin would be to use 
immunohistochemistry (IPIC) whereby the toxin is recognised by specific anti-toxin 
antibodies and detected with a secondary fluorophore-labelled antibody. This 
technique requires fixation of the specimen which prevents real-time visualisation
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and raises the possibility that artefacts may be produced by fixation. It also 
requires that antibodies are able to penetrate to the site of localisation and this can 
be a limiting factor with this technique. However, anti-eGFP antibodies are widely 
available and very specific, so this technique could be used to confirm localisation 
findings. This may be especially useful in tissue samples where levels of auto­
fluorescence are often high and the use of a fluorophore with a different emission 
wavelength may be useful to demonstrate that the localisation pattern is a specific 
event.
One of the major disadvantages of eGFP is that it is a 27kDa p-barrei protein and 
so is much larger than most chemically-conjugated fluorophores or FIAsH tagging 
systems.
In design of fusion constructs, eGFP may be located as an N-terminal or C- 
terminal fusion, or fused between domains of the protein. From previous work, we 
know that the C-termlnus is critical to toxin activity as modification of C-termina! 
residues drastically reduces the binding activity of the toxin (Baba et al., 2001 ; 
Owen et al., 1994). Domain 4 of the protein is thought to be the only contiguous 
domain, and it is likely that addition of eGFP at this site would radically alter the 
activity of the protein. Based on the homology model for the structure of PLY 
(Rossjohn et al., 1998) and the model for the mode of action of the toxin as 
discussed in the introduction to this thesis, it is likely that addition of eGFP to the 
C-terminus or between domains 123 and domain 4 would hinder the binding of the 
protein to the cells or the conformational change required for pore formation. The 
N-terminus is thought to be much less critical for activity, although deletion of 21
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residues from the N-terminus of PLY has been shown to drastically reduce the 
activity of the toxin (Baba et al., 2001). It was therefore considered that tagging of 
the N-terminus represented the best chance for production of the fully active 
protein.
Comparison of the haemolytic and cytolytic properties of eGFP-tagged PLY 
to wiid-type toxins
In order to be confident that the eGFP-labelled toxin was a suitable substitute for 
the wild-type toxin in tracking experiments, it was necessary to demonstrate that 
the properties of the toxin were not affected by the addition of the eGFP-tag.
Comparison of the haemolytic activity of eGFPPLY to recombinant PLY revealed 
that it has a specific activity identical to pneumolysin when expressed in molar 
terms. This indicates that the addition of the 27 kDa eGFP moiety to the N- 
terminus of pneumolysin did not inhibit the haemolytic activity of the toxin.
The A6 mutant of eGFPPLY, A6eGFPPLY was not haemolytic, even at 
concentrations 100,000 times greater than that required for 100% erythrocyte lysis 
with PLY or eGFPPLY. This A6 mutation of PLY has previously been shown to be 
non-lytic (Kirkham et a!., 2006b) therefore as expected the A6eGFPPLY molecule 
has inherited this property from the parent toxin.
In addition to the haemolytic activity of pneumolysin, the molecule has been shown 
to cause cell toxicity to a number of nucleated cell types at sub-lytic concentrations 
(Braun et a!., 2002; Flirst et a!., 2002). Although the haemolytic activity of the
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eGFPPLY was identical to that of PLY, we were interested to determine whether 
the proteins shared the same cytotoxic potential. Cytotoxicity of the toxins to L929 
mouse fibroblasts was measured by MTT uptake assay. Both eGFPPLY and PLY 
were cytotoxic to L929 fibroblasts and both had similar cytotoxicity within the 
resolution provided by variability within the assay.
A6eGFPPLY, A6PLY and eGFP were not cytotoxic to L929 cells even at high 
concentrations. This confirms that A6eGFPPLY had the detoxified properties of 
A6PLY as described by Kirkham et al (Kirkham et al., 2006b).
Comparison of pore formation by tagged and untagged toxins by JEM
Transmission electron microscopy was used to compare the pores produced by 
eGFPPLY to those produced by PLY to determine whether there were any 
morphological differences. Pores produced by eGFPPLY were similar in 
appearance to those formed by PLY. There was no apparent difference in the size 
of complete pores, and arcs and double arcs were formed by both eGFPPLY and 
PLY. No pores were formed by A6eGFPPLY and this correlates with the lack of 
haemolytic activity previously measured.
No difference in the appearance of the pore structures, either in width of the ring or
diameter of the pores was observed and the presence of the eGFP moiety was
therefore not detected. It is possible that the eGFP domain of the fusion protein
sits vertically above domain 1 in the pore structure, preventing an increase in width
of the oligomeric ring. This could be further investigated using immunogold
labelling to identify the position of eGFP, although the required length of the
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antibody chain would distance the gold particle from the eGFP domain so that it 
would not be possible to determine exactly where the domain was situated. Exact 
localisation of the eGFP moiety could be determined by cryo-electron microscopy 
as previously used to visualise the pore structure of pneumolysin (Gilbert et a i, 
1999; Tilley efa/.,2005).
Visualisation of toxin binding by epifluorescence microscopy
Part of the aim of this project was to produce a tagged form of PLY that could be 
used to visualise the localisation of the toxin. Human erythrocytes treated with 
eGFPPLY and A6eGFPPLY were examined by fluorescence microscopy. Addition 
of the toxin highlighted the plasma membrane of the erythrocytes in green, 
indicating that both eGFPPLY and A6eGFPPLY bound to erythrocyte membranes. 
As expected from the haemolytic assay results previously discussed, eGFPPLY 
lysed human erythrocytes whereas A6eGFPPLY was non-lytic. Lysis was evident 
by the retention of the erythrocyte’s bi-concave shape and the leakage of 
haemoglobin upon cell lysis observed by brightfield microscopy (not shown).
The concentration of eGFPPLY used in this microscopy work was 700nM since
this gave a clear and high intensity signal, although binding of the toxin to cells
could be visualised at concentrations down to 700pM in preliminary microscopy
experiments. For wild-type pneumolysin, 700nM is equivalent to 37.1jig/mL. It is
difficult to estimate whether this concentration is physiologically relevant since the
total amount of PLY that is released by S. pneumoniae in vivo is not known.
Studies of cerebral spinal fluid CSF from patients with pneumococcal meningitis
showed that pneumolysin was present in the supernatant of CSF at concentrations
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ranging from 0.85ng/ml to 180ng/ml (Stringaris et al., 2002). However, since it is 
possible that much of the pneumolysin produced may have bound to host cells, 
this does not give an accurate figure for the amount of PLY produced, and 
therefore the amount of pneumolysin that should be added to cells in vitro to 
simulate physiological events.
A punctuate appearance was observed on erythrocytes treated with A6eGFPPLY 
and further examination revealed these to be fluorescent linear structures 
associated with the surface of the erythrocyte. Although it appeared that these 
structures occurred on and slightly protruded from the plasma membrane, the 
resolution of the fluorescence micrographs limited the amount of information that 
could be obtained about the nature and attachment of these structures.
Ohno-iwashita et al have used GFP-tagged domain 4 of perfringolysin as a probe 
for lipid rafts (Ohno-lwashita et al., 2004). Based on their previous work which 
demonstrated that a proteolyticaily-derived fragment of PFO selectively bound to 
lipid rafts, the group hope to use the probe to monitor lipid rafts in real-time and to
study lipid raft dynamics (Ohno-lwashita et a i, 2004).
Binding of eGFPPLY to cochlear hair cells of the rat
Epifluorescence microscopy of eGFPPLY was successfully used in collaboration 
with Dr. D. Dulon’s group at the University of Bordeaux to study the binding of
eGFPPLY to rat cochlear hair cells (Beurg et a i, 2005).
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This study provided further verification of the similarity between the properties of 
eGFPPLY and PLY as the toxicity of eGFPPLY in an organ of corti (OC) explant 
culture model and was found to be similar to that of PLY (Beurg et al., 2005). 
eGFPPLY binding to IHCs and OHCs could be visualised and a homogenous 
distribution on the plasma membrane was observed. The use of eGFPPLY 
allowed a comparison of the amount of toxin bound to cells and no difference was 
observed between the amount of eGFPPLY bound to freshly dissociated inner hair 
cells (IHCs) and outer hair cells (OHCs). However, in OC explant cultures, 
eGFPPLY appeared to preferentially label the hair bundles of both IHCs and 
OHCs with the staining being more pronounced in the OHCs.
Measurement of the fluorescence of cells recorded by epifluorescence microscopy 
showed that raised extracellular calcium reduced the binding of eGFPPLY to IHCs 
and OHCs (Figure 3.8). This was not a result of reduction of the fluorescence of 
eGFPPLY due to increased calcium concentration since these results were 
confirmed by examination of PLY binding in OC explant in the presence of 1.8mM 
or 10mM calcium using PLY-specific antibody (Beurg et al., 2005). The 
mechanism is unknown and it is also not known whether this is an effect restricted 
to rat cochlear hair cells. This effect appears to be different from that observed in 
studies on the effect of calcium on PLY-induced channel conductance (Korchev et 
ai, 1992; Korchev et a i, 1998), since CDC-induced conductance channels were 
inhibited by di-valent cations in cells pre-treated with toxin (Menestrina et a i, 1990; 
Olofsson et a i, 1993).
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Examination of toxin-treated erythrocytes by scanning electron microscopy
To gain a more detailed view of the structures that occurred on A6eGFPPLY- 
treated cells and to investigate whether they were also present in cells treated with 
A6PLY, toxin-treated erythrocytes were examined by scanning electron 
microscopy. In addition to eGFPPLY and AGeGFPPLY treated samples, PLY and 
A6PLY treated samples were included to determine whether the effect was related 
to the presence of the eGFP tag or if it was a property inherent to the A6 mutant of 
PLY.
Linear structures have previously been observed by TEM to be present on the 
surface of rat adipocytes treated with A6PLY (L. Kirkham, University of Glasgow, 
unpublished results). The SEM examination of erythrocytes treated with A6PLY 
and A6eGFPPLY confirmed that formation of these structures is a property of 
A6PLY, and is not an artefact from the addition of the eGFP moiety. The structures 
were very large and roughly circular in cross-section. It was not possible to 
determine their dimensions accurately by the SEM approach used. They appeared 
to be attached to the cell in a number of places along their length and were able to 
span between cells, and this may be involved in aggregation of erythrocytes when 
treated with A6PLY (Kirkham et a/., 2006b).
No structures were observed on the surface of erythrocytes treated with PLY and 
eGFPPLY but these cells lost the bi-concave shape of untreated cells and 
appeared to be slightly larger with crumpled membranes, most likely as a result of 
lysis of the cells.
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An assumption is being made that the structures are composed of oligomerised 
toxin and not composed of target cell materials re-arranged as a result of toxin 
activity. The fluorescent nature of the structures suggests that toxin must be 
present but this could also be verified using immuno-gold labelling for the toxin.
Further study of how these structures form and the arrangement of the toxin 
monomers on these large oligomeric structures may assist with studies of 
monomeric interactions of pneumolysin.
Confocal fluorescence microscopy of Detroit D562 cells treated with eGFP- 
tagged toxin
Laser scanning confocal electron microscopy was used to study the localisation of 
eGFPPLY and A6eGFPPLY on Detroit 562 cells, a human pharyngeal cell line 
(Peterson et al., 1971). eGFPPLY caused a marked rounding-up of cells and was 
largely bound to the plasma membrane of the host cell. A6eGFPPLY also bound to 
the plasma membrane but did not cause cells to round up -  the actin-cytoskeleton 
of these cells appeared identical to those of untreated or eGFP-treated cells.
The experiments discussed here have shown that eGFPPLY is a useful tool for 
monitoring the localisation of PLY by conventional fluorescence of laser scanning 
confocal fluorescence microscopy. It is likely that the same approach could be 
used to study other members of the CDC family or to compare any differences that 
may occur between the localisation of different members of the CDCs.
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It is possible that the toxin could also be used in more complex cell systems -  
through direct addition to tissues or application in vivo, followed by sectioning and 
study by fluorescence microscopy. Developing technologies such as two-photon 
microscopy and live imaging systems may allow real-time tracking of toxin 
localisation in vivo, and this could give new insights into how and where the toxin 
acts.
Expression of the eGFPPLY fusion protein in the host organism
It may be also possible to express the eGFPPLY fusion protein in S. pneumoniae 
to allow tracking of the toxin expressed in its host organism during a model 
infection. Comparison of the virulence of this new construct to wild type S. 
pneumoniae would give a clear indication whether any important properties of the 
toxin had been altered by the addition of the eGFP tag. Such a construct could be 
used in combination with the live imaging systems mentioned above or with 
sectioning and fluorescent microscopic examination of tissues.
As part of this project, we attempted to replace the PLY allele in S. pneumoniae 
D39 with eGFPPLY using Janus mutagenesis (Sung et a!., 2001). The D39-Janus 
construct was successfully generated by Dr. Gavin Paterson but introduction of 
eGFPPLY failed on repeated attempts, and sequencing and PGR analysis of 
resulting clones indicated that unexpected truncation events appeared to be 
occurring in the eGFPPLY gene upon incorporation into the S. pneumoniae 
genome.
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Another potential application of the eGFPPLY is use in determining whether PLY 
demonstrates cell tropism in complex cell systems. Fluorescence intensities of 
cells from complex mixtures of cells could be compared using fluorescence 
microscopy or FACS to compare the binding preference of PLY in heterogeneous 
cell systems. It is already recognised that different eukaryotic cell types can have 
different susceptibilities to pneumolysin (Hirst et a!., 2002). The FACS based 
binding assay or microscopic techniques described here could be used to 
investigate whether cell tropism occurs, perhaps as a result of different binding 
affinities or greater access to particular cell types.
Development of a fluorescence-based quantitative binding assay for PLY
A possible application of eGFPPLY and ABeGFPPLY is use in a FACS-based 
binding assay. Potential applications of this assay would include use as a 
quantitative PLY binding assay for cellular receptor studies, discovery of small 
molecule inhibitors and other inhibitors of PLY binding, or investigations of the 
cellular tropism of PLY. A FACS-based binding assay using eGFPPLY and 
A6eGFPPLY was therefore developed to demonstrate the level of sensitivity and 
dynamic range of detection of toxin binding by this method.
The fluorescence of eGFPPLY-treated or A6eGFPPLY-treated erythrocyte
membranes increased with the concentration of the toxin. Application of the same
molar concentrations of eGFP did not lead to an increase in fluorescence of
erythrocytes, confirming that the effect was not due to non-specific incorporation of
eGFP._________________________________________________________________
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The dynamic range of sensitivity was very good -  and binding of eGFPPLY could 
be quantified above background fluorescence over a range of at least 100-fold 
variation in toxin concentration from 0.7nM to 70nM.
The concentration of eGFPPLY used in this flow cytometry work ranged from 
0.7nM to 70nM. For wild-type pneumolysin, this range is equivalent to 37.11ng/mL 
to 3.71{ig/mL. As mentioned previously, pneumolysin has previously been found to 
be present in CSF from patients at concentrations ranging from 0.85ng/mL to 
180ng/mL (Stringaris et al., 2002), but due to the likelihood that much of the 
pneumolysin present would bind to host cells, it does not give guidance on how 
much pneumolysin is produced in vivo. Although the flow cytometry assay was not 
tested at the lower concentrations in this range, it was capable of detecting 
eGFPPLY binding to erythrocytes at concentrations equivalent to the higher PLY 
concentrations present in CSF. As shown in the haemolytic assays earlier in this 
section, PLY and eGFPPLY cause 100% lysis at 0.7nM concentration, therefore it 
is unknown whether this technique can detect binding at sub-lytic concentrations.
A broader range of fluorescence intensity values was obtained for each 
concentration of eGFPPLY than AGeGFPPLY resulting in different profiles on the 
flow cytometry histograms. The cause of this is unknown but it may result from the 
lytic effect of eGFPPLY. The mean fluorescence at each concentration of toxin 
was greater for eGFPPLY than AGeGFPPLY. It is possible that this could also 
reflect cell lysis by eGFPPLY. A portion of the fluorescence may be absorbed by 
the haemoglobin remaining in the AGeGFPPLY-treated erythrocytes, or the
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fluorescence of the membrane at the side distal to the fluorescence detector may 
not be read, resulting in lower fluorescence readings.
It was therefore demonstrated that toxin binding can be easily quantified using 
eGFPPLY and AGeGFPPLY in a flow cytometry-based assay. It is hoped that this 
will be useful in further research and characterisation of toxin mutants where it 
offers an alternative to dot-blot or western blot techniques that are currently 
commonly used to monitor CDC binding to target cells (Nato et al., 1991; Owen et 
al., 1994). A different flow cytometry-based binding assay based on cross-linking a 
chemical fluorophore to the toxin has been developed (Giddings et a i, 2003). The 
flow cytometry based technique offers good sensitivity and it is more rapid than 
immunoblotting, and it could therefore allow binding determination where a large 
number of samples are required to be measured, such as in high throughput 
screening.
The flow cytometry technique is also able to determine the quantity of toxin bound 
to single cells rather than a population as a whole. The quantity of PLY per cell 
can be plotted against specific cell markers to ascertain whether there is a greater 
affinity for particular cells in a mixture of cell types. Fluorescence-activated cell 
sorting (FACS) could be used to select cells within a population that have been 
successfully transformed or altered to affect toxin binding activity.
The eGFPPLY binding assay was used successfully by our collaborators at the 
University of Pretoria, South Africa to measure the antagonistic effect of 
docosahexaenoic acid (DMA) on binding of PLY to human neutrophils (FickI et al..
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2005). The presence of DHA at concentrations of 5 or 10|ag/ml reduced the 
binding of eGFPPLY, and this effect was also observed where neutrophils were 
pre-incubated with DHA and then subsequently washed. It was therefore 
suggested that this is a cell-directed mechanism of action rather than a direct 
inactivation of the toxin (FickI et al., 2005). It is likely that the interference to PLY 
binding by DHA is in part responsible for the reduction on PLY-mediated calcium 
influx, but there may be other factors involved since Ca-infiux was reduced by 86% 
but binding and haemolysis were reduced by only 18% and 21.8% respectively 
upon addition of 5jig/mL DHA.
Further work
Although eGFPPLY has been shown to be very similar to PLY in terms of 
haemolytic activity and pore formation, it has not been tested to determine whether 
it is capable of all of the same biological activities of the unlabelled toxin, such as 
induction of cytokine production, complement activation or activation pf the p38 
signalling pathway. If would be useful and interesting to determine whether the 
addition of the eGFP tag has altered the activity of pneumolysin in any way by 
running as many such assays as possible.
Similarly, although it has been determined that eGFPPLY can be visualised when 
bound to cells, no experiments have been performed to ensure that the 
localisation of the tagged toxin is the same as the unlabelled toxin. This would 
require the use of immunohistochemistry but would be another useful step in 
validating eGFPPLY as a tool.
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Conclusions
• The eGFP-tagged toxins produced, eGFPPLY and AGeGFPPLY, are not 
altered in haemolytic and cytotoxic activities relative to their untagged 
parent toxins.
• There are no visible differences in the pores produced by eGFPPLY from 
those produced by PLY.
• eGFPPLY can be used in a sensitive and quantitative binding assay using 
flow-cytometry.
• eGFPPLY and AGeGFPPLY binding and localisation on target cells can be 
monitored by fluorescence and laser scanning confocal fluorescence 
microscopy.
• AG PLY and AGeGFPPLY produce large rod-like structures on erythrocyte 
membranes that are capable of spanning between cells.
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Chapter 4: Intermedilysin -  a rogue 
member of the CDC family
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Summary
intermedilysin (ILY) is a member of the CDCs produced by S. intermedius. It is 
unique within the group in that it exhibits human-specific haemolysis, with 1% of 
activity remaining on erythrocytes of chimpanzees and cynomolgus monkeys but 
no activity on erythrocytes from all other species tested (Nagamune et a i, 1996). 
Initial studies suggested that this is due to binding of a different cellular receptor to 
other toxins of the family and that this receptor was a protein (Nagamune et al, 
1996).
As a prelude to experiments to determine the cellular receptor for ILY, eGFP- 
tagged forms of ILY and A6ILY - eGFPslLY, and AGeGFPslLY - were produced to 
allow tracking of the localisation of ILY and for use in development of a 
quantitative binding assay. It was confirmed that these proteins could be easily 
visualised by fluorescence microscopy and that binding could be detected by flow 
cytometry.
This FACS-based binding assay was intended for use to screen mouse tissue- 
culture cells transformed with a human-cDNA library to identify the human cell- 
specific receptor for intermedilysin. With the same aim, a two-hybrid screen was 
also used to identify proteins from a human brain cDNA library that were capable 
of interaction with ILY. No likely receptor candidates were identified. During the 
course of this work, the cellular receptor for ILY was identified as CD59, therefore 
the FACS based screen was not attempted and candidate protein.protein 
interactions were not further investigated.
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In order to determine which region is responsible for the human specificity of 
intermedilysin, a bank of chimeras between ILY and PLY was created. The 
chimeric toxins were expressed and purified and the specificity of the mutants was 
determined by haemolytic assay on human and rabbit erythrocytes. It was found 
that the specificity of the chimeric toxin was determined by the origin of the C- 
terminal 53/56 residues, indicating that this region of domain 4 is responsible for 
the human specificity of intermedilysin.
To further resolve the region involved in human specificity or cholesterol-binding, a 
series of small substitution mutants was created. These revealed that promiscuous 
cell binding activity of the other CDCs was conferred by residues in the 
undecapeptide loop as this property could be transferred to ILY by introduction of 
the typical undecapeptide sequence.
Surface-plasmon resonance analysis of substitutions of ILY and PLY was used to 
detect any mutants possessing altered binding affinity. However, problems with 
aggregation of purified proteins prevented a valid comparison from being made.
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Results
Construction of pET33bmlLY
A plasmid containing the coding sequence for mature intermedilysin (mILY) was 
constructed in pETSSb to allow high level expression with the addition of a six- 
histidine tag to facilitate protein purification. mILY is composed of residues E34- 
D532 of ILY such that the putative signal sequence is removed. The pET33bmlLY 
plasmid was transformed into BL21(DE3) E. co//for protein expression.
Initial cloning was confirmed by PGR using gene specific primers and primers that 
anneal to the T7 promoter and T7 terminator sequences flanking the multiple 
cloning site of pET33b.
The construction of all plasmids was checked by DNA sequencing. The sequence 
was confirmed to be as expected with no mutations present. Plasmid maps of 
pET33bEGFPPLY and pET33bDel6EGFPPLY plasmids are shown in Figure 3.1. 
Constructs were transformed into BL21(DE3) E. co//for protein expression.
Construction of vectors for expression of chimeric toxins between PLY and 
ILY
Plasmids were constructed containing the coding sequences of eight chimeric 
toxins between PLY and ILY. The individual components were first amplified using 
specific primers as described in the materials and methods section then these
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were joined in an overlap PCR reaction to produce full-length toxin chimeras. 
These DNA fragments were cloned into pET33b(+) and the sequence of the 
resulting clones was confirmed by DNA sequencing. All plasmids were 
transformed into BL21(DE3) E. co//for protein expression.
Table 4.1: Crossover positions of PLY/ILY chimeric toxins
Site DNA sequence position
Amino acid sequence 
position
PLY Mature ILY PLY Mature ILY
1 441 516 147 172
2 759 834 253 276
3 993 1068 331 356
4 1251 1326 417 442
NB Residues are the last residue before the crossover position.
Site 1 Site 2 Sites Site 4
Figure 4,1: Schematic diagram of chimeric proteins between PLY and ILY
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Figure 4.2: Alignment of PLY and mILY amino acid sequences indicating conserved regions 
selected as cross over junctions in ILY/PLY chimeras (labelled 1, 2, 3 & 4). Sequence 
alignment generated using DNAstar software.
Expression and purification of pneumolysin, intermedilysin and chimeric 
toxins
Recombinant pneumolysin, intermedilysin and chimeric toxins were initially 
expressed and purified by nickel-affinity chromatography using the Swell-Gel tab 
system. Purified protein preparations were assessed by SDS-PAGE to be of 
greater than 90% purity.
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Haemolytic activities of chimeric toxins
The haemolytic activities of chimeras A-H and PLY and mILY were determined by 
semi-quantitative haemolysis assay (Table 4.2). Pneumolysin, chimera D, chimera 
F and chimera H were lytic to both horse and human erythrocytes whereas ILY, 
chimera C, chimera E and chimera G were lytic to human but not horse 
erythrocytes. Chimeras A and B were not lytic on either human or horse 
erythrocytes, and chimera B caused aggregation of both human and horse 
erythrocytes.
Table 4.2: Haemolytic activity of PLY, ILY and chimeric 
toxins A-H by semi-quantitative haemolysis assay.
Human Horse
PLY + +
ILY + -
A - -
B - (Aggregation) - (Aggregation)
C + -
D + +
E + -
F + +
G + -
H + +
Haemolytic activities of chimeric toxins G and H
In order to allow full characterisation and comparison of their haemolytic activities, 
PLY, mILY, chimera G and chimera H were purified by Nickel-affinity 
chromatography. Protein preparations were estimated by Coomassie-blue stained 
SDS-PAGE to be of greater than 98% purity.
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Haemolysis assays were performed using ILY, PLY, chimera G and chimera H on 
human and rabbit erythrocytes. Specific activities of the toxins were calculated and 
are shown in Table 4.3. All toxins were haemolytic on human erythrocytes, 
although the haemolytic activity of chimera G was very low at 1.785x10^ HU mg'V 
The activity of chimera H was also lower than the activities of either of the two 
parent toxins, PLY and ILY. PLY and chimera H were both haemolytic to rabbit 
erythrocytes whereas ILY and chimera G were non-lytic (Figure 4.3).
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Figure 4.3: Haemolysis assays of PLY, ILY, chimera G and chimera H on A) Human 
erythrocytes and B) Rabbit Erythrocytes.
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Table 4.3: Specific activities of PLY, ILY, chimera G and chimera H on human 
or horse erythrocytes
Human Horse
PLY 9,09x10'’ HU mg 3.87x10“ HU mg-’
ILY 2.02x10^ HU mg ’ Non-lytic
Chimera G 1.785x1 o'’ HU m g’’ Non-lytic
Chimera H 3.616x10"HU mg-’ 1.051x10" HU mg ’
Inhibition of action of chimeras G and H by ghost erythrocytes
In order to determine whether the species-specific haemolytic activities of 
chimeras G and H were due to binding specificities, the inhibition of the action of 
these toxins on human erythrocytes by human or rabbit erythrocyte ghosts was 
determined (Figure 4.4).
Inhibition of Activity of Chimeras G and H by 
Erythrocyte Ghosts
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Figure 4.4: Inhibition of the haemolytic activity of chimeras G and H by human or rabbit 
erythrocyte ghosts
Chimera H was absorbed by both human and rabbit erythrocyte ghosts indicating 
that it was capable of binding to either of the erythrocyte species. Chimera G was
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absorbed by human but not rabbit ghost erythrocytes and therefore demonstrated 
a human-specific binding activity.
Effect of trypsinisation of erythrocytes on susceptibility to PLY and ILY 
mediated lysis.
Nagamune et al, 1996 showed that treatment of erythrocytes with trypsin reduced 
their susceptibility to lysis by intermedilysin. This effect was confirmed and further 
investigated by determining the effect of the trypsin treatment time on lysis by 
intermedilysin. The effect on lysis by pneumolysin was also investigated.
Trypsin treatment of human erythrocytes was found to reduce their susceptibility to 
lysis by ILY (Figure 4.5). The effect of ILY was progressively reduced as trypsin 
treatment time was increased.
The effect of trypsin treatment on susceptibility of human erythrocytes to 
pneumolysin showed the opposite effect (Figure 4.5) - trypsinisation of 
erythrocytes decreased the concentration of PLY required for haemolysis. The 
maximum effect was reached within 1 hour of trypsin treatment.
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Effect of trypsinisation of erythrocytes on lysis by mILY
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Figure 4.5: The effect of trypsinisation of human erythrocytes on lysis by mILY and PLY
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Construction of pDest32-D41LY Yeast-2-hybrid bait vector
A yeast-2-hybrid assay was performed to screen for proteins that are able to 
interact with ILY and therefore may be candidate receptors for ILY. Since this 
assay requires the expression of the toxin ligand in the yeast cytoplasm, domain 4 
of ILY was chosen as the ‘bait’ fusion partner to the Gai4-DNA-binding domain as 
this is capable of specific binding to human cells (Nagamune et al., 2004a) but is 
much smaller than the whole toxin molecule. A human brain cDNA library was 
selected for the ‘prey’ as it has previously been shown that brain and liver cells are 
highly sensitive to ILY (Nagamune et a i, 1996).
The D4ILY coding sequence was amplified from pQE9mlLY using primers that 
added Gateway Att-BI and Att-B2 sites to the ends of the coding sequence. A 
one-tube gateway cloning reaction was used to insert the D4ILY PCR product into 
pDEST32 (the DNA binding domain fusion vector) via pDONR221.
One clone was selected and the full sequence between the gateway flanking 
sequences was confirmed to be correct by DNA sequencing.
Yeast-2-hybrid screen with pDest32-D4ILY against human brain oDNA library
A yeast-2-hybrid screen was performed using a bait plasmid (pDest32-D4ILY) 
containing D4ILY fused to the DNA binding domain of Gal4 against a human foetal 
brain cDNA library.
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A sequential transformation method was used as this is reported to give greater 
library coverage than combined transformation. Firstly, the pDest32-D4ILY 
plasmid was transformed into MAV203 yeast and presence of the plasmid was 
confirmed by PCR. The resulting MAV203 yeast clone containing the pDest32- 
D4ILY bait vector was then transformed with a human brain cDNA Gal4-AD-fusion 
library. Cells were plated onto SC~leu-trp-his+25mM 3AT and SC-leu-trp plates 
and incubated at 28°C for 3 days.
To ensure full coverage of the cDNA library where all cDNAs present in the library 
have been screened, it is necessary to ensure that the number of transformants is 
several fold greater than the likely maximum number of cDNAs present. Invitrogen 
suggest that greater than 1x10® transformants must be screened to ensure 
adequate library coverage. pDest32 codes for leucine biosynthesis and pEXP- 
AD502 codes for tryptophan biosynthesis.
Since MAV203 yeast are auxotrophic for both of these amino acids, colonies will 
only grow if both plasmids are present. The colonies on the SC-leu-trp plates were 
counted and multiplied by the dilution factor to give the total number of 
transformants screened in the assay. However, since uracil and histidine are 
provided in the medium, no protein:protein interaction is required. In this screen, it 
was calculated that greater than 2.4x10® transformants were screened.
29 colonies were obtained from the primary screen and these were further tested 
for activation of the remaining two reporter genes. Confirmatory assays were 
performed for all of the positive colonies from the D4ILY screen (1-29) and
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controls A-E on YPAD (with membrane for B-gal assay), SC-leu-trp-ura, SC-leu- 
trp-his(+25mM 3AT), and SC-leu-trp+2mM 5F0A. Five control strains of known 
protein:protein interaction strength were also included to act as reference strains 
for interpretation and ensure that the replica cleaning step was sufficiently 
thorough to eliminate false positives. Plates were replica cleaned as described in 
the protocol (Invitrogen Proquest Manual).
After 24 hours, the membrane was removed from the YPAD plates and an X-gal 
assay performed. Results were monitored after 1 hour and after 24 hours.
The results of the confirmatory assays are shown in Table 4.4.
The inserts from clones 1-29 were amplified by PCR using primers 43L and 43M 
which flank the MCS of pDest32. PCR products were run on an agarose gel, gel 
purified and DNA sequenced using primer 43L. For those clones where a product 
was not obtained by PCR, plasmids were purified using the Qia-prep plasmid 
miniprep kit and transformed into E. coli. Plasmids were then miniprepped from 
each E. coli clone and the insert was DNA sequenced using primer 43L which 
primes upstream of the insert in the flanking region of the MCS of pDest32.
Returned DNA sequences were compared against the human genome sequence 
using stand-alone NCBI blast v 2.2.5 (Altschul et a!., 1990) to determine their 
identity. The top hits for each clone for which sequence data was obtained are 
shown in Table 4.5. A number of the clones contained only very short coding 
sequences in the multiple cloning site of the prey plasmid. These results could not
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give reliable results in the BLAST search due to their short length, therefore these 
results are not shown in Table 4.5.
Table 4.4: Confirmatory assays of yeast-2-hybrid clones
D41LY Y2H 
clone # -URA -His P-gal +5F0A
1 + ++ ++ 4—h
2 ++ ++ H—H
3 + + H—h 4—h + +
4 + ++ + 4—h
5 ++ + + 4-4- ++
6 - + + 4-4-
7 ++ ++ 4-4- "
8 - ++ 4- + 4-
9 ++ + +4-
10 - ++ 4- -j-4-
11 weak (+) + + 4-4- 4-4-
12 - + + 4“
13 + + + + + + 4-4-
14 + + + + + + 4-4-
15 + + + + 4-4- 4-4-
16 - + 4-4- 4-4-
17 + + + + 4 - 4 - 4” f-
18 + + ++ 4—H 4-4-
19 ++ + + 4—[- -
20 - + + + 4- 4-4-
21 + + + + 4-4- +(weak)
22 - + ++ + +
23 + + + + 4—h 4-4"
24 + + + + 4—h ++
25 ++ ++ 4-4- weak
26 - (very weak) ++ 4—H 4-4-
27 -  (very weak) + + 4- -f-4-
28 -  (very weak) ++ + + +"4-
29 -  (very weak) ++ 4- + +
Control A - - - +/- inconsistent
Control B - + - -/weak
Control C ++ ++ + ■*
Control D ++ ++ 4-4-
Control E ++ ++ 4-4- -
A number of clones yielded two PCR products, despite the clones previously being 
streaked to single colonies. It is likely that these clones took up two plasmids 
during the transformation process. As a result, where two plasmids were present
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in a strain, only one may have interacted with the bait protein. For each of the 
positive clones, the interaction must be re-confirmed by purification of the plasmids 
and repeat of the yeast-2-hybrid assay.
Table 4.5: Top blast hits of proteins interacting with D4ILY in a yeast-2-hybrld screen 
Clone Blast Hits
1 Homo sapiens BCL2/adenovirus E1B interacting protein 3 gl45709255
2 Homo sapiens myosin X (MYO10), mRNA 211/216
3 Homo sapiens kinesin family member 17, mRNA 183/191
3 Homo sapiens glucosidase, beta (bile acid) 1 (GBA2), mRNA 153/153 & Homo sapiens
mitochondrial RNA-processing endoribonuclease RNA (RMRP) 153/153
4 Homo sapiens LYST-interacting protein L1P8, mRNA 332/339
5 Homo sapiens heterogeneous nuclear riboprotein G mRNA 348/350 & Homo sapiens RNA
binding motif protein, X-linked, mRNA 348/350 & Homo sapiens kynurenine
aminotransferase III, mRNA 338/350
6  Homo sapiens EGF-containing fibulin-like extracellular matrix 444/450
6  Homo sapiens EGF-containing fibulin-like extracellular matrix 305/319 & Human extracellular
protein (S I-5) mRNA 249/260
6  Homo sapiens regulatory element binding transcripion factor 333/344
7 Homo sapiens kinesin family member 17 (KIF17) 497/508
9 Homo sapiens pleckstrin homology-like domain, family B, member 1 511/532 & Homo
sapiens DLNB07 mRNA, complete cds 511/532
9 Homo sapiens kinesin family member 17, mRNA 453/463
10 Homo sapiens transcription factor CP2 454/470
11 PREDICTED: Homosapiens Zinc finger protein 592 459/471 & Homo sapiens mRNA for
KIAA0211 gene 459/471
13 Homo sapiens glutathione S-transferase A4 (GSTA4), mRNA 453/458
14 Homo sapiens kinesin family member 17 (K1F17) 252/255
15 Homo sapiens kinesin family member 17 (KIF17) 334/342
23 H. sapiens actinin, alpha 1 mRNA 180/191
28 Homo sapiens kinesin family member 17, mRNA 320/322
Construction of eGFPmlLY, eGFPslLY and A6eGFPslLY expression vectors 
pET33bEGFPmlLY
An expression construct containing the eGFP coding sequence fused to the N- 
terminus of mature ILY was constructed. The eGFP and mlLY coding sequences 
were amplified by PCR and joined by overlap PGR. The resulting PCR product 
was cloned into pET33b. The ligation mixture was transformed into TOP10 E. coli
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and the plasmid was purified and checked by DNA sequencing. The sequence 
was confirmed to be correct over the complete coding sequence for eGFPmlLY.
Expression and purification of eGFPmlLY
eGFPmlLY was expressed and purified by nickel-affinity chromatography. The 
purified protein was run on an SDS-PAGE gel and stained with Coomassie blue 
stain. A single protein band corresponding to approximately 35kDa was observed 
(Figure 4.6).
1 27  lane 1 Kaleidoscope marker
lane 2 blank
i  lane 3 eGFPmlLY
kDa (approx 35kDa)
40
Figure 4.6; Coomassie-stained SDS- 
32 PAGE gel of purified protein from
eGFPmlLY purification.
It was therefore likely that either premature transcriptional termination or 
proteolytic cleavage of the whole protein had occurred. A qualitative haemolytic 
assay was performed using the crude lysate on human and horse blood and the 
lysate was found to cause lysis only on human erythrocytes. Since a sufficient 
quantity of the mILY component was present to cause human-specific lysis, the 
truncated protein that was purified is most likely a result of proteolysis of 
eGFPmlLY. From the size of the remaining fragment and the production of a 
fluorescent green protein and active mILY toxin, cleavage is most likely to have 
occurred at or around the junction between eGFP and mILY.
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Construction of pET33bEGFPsfLY
Owing to difficulties experienced with cleavage or instability of the eGFPmlLY 
fusion protein, another fusion construct was made with a shortening of mILY at the 
N-terminus. Whereas mlLY codes for residues E34-D532 of full-length ILY, short 
intermedilysin (slLY) codes for residues A60-D532 of ILY.
The eGFP cds was amplified from pET33bEGFPPLY by PCR and the siLY 
fragment was amplified from pET33blLY. PCR products were gel purified and an 
overlap PCR reaction was performed to join the two products. The resulting PCR 
product was digested with Spel and Sad, ligated into Nhel/SacI cut pET33b and 
the ligation reaction was transformed into TOP10 E. coli. The sequence of the 
insert was checked by DNA sequencing and no errors were found.
Construction of pET33bDel6EGFPsILY
A deletion mutation, termed A6mlLY (deletion of residues equivalent to A204 and 
R205 of ILY precursor) which is based on the A6PLY deletion mutation previously 
described (Kirkham et al., 2006b), was introduced to pET33bEGFPslLY by SDM 
(Stratagene Quikchange XL SDM kit). Construction of was checked by DNA 
sequencing.
Plasmid maps of pET33bEGFPslLY and pET33bDel6EGFPslLY are shown in 
Figure 4.7.
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Figure 4.7:Plasmid maps of pET33bEGFPslLY and pET33bDel6EGFPslLY 
Expression of eGFPslLY and AGeGFPslLY
Recombinant eGFPslLY and AGeGFPslLY were expressed and purified by nickel- 
affinity chromatography followed by anion exchange chromatography. Purified 
proteins were dialysed into PBS and Tris buffer as Tris-buffered eGFPslLY was 
required for collaborative work with UWCM Cardiff. Proteins were estimated by 
Coomassie-blue stained SDS-PAGE to be greater than 98% pure (Figure 4.8).
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Figure 4.8: Coomassie-stained SDS-PAGE gel of eGFPslLY and AGeGFPslLY in PBS or Tris 
buffer.
The haemolytic activities of mILY, eGFPslLY and AGeGFPslLY were determined 
to investigate the effect of the addition of the eGFP tag (Figure 4.9). The specific 
activity of eGFPslLY (2.85x10^ FlU/M) in this assay was calculated to be slightly 
greater than that of the wild-type toxin, mILY (1.53x10^ HU/M). AGeGFPslLY was 
not haemolytic at concentrations up to 0.75mM.
mILY
eGFPslLY
AGeGFPslLY
I I I
10 ^  10-® 10 ® 10^  10 ® 10-2 10 ^ 10°  10^
Toxin Concentration (mM)
Figure 4.9: Haemolytic activities of mILY, eGFPslLY and AGeGFPslLY
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Laser scanning confocai fluorescence microscopy of eGFPslLY and 
AGeGFPslLY binding to human and horse erythrocytes
Laser scanning confocai fluorescence microscopy was used to visualise the 
binding of eGFPslLY and AGeGFPslLY to erythrocytes. Human or horse 
erythrocytes were treated with 700nM eGFPslLY, AGeGFPslLY or eGFP and 
viewed by confocai fluorescence microscopy to determine whether the tagged 
toxins retained human cell binding specificities and could be used to detect cell 
binding by fluorescence microscopy.
eGFPslLY and AGeGFPPLY both bound to the plasma membranes of human 
erythrocytes but neither bound to horse erythrocytes. eGFP alone did not bind to 
the plasma membrane of either human or horse erythrocytes.
eGFPslLY-treated human erythrocytes appeared very crumpled and folded. 
Membranes treated with AGeGFPslLY retained a smoother membrane shape and 
overall rounded appearance, although they appeared to be distorted from the 
usual bi-concave shape of erythrocytes.
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Figure 4,10: Laser scanning confocai microscopy of human and horse erythrocytes treated 
with eGFPslLY, AGeGFPslLY or eGFP. Magnification x63 under oil immersion. Green channel 
(Ex. 488nm Em. BP 505-530nm) shows localisation of eGFP. Laser intensity and amplifier 
gain settings were the same for all images captured.
A) Human erythrocytes + 700nM eGFPslLY
B) Horse erythrocytes + 700nM eGFPslLY
C) Human erythrocytes + 700nM AGeGFPslLY
D) Horse erythrocytes + 700nM AGeGFPslLY
E) Human erythrocytes + 700nM eGFP
F) Horse erythrocytes + 700nM eGFP
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Detection of eGFPslLY and AGeGFPslLY binding to erythrocytes and U937 
cells by flow cytometry
As a prelude to experiments to determine the cellular receptor of mILY, as alluded 
to further in the discussion section, a FACS-based cell binding assay was 
developed.
Human or horse erythrocytes were treated with eGFPslLY, AGeGFPslLY, eGFP or 
mILY at concentrations of 0.7nM, 7nM and 70nM. Following incubation, the 
fluorescence of the erythrocytes was measured by flow cytometry using a 
FACScalibur flow cytometer on the FL-1 channel (Ex 488nM, Em 530nM) (Figure 
4.11).
Human erythrocytes treated with eGFPslLY and AGeGFPslLY showed an increase 
in fluorescence. The fluorescence increased with the concentration of toxin used in 
the assay. eGFPslLY and AGeGFPslLY did not bind to horse erythrocytes as no 
increase in fluorescence was observed upon addition of the toxins to horse 
erythrocytes.
The range of fluorescence values for erythrocytes treated with eGFPslLY was 
greater than those for AGeGFPslLY, resulting in a broader histogram profile. A 
similar profile was previously observed for eGFPPLY and AGeGFPPLY (chapter 3) 
and this effect may be a result of lysis of the erythrocytes by eGFPslLY.
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Figure 4.11: Flow cytometry analysis of eGFPslLY binding to human and horse 
erythrocytes. Histograms show fluorescence of human and horse erythrocyte membranes 
detected by flow cytometry FL-1 channel, (Excitation 488nM, Emission 530nM). A: eGFPslLY 
on human erythrocytes, B: AGeGFPslLY on human erythrocytes, C: eGFP on human 
erythrocytes, D: eGFPslLY on horse erythrocytes. E: AGeGFPslLY on horse erythrocytes F: 
eGFP on horse erythrocytes, G: mILY on human erythrocytes, H: mILY on horse 
erythrocytes. I: Untreated human erythrocytes, J: Untreated horse erythrocytes. 
Toxin/protein concentration is denoted by the colour of the histogram line; Green -  70nM, 
Red -  7nM, Blue - 0.7nM, Black - No toxin._____________________________________________
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Construction of vectors for expression of mutants with small substitutions 
within domain 4 of PLY and ILY
To further resolve the region of the GDC responsible for determining promiscuity 
or human-specificlty, a series of mutants of domain 4 within PLY or ILY were 
constructed. These mutations were designed to swap small regions of sequence 
between PLY and ILY. Mutations were introduced either by SDM or PCR-based 
mutagenesis according to the mutagenesis strategy indicated in Table 4.6. A 
diagram indicating the location of the mutations relative to the primary sequences 
of ILY and PLY is shown in Figure 4.12. Primers used are also indicated in Table 
4.6.
Table 4.6: Design and creation of small substitution mutants of PLY and ILY
Mutation Primers Mutagenesisstrategy
Plasmid
backbone
ILY Sub 1 
ILY Sub 2 
ILY Sub 3 
ILY Sub 4 
ILY Sub 5 
ILY Sub 6 
ILY Sub 7
ILY Sub 8
ILY Sub 9
ILY Sub 10
ILY Sub 11 
ILY Sub 12
ILY Sub 13
ILY Sub 14 
ILY Sub 15
PLY Sub 8
PLY Sub 9
PLY Sub 10
mlLYT481l
mILY L464T, 1465V
mILY I447L, R448S
mILY S467E, N469T
mILY P475R, Q476K, N478T
mlLY H487Y
mILY F490V
mILY V451I, L452R, G453E,
A454G
mlLY P461W
mlLY V495E, K496N, AN498, 
AT499, AD500 
mILY R400Q 
mILY Y404T
mILY I418L R419T S420P 
R421K
mILY N429D R430L 
mILY F440L
PLY 1425V. R626L, E427G,
C428A
PLY W433P
PLY E469V, N470K, (ins)472N, 
(ins)473T, (ins)474D_________
35K + 35S SDM pQE9mlLY
35L + 350 SDM pQEQmlLY
35M +35N SDM pQE9mlLY
35P + 35Q SDM pQE9mILY
35R + 35T SDM pQE9mlLY
35U + 35V SDM pQE9mlLY
35W + 35X SDM pQE9mlLY
330 + 33D SDM pET33bmlLY
32Y + 32Z SDM pET33bmlLY
26W + 32U PCR mutagenesis pET33bmlLY
460 + 46R SDM pQE9mlLY
46S + 46T SDM pQE9mlLY
46U + 46 V SDM pQE9mlLY
46W + 46X SDM pQE9mlLY
46Y + 46Z SDM pQE9mlLY
33A + 33B SDM pET33bPLY
32W + 32X SDM pET33bPLY
9Y + 32V PCR mutagenesis pET33bPLY
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Figure 4.12: Diagram showing location of mutations of ILY and PLY present in ILY and PLY 
substitution mutants
Expression of toxin mutants with small substitutions within domain 4 of PLY 
and ILY
All small substitution mutants, in addition to ILY and PLY were purified by nickel- 
affinity chromatography. All proteins were run on an SDS-PAGE gel, Coomassie- 
stained and protein purities estimated to be greater than 95%.
Haemolytic activity of toxin mutants with small substitutions within domain 4 
of PLY and ILY
Haemolysis assays of all small substitution mutants, in addition to ILY and PLY,
were performed on human erythrocytes to determine whether any of the mutants
had reduced haemolytic activity (Figure 4.13). Most of the toxin mutants had
similar activities to ILY and PLY, although ILY substitution 10 had the highest
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recorded activity. Much reduced specific haemolytic activities were obtained for 
ILY sub 8, ILY sub 13, PLY sub 8 and PLY sub 9 (Figure 4.13).
Figure 4.13: Haemolytic activity and calculates specific activities of ILY substitutions 1-15 
and PLY substitutions 8-10 on human erythrocytes
Haemolytic activities of ILY substitutions 1-15 and PLY 8-10
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Specific haemolytic activities of ILY and PLY substitution mutants
Toxin
Specific
activity
(HU/mg)
PLY 3.94 xIO^
ILY 2.13x10"'
ILY1 5.82 xIO"'
ILY2 1.13x10®
ILY3 4.17 xIO"'
1LY4 4.56 x10^
ILY5 4.60 xIO"'
ILY6 5.06 xIO"'
ILY7 2.79 xIO"'
ILY8 2.62 xIO®
ILY9 2.11 xIO"*
ILY10 2.60x10®
PLY8 2.39x10®
PLY9 6.74 xIO^
PLY10 5.63 xIO"'
ILY11 1.05 x10®
ILY12 5.77 xIO"'
ILY13 1.66 xIO®
ILY14 4.23 xIO"'
ILY15 1.36 xIO®
Specific activités of ILY and PLY substitution mutants
a  1 OOE+04 -i
■ 1 OOE+03
Substltution mutant
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Measurement of CD59 binding activity by Surface Pfasmon Resonance
Measurement of binding of the ILY and PLY substitution mutants was examined by 
surface plasmon resonance (SPR) to determine whether any of the mutants 
showed altered binding capability which might indicate that the mutated residues 
are important in binding to it’s cellular receptor, human CD59 (Giddings et al, 
2004). This work was a collaboration with Prof Paul Morgan and Dr Tim Hughes 
from UWCM, Cardiff and the binding assay was performed by Dr Tim Hughes.
The binding of each of the ILY substitution mutants to thiol-coupled CD59 was 
assessed by surface plasmon resonance using a Biacore 3000. 40pl of each of the 
substitution mutants, as well as ILY and PLY were passed through the CM-5 thiol 
coupled CD59 sensor chip at 25pg/mL and the response difference was monitored 
over 5 minutes. The sensor chip was washed twice with two 10pl injections of 
50mM NaOH prior to the injection of the next sample.
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Figure 4.14: Biacore sensorgram for analysis of ILY and PLY substitution mutant binding to 
CD59. 40|il of each toxin was passed over a CD59-coated CMS sensor chip at a 
concentration of 25|ig/mL in the following sequence: A) ILY Sub 1, B) ILY Sub 2, C) ILY Sub 
3, D) ILY Sub 4, E) ILY Sub 5, F) ILY Sub 6, G) ILY Sub 7, H) ILY Sub 8 ,1) ILY Sub 9 J) ILY Sub 
10, K) ILY Sub 11, L) ILY Sub 12, M) ILY Sub 13, N) ILY Sub 14, O) ILY Sub 15, P) PLY Sub 8, 
Q) PLY Sub 9 and R) PLY Sub 10. Sensor gram shows response measurement for test flow 
cell with CD59-coupling (violet line), control flow cell without CD59-coupling (blue line) and 
subtraction of control from test flow cell values (black line).
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Figure 4.15: Biacore sensorgram analysis of ILY and PLY binding to CD59. 40|xl of each 
toxin was passed over a CD59-coated CM5 sensor chip at a concentration of 25pg/mL in the 
following sequence: A) mILY, B) PLY Sensor gram shows response measurement for test 
flow cell with CD59-coupling (violet line), control flow cell without CD59-coupling (blue line) 
and subtraction of control from test flow cell values (black line).
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Figure 4.14 and Figure 4.15 show that binding to CD59 was observed for ILY and 
all of the ILY substitution mutants, but was not observed for PLY or any of the PLY 
substitution mutants. The response obtained for the ILY and the mutants varied 
from 300 response units for ILY sub 13 up to 3000 response units for ILY sub 9. 
ILY yielded a response difference of 2100 response units. However, a number of 
the protein preparations appeared cloudy prior to assay and were centrifuged to 
remove any large protein aggregates present. It is highly likely that this would 
affect the binding response therefore these data cannot be used quantitatively. A 
number of the mutant proteins also bound very tightly to the chip and were not 
completely removed by the two sodium hydroxide washes between samples. If this 
was a specific binding event, this could affect the number of available sites for 
binding.
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Discussion
Unlike the other CDCs described to date, the haemolytic activity of ILY is human- 
specific (Nagamune et a/., 1996). The initial study by Nagamune and colleagues 
did not Identify which part of the intermedilysin molecule was involved in species 
restriction. In order to determine which region of ILY was responsible for human 
specificity, a bank of chimeric toxins were produced between ILY, which is human- 
specific and PLY, which has broad specificity. Crossover regions were selected to 
be at regions containing runs of amino acids identically conserved between PLY 
and ILY, as indicated in Figure 4.2.
Initially, chimeric toxins were purified using swell-gei Ni-NTA tablets. These tablets 
allowed rapid purification of small quantities of the toxins for characterisation of 
their species specificities.
All of the chimeric toxins that shared the C-terminal 56 residues of ILY were active 
on human erythrocytes, with the exception of chimera A, which has no haemolytic 
activity on human or horse erythrocytes. Similarly, all of the toxins carrying the 0- 
terminal 53 residues of PLY had broad specificity, with the exception of chimera B 
which aggregated both human and horse erythrocytes. It can therefore be 
concluded that it is the 56 C-terminal residues of ILY that are responsible for 
human specificity and the 53 C-terminal residues of PLY are responsible for its 
promiscuity.
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Chimera A and B were reciprocal swaps that crossed over within the conserved 
VPARMQYE motif. Interestingly, the aggregation of erythrocytes observed for 
chimera B is also a characteristic of a deletion mutant of this region - A6PLY (Lea- 
ann Kirkham, PhD thesis) and this may signify that like the A6 mutant, chimera B 
can bind to cell but fails to form pore structures. It is possible that crossovers at 
this position suffer from steric clashes, folding problems or similar incompatibilities 
between the two sections of the toxins such that the considerable conformational 
change required (Tilley et al., 2005) is restricted. However further work would be 
required to determine the reason for the lack of activity of these chimeras.
Chimeras G and H were purified by nickel-affinity purification using FPLC in order 
to yield larger quantities and more pure preparations for further study. The species 
specificities of chimeras G and H were the same as determined with the swell-gel 
purified chimeras -  i.e. chimera G was human specific and chimera H had broad 
specificity. Both toxins had reduced activity on human erythrocytes when 
compared to ILY or PLY -  chimeras G and H had 110-fold and 5-fold reduced 
activity compared to ILY. The specific activity of ILY was 5-fold lower than PLY, 
and this appears to be a result of an intrinsic lower activity of the toxin.
It is difficult to determine the reason for the greatly reduced activity of chimera G. It
may indicate that only part of the receptor-binding site was transferred to the PLY
backbone. Alternatively, if the entire site was transferred, perhaps the binding site
is not folded in the optimal conformation due to incompatibilities between the two
halves of domain four. There may be differences in the angle that domain 4 of ILY
sits relative to the rest of the molecule (Polekhina et a!., 2005) and perhaps this is
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incorrect in chimera G to allow optimal binding. The overall folding and shape of 
the molecule may simply be disrupted leading to inhibited binding or pore 
formation.
Erythrocyte ghost absorbtion assays were performed to determine whether the 
chimera cross-overs were species specific in their binding actions or whether 
specificity was determined at a later stage of the mode of action. Chimera G was 
inhibited by human erythrocyte ghosts but not rabbit erythrocyte ghosts, whereas 
chimera H was inhibited by both human and rabbit erythrocyte ghosts. This 
indicates that the human-specific action was a result of human-specific binding 
rather than a downstream process.
Nagamune et al showed that trypsin-treated erythrocytes were less susceptible to 
lysis by intermedilysin (Nagamune et al., 1996). This effect was confirmed and 
further investigated here and it was found that susceptibility to intermedilysin 
reduced as trypsin treatment time increased. The control without trypsin was 
equally susceptible to ILY lysis as trypsinised erythrocytes to which trypsin 
inhibitor was added immediately. This confirmed that the inhibition was a result of 
the action of the enzyme on the erythrocytes and neither the presence of the 
trypsin nor trypsin inhibitor.
This study also investigated the effect of trypsinisation of PLY-mediated 
haemolysis and found that trypsinised cells were more susceptible to PLY. This 
may be due to greater access of the toxin to the cell membrane when surface 
proteins are cleaved, or possibly a reduction in stability of the membrane. The
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maximum effect was reached within one hour suggesting that the proteins involved 
were cleaved quickly by trypsin.
Following this work and the suggestion that there was a protein receptor for ILY, a 
yeast-2-hybrid system was developed and used to screen for proteins capable of 
interacting with ILY. The screen used domain 4 of ILY fused to the DNA-binding 
domain of GAL-4 as the bait protein and a human brain cDNA library was the prey 
library. Greater than 2.4x10® transformants were screened and this was more than 
twice the recommended number to give full library coverage.
23 putative interacting proteins were identified, although only one was surface- 
expressed. As with all yeast-2-hybrid screens, the interactions need to be 
confirmed by other means and the biological-relevance examined before an 
interaction can be positively identified. During the course of this experiment, the 
receptor for ILY was identified as CD59 (Giddings et a i, 2003) and therefore 
further work was not carried out on these putative interacting proteins.
Production of eGFP-tagged intermedilysin
Another method of identification of the receptor for ILY was proposed and this 
required the production of a non-lytic and fluorescent-tagged form of ILY. The 
experiment involved transfecting a mouse tissue culture cell line with a human 
cDNA library and addition of the non-lytic, fluorescent ILY toxin. This would be 
expected to bind to transfected cells expressing the human cellular receptor for 
ILY and these cells could be selected using a FACS machine and the selected
Page 144
clonal lines grown up. Plasmid recovery and DNA sequencing would than allow 
identification of the cellular receptor ILY.
Previously, eGFP-tagged forms of PLY and A6PLY were produced (this thesis) 
and these were found to be easily detected by flow cytometry. The A6PLY mutant 
was found to be a binding, non-lytic mutant of PLY (Kirkham et a l, 2006b) and 
eGFP tagged toxins were shown to be detectable by fluorescence microscopy and 
flow cytometry, therefore a similar strategy was employed for ILY.
An initial attempt to produce eGFP-tagged mature ILY (mILY) produced a purified 
protein of approximately 35kDa. This protein was fluorescent and was capable of 
binding to the His column to allow purification, and this suggests that the protein 
was susceptible to proteolytic cleavage. Cleavage between the eGFP and mILY 
portions would produce a protein of this approximate molecular weight. Another 
possible explanation was that premature transcriptional termination was occurring, 
however since human-specific haemolytic activity of a crude lysate was observed, 
this is unlikely. It was therefore concluded that proteolytic cleavage was likely to be 
occurring within the N-terminal region of ILY and therefore a shorter construct, 
eGFPslLY, was produced.
The N-terminal shortened form of ILY, sILY (short intermedilysin), is composed of 
residues A60-D532 of ILY. sILY contains the whole portion of ILY that corresponds 
to PLY in an amino acid alignment but the N terminal region which has no 
corresponding equivalent in PLY is removed.
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eGFPslLY was found to have slightly higher specific haemolytic activity compared 
to ILY confirming that eGFP-tagging did not significantly alter the haemolytic 
activity of the toxin. The difference between the activities of the toxins is not any 
greater than that which can be observed between batches from the same toxin but 
it is not possible to determine whether there is any true difference in specific 
activity as a result of addition of the eGFP tag.
AGeGFPslLY, a mutant form of eGFPslLY with a deletion of A204 R205 of ILY 
corresponding to those deleted in A6PLY, was non-lytic. This confirmed that the 
mutation of these residues eliminated haemolytic activity as described for A6PLY 
(Kirkham etal., 2006b).
The degree of binding of eGFPslLY and AGeGFPslLY to human and horse 
erythrocytes was measured by fluorescence microscopy and flow cytometry.
Laser scanning confocai microscopy revealed that both toxins could be visualised
bound to the membranes of human erythrocytes but no binding was observed to
horse erythrocytes. eGFP alone did not bind to human or horse erythrocyte
membranes, indicating that no non-specific binding events were taking place and
that the fluorescence of the human erythrocyte membranes was not a result of
intrinsic autofluorescence. Human erythrocyte membranes treated with eGFPslLY
appeared crumpled and folded, probably as a result of lysis of the cells.
AGeGFPsILY-treated human erythrocytes remained more smooth but their
morphology appeared to have been slightly altered from the bi-concave shape
typical of erythrocytes. This may be a result of the suspension buffer not being
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isotonie for erythrocytes, physical pressure on slide preparation, or an action of the 
toxin.
Flow cytometry also confirmed that eGFPslLY and AGeGFPslLY bound to human 
but not horse erythrocytes. Human erythrocyte fluorescence increased with the 
concentration of toxin added. The fluorescence increase upon addition of 
eGFPslLY and AGeGFPslLY was less than that previously observed upon addition 
of eGFPPLY and AGeGFPPLY. This could suggest that a lesser quantity of ILY is 
able to bind to erythrocytes than PLY, perhaps due to a lower availability of CD59 
than for the receptor for PLY. However, we also cannot exclude the possibility that 
eGFPslLY may have a lower fluorescence per molar quantity as this would lead to 
the same result.
Since AGeGFPslLY was confirmed to be a human-specific binding, non-lytic 
mutant of ILY, it is therefore a suitable reagent for use in a FACs-based assay to 
identify the receptor for ILY. As eluded to earlier, during the course of this 
experiment the cellular receptor for ILY was identified by another group (Giddings 
et al., 2004) therefore the FACS-based screen was not completed.
A number of mutants with small substitutions in domain 4 of PLY and ILY were 
developed. These mutants were designed to mutate regions of difference between 
ILY and PLY to the sequence found in the other toxin. An abolition or reduction in 
activity of the substitutions made in ILY might indicate that the receptor binding 
site has been disrupted.
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The haemolytic activities of all of the toxins on human erythrocytes was therefore 
measured. Most of the substitution mutants had similar specific activities 
compared with wild-type ILY and PLY. ILY sub 8, ILY sub 13, PLY sub 8 and PLY 
sub 9 were found to have drastically reduced activities compared with the other 
toxins.
The activities of the toxins having ‘similar’ activities to the wild-type were spread 
over an approximately 10-fold range of toxin concentrations. The activity of PLY 
was greater than ILY in this assay and may be true differences between the 
activities of the toxins. However, the accuracy of this assay is likely to be 
influenced by the purity of the toxins and the proportion of fully active/non­
denatured toxin in the preparation. In addition to this, variation may occur as a 
result of aggregation of these proteins in solution. The samples used for 
haemolytic assay were centrifuged prior to use to check for aggregation, however 
it is possible that this was insufficient to eliminate micro-aggregation that may have 
occurred prior to more noticeable aggregation and this could have an effect on 
haemolytic activity. All preparations were purified twice and the same pattern of 
haemolysis was observed with the same pattern of specific activities but with a 
similar spread of data.
It is not possible to state from the results whether the reduced haemolytic activities 
observed for ILY sub 8, ILY sub 13, PLY sub 8 and PLY sub 9 were a result of 
alteration of residues important in cell binding or pore formation, or a result of 
differences in the structure / stability of the overall toxin molecule. It is also not 
clear whether differences in binding affinity would lead to variation of the endpoint
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of a haemolytic assay, or if any affinity of binding would be sufficient to allow 
subsequent steps in pore formation to take place.
In order to investigate whether the binding affinities of any of the mutants were 
altered from the wild-type toxin, CD59 binding was measured by surface plasmon 
resonance (SPR) using sensor chip coated with CD59. SPR revealed that ILY and 
all of the ILY mutants bound to CD59 but PLY and the PLY-based substitution 
mutants did not bind CD59. It is therefore likely that CD59-binding ability has not 
been introduced to the PLY mutants or entirely abolished from any of the ILY 
substitution mutants. It is interesting that the lowest binding activity measures was 
for ILY sub 13, which had the lowest specific activity. However, due to problems 
with protein aggregation, quantitative results can not be obtained from this assay.
This assay should be repeated using newly purified protein preparations, and 
better stability may be obtained using an alternative buffer. Proteins should be 
checked for aggregation using techniques such as dynamic light scattering or 
analytical ultracentrifugation prior to repeat of the binding assay. If aggregation 
remains a problem, it may be beneficial to pass the preparation through a gel 
filtration column immediately prior to assay.
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C h a p t e r s :  Immunisation studies with 
Anthrolysin O, the CDC from B a c i l l u s
a n t h r a c l s
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Summary
Anthrolysin O (ALO) is a toxin produced by Bacillus anthracls, the causative agent 
of anthrax. It is a member of the cholesterol-dependent cytolysin (CDC) group of 
toxins, many of which are potential vaccine candidates that protect against their 
producing organisms. Pore formation by ALO was studied by transmission 
electron microscopy and pores were found to be consistent with those formed by 
other members of this toxin family. We constructed and characterised a novel 
genetic toxoid of anthrolysin O, A6mALO, which was able to bind to cells but was 
incapable of pore-formation or haemolysis. The capacity of the haemolytic and 
non-haemolytic forms of ALO to protect against challenge with the toxin or B. 
anthracls was determined. Immunisation with both active and non-haemolytic 
forms of ALO elicited protection against lethal i.v. challenge with ALO but neither 
was protective against B. anthracls in a murine i.p. challenge model. Immunisation 
with another CDC, pneumolysin, did not confer cross-protection against challenge 
with ALO. Histopathological investigation following lethal i.v. challenge with ALO 
revealed acute pathology in the lungs with occlusion of alveolar vessels by fibrin 
deposits.
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Introduction
Bacillus anthracis is a Gram-positive spore-forming bacillus that is the causative 
agent of anthrax. Primarily a disease endemic to herbivores, anthrax can also 
affect humans, most often through contact with infected animals or their products. 
The disease is classified as cutaneous, gastrointestinal or inhalational anthrax 
according to the route of infection. While fatality rates from cutaneous anthrax are 
less than 1% with antibiotic treatment, they are extremely high for gastrointestinal 
and inhalational forms of the disease as infections have often progressed too far 
for treatments to be effective (Oncu et a!., 2003).
Two major virulence determinants of S. anthracis have been well characterised; an 
anti-phagocytic poly-D-glutamic acid capsule that is encoded on plasmid pX02 and 
two toxins, lethal factor (LF) and edema factor (EF), encoded on plasmid pX01. 
These enzymatic toxins are translocated across the cell membrane by a third 
bacterial protein, protective antigen (PA), and interfere with host cell signalling 
pathways (Duesbery et al., 1998; Leppia, 1982). The toxins are responsible for 
much of the acute pathology of anthrax and LF and EF, in combination with PA, 
are capable of causing many of the clinical signs associated with the disease (Fish 
etal., 1968; Klein eta!., 1962).
During inhalation anthrax, B. anthracis spores are phagocytosed by alveolar 
macrophages which transport the bacterium across the alveolar barrier upon 
migration to the lymph nodes (Guidi-Rontani et al., 1999). The spores then 
germinate within the phagolysosome of the macrophage, and escape from the
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macrophage allowing the bacterium to proliferate within the bloodstream. The role 
of the LF and EF in release from the macrophage is unclear and contradictory 
results have been obtained as to whether expression of these toxins is linked to 
loss of macrophage viability and survival of the germinated bacterium (Dixon et at., 
2000; Guidi-Rontani et al., 2001).
There is also evidence for the presence of chromosomally-located virulence 
factors since strains of B. anthracis cured of both plasmids (pXOT, pX02") retain 
some virulence in mice (Fouet etal., 1995). A gene encoding Anthrolysin O (ALO), 
a member of the family of cholesterol-dependent cytolysins (CDCs), was recently 
discovered in the genome sequence of B. anthracis Ames (Read et a!., 2003). 
Many other members of this toxin family have been shown to be virulence factors 
of their producing organisms (Awad et a!., 2001; Cossart et al., 1989; Jost et al., 
1999; Rubins et al., 1995) and it has been proposed that ALO may have a role in 
the virulence of B. anthracis (Shannon et al., 2003; Wei et al., 2005). ALO is 
secreted in an active form by B. anthracis Sterne and was shown to be inhibited by 
cholesterol, a characteristic of many members of the CDC family (Shannon et al., 
2003). ALO has been shown to activate Toll-like receptor 4 leading to induction of 
macrophage apoptosis in combination with LF (Park etal., 2004).
Another Gram-positive pathogen which is capable of phagosomal escape within 
the macrophage is Listeria monocytogenes. This activity is a result of the 
combined effects of listeriolysin O (LLO), phosphatidylinositol-specific 
phospholipase C (PI-PLC) and phosphatidylcholine phospholipase C (PC-PLC) 
(Camilli et al., 1993; Gedde et al., 2000; Portnoy et al., 1992). In addition to a
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homolog of LLO, homologs of the PI-PLC and PC-PLC genes of L  
monocytogenes are also present in 6. anthracis (Read et al., 2003). Given the 
similar requirement of B. anthracis for escape from the phagosome of 
macrophages, it is possible that ALO plays a role in the disruption of the 
phagosomal and/or plasma membranes. Recombinant strains of L. 
monocytogenes expressing anthrolysin O were capable of escape from the 
phagocytic vacuole but unlike LLO also damaged the plasma membrane of the cell 
(Wei ef a/., 2005).
Immunisation with liposome-encapsulated LLO has been shown to induce 
protective immunity against L. monocytogenes (Tanabe et al., 1999), and a 
number of other members of the CDC family, or peptides and genetic toxoids 
derived from them, have been shown to protect against infection with their 
producing organisms (Jacobs et al., 1994; Jost et al., 2003; Kirkham et al., 2006b; 
Paton etal., 1983).
Based upon these previous studies and the potential for the involvement of ALO in 
the pathogenicity of B. anthracis we have investigated the capacity of 
immunisation with mature ALO (mALO) or a novel genetic toxoid, A6mAL0, to 
protect against challenge with mALO or B. anthracis in a murine model. Another 
member of the CDC family, pneumolysin (PLY), was included in the study to 
investigate whether other members of the CDCs could induce cross-protection 
against ALO.
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Results
Construction of plasmid vectors
A 2433bp DMA fragment containing the coding sequence for anthrolysin O and 
upstream and downstream regions was amplified by PCR from B. anthracis Ames 
genomic DMA and transformed into pCR2.1-T0P0. This initial cloning step was 
done by Prof. R. Titball, DSTL. The coding sequence for mature anthrolysin O 
(mALO), which is composed of residues E35-H512 of ALO such that the putative 
signal sequence has been removed, was amplified by PCR and cloned into 
pET33b. The resulting plasmid is referred to as pET33b-mALO. Primers were 
designed so that the fragment would in frame with the N-terminal His-tag and the 
C-terminal His-tag in the vector is not expressed.
A deletion mutation of ALO named A6mALO was then produced. This mutant is 
based on the A6PLY mutation described by Kirkham and colleagues (Kirkham et 
a!., 2006b). Residues A156 and R157 of mALO (corresponding to A190 R191 of 
ALO) were deleted in pET33b-mALO at by site directed mutagenesis to form 
pET33b-A6mALO.
All pET33b-based plasmids were transformed into BL21(DE3) E. coli for protein 
expression.
The construction of all plasmids was confirmed by DNA sequencing. A silent 
mutation, T>C at position 1227 of mALO was found to be present.
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A6mAL0 is non-haemolytic but retains binding activity
A mutant of mALO with a deletion of amino acid residues A156 and R157 was 
constructed. This mutant, named A6mAL0, was based on A6PLY where the 
deletion of two corresponding amino acid residues of PLY abolished the 
haemolytic activity of the protein (Kirkham et al., 2006b). A6mALO was 
characterised to determine whether this mutant possessed similar toxoided 
properties to those of A6PLY.
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Figure 5.1: Haemolysis assay of purified mALO and A6mAL0 toxins on human and horse 
erythrocytes.
The specific activities of recombinant mALO and ABmALO proteins on human and 
horse erythrocytes were measured by haemolysis assay (Figure 5.1). mALO was 
lytic to both human and horse erythrocytes, with specific activities of 6x10® and 
3.3x10® HU m g'\ respectively. No lysis was detected on human or horse 
erythrocytes treated with A6mAL0 at concentrations up to 0.1 mg/ml.
The ability of mALO and ABmALO to bind to human erythrocyte membranes was 
determined by erythrocyte binding assay (Figure 5.2). Both toxins bound to human
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erythrocyte membranes. For mALO, most of the recovered toxin was in a very high 
molecular weight state consistent with oligomers produced upon pore formation, 
with a small proportion of a lower molecular weight corresponding to the size of 
the toxin in the monomeric state. For A6mAL0, no high molecular weight species 
was present and all of the recovered toxin corresponded to the molecular weight of 
monomeric toxin.
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Figure 5.2: Binding assay of mALO 
and A6mAL0 to human erythrocytes. 
Erythrocyte membranes were treated 
with A) 4p.g/mL mALO B) 4p,g/mL 
A6mALO 0) PBS and incubated for 10 
minutes at 37°C. Membranes were 
washed in PBS, the pellet was 
resuspended in SDS-PAGE sample 
buffer and samples were run on an 
SDS-PAGE gel. Proteins were 
transferred to a nitrocellulose 
membrane and an immunoblot was 
performed using anti-mALO anti­
serum from mice as the primary 
antibody (1:1000 dilution) and anti­
mouse IgG HRP-linked secondary 
antibody (1:2000 dilution).
Electron microscopy of erythrocyte membranes treated with mALO and 
AGmALO
Human erythrocyte membranes treated with mALO and A6mAL0 were negative 
stained and examined by transmission electron microscopy (Figure 5.3). Pores 
were visualised on membranes treated with mALO but no pores were visible on 
membranes treated with AGmALO. For mALO pores, the mean inner pore
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diameter was measured to be 26.1nm ±0.8nm with a ring width of 6.4 ±0.4nm 
(n=20, mean ±95% confidence interval).
"  A <
Figure 5.3: Transmission electron micrographs of human erythrocyte ghost membranes 
treated with A) mALO and B) AGmALO visualised by negative staining with uranyl formate. 
Pores were observed on mALO treated membranes (arrow).
Determination of the toxicity of mALO to A/J mice
In order to determine the toxicity of anthrolysin O in vivo, groups of female A/J 
mice were challenged i.v. with doses of between 0.1-5pg mALO. All mice in the 
group treated with 0.1 pg mALO survived, whereas no mice survived in the group 
treated with 5pg mALO (Figure 5.4). The experimental L D 5 0  was calculated by 
interpolation to be 0.7 mg, equivalent to 35mg kg‘\  In most cases where treatment 
was terminal, fatality occurred within minutes of injection.
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Figure 5.4: Survival of A/J mice after i.v. challenge with different concentrations of mALO 
toxin.
Histopathological investigation of mice lethally challenged with Anthrolysin 
O
Spleen, heart, kidney, liver and lung tissues from 2 mice that died immediately 
from i.v. challenge with 1jig mALO, and a naïve control mouse, were examined 
histologically. Examination of the lung sections from the mice challenged with 
mALO revealed multifocal intravascular fibrin deposition with alveolar congestion 
and oedema (Figure 5.5). Many small to medium sized pulmonary vessels were 
fully occluded by thrombi. Vessels of an untreated mouse lacked fibrin thrombi. 
Examination of the other tissues of the mALO challenged mice revealed minimal 
pathology in these cases of peracute mortality.
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BFigure 5.5; Light microscopy of histological sections of lungs taken from mice lethally 
challenged with mALO or a naïve control mouse. Sections were stained with Martius Yellow- 
Brilliant Crystal Scarlet-Soluble Blue (MSB) stain. RBCs are yellow, new fibrin is orange/red 
and older fibrin is blue, muscle is paler red, collagen is blue, and epithelial cells stain with a 
bright red appearance. Magnification 400x.
A) Mouse 1: Fibrin-occluded vessel (arrow) at the junction with patent vasculature 
containing red blood cells.
B) Mouse 2: Occlusion of vascular lumen by an acellular thrombus (arrow).
C) Control Mouse: Normal lung with patent vessel containing (yellow) red blood cells.
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Determination of the effect of immunisation with mALO, AGmALO and PLY
against challenge with the mALO toxin
Groups of A/J mice were immunised with the mALO, A6mAL0, or PLY antigens 
with adjuvant, and control groups were administered adjuvant alone or left 
untreated. Anti-mALO and anti-PLY IgG levels were determined by ELISA from 
sample bleeds taken from all mice 9 days prior to challenge with mALO (Figure 
5.6). High anti-mALO IgG titres were present in the sera from groups immunised 
with mALO and AGmALO but 100-fold lower levels were detected in the group 
immunised with PLY. Anti-PLY titres were high in groups immunised with mALO 
and PLY but were 100 fold lower in groups immunised with AGmALO.
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Figure 5.6: Anti-mALO (A) and anti-PLY (B) ELISAs showing titres (1/dilution of serum 
giving A540 of 0.3) of anti-mALO IgG antibody detected for each immunised group of 
animals subsequently challenged with mALO (n= 8  for each group). Horizontal bar denotes 
mean titre.
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Toxin neutralising activity was measured using serum neutralisation assays of 
mALO and PLY activity with pooled serum from each of the immunisation groups 
(Figure 5.7). Serum from groups immunised with mALO and AGmALO had 10-fold 
greater capacity for neutralisation of mALO activity than PLY immunised serum or 
the control groups.
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Figure 5.7: Neutralisation of A) mALO or B) PLY activity by 
pooled sera from each Immunised group.
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Serum from the PLY immunised group neutralised the activity of PLY to the 
greatest extent and this was similar to the extent of neutralisation of mALO by the 
mALO immunised group serum. The background level of neutralisation by naïve 
serum in the PLY neutralising assay was greater than for the mALO neutralising 
activity. Levels of PLY neutralisation by the serum from ALO and A6mAL0 
vaccinated groups were similar to that of the naïve control group.
In order to determine the level of protection afforded by immunisation with mALO, 
AGmALO and PLY to lethal challenge with the mALO toxin, the immunised mice 
were challenged i.v. with 5pg mALO.
All of the mice immunised with mALO or AGmALO survived whereas none of the 
mice in the groups immunised with PLY, adjuvant alone or in the naïve group 
survived (Figure 5.8).
100
D) 50CO
-  r  I ImALO ABmALO PLY Alhydrogel Naive
Antigen
Figure 5.8: Survival of mice immunised with mALO, AGmALO, PLY or adjuvant alone after 
challenge with mALO. Survival expressed as percentage of mice surviving 14 days after 
challenge (n=8 for each group).
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Evaluation of the protection afforded by immunisation with mALO, AGmALO
and PLY against challenge with S. anthracis spores
To investigate whether immunisation with mALO protected against challenge with 
B. anthracis spores, groups of female A/J mice were immunised i.p. with mALO, 
AGmALO, PLY or rPA, then infected with B. anthracis STI spores. Adjuvant-only 
and naïve groups were also included. Complete protection was afforded to all mice 
immunised with rPA but no protection was afforded to the mice immunised with 
ALO, AGmALO, PLY, or the control groups (Figure 5.9).
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Figure 5.9: Survival of immunised A/J mice following i.p. challenge with 10 6. anthracis 
strain STI spores.
Sample bleeds were obtained from all mice 8 days prior to challenge to confirm 
that a response to the antigens was produced. The levels of anti-mALO IgG were 
determined by ELISA and very high titres of anti-mALO IgG were detected in the 
sera from groups Immunised with mALO and AGmALO (Figure 5.10). The level of 
anti-mALO IgG detected for the group immunised with PLY was greater than three
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orders of magnitude lower although this was still higher than that of adjuvant-only 
or naïve groups.
# # #
goo 0)
■o
< È
Figure 5.10: Determination of levels of anti-mALO IgG in sera from groups of mice 
immunised with mALO, AGmALO, PLY and adjuvant, prior to challenge with B. anthracis. 
Horizontal bar denotes mean titre.
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Discussion
In this study, a mutant version of mALO was created with a double amino acid 
deletion at the predicted domain 1 / domain 3 interface. This mutant protein was 
termed AGmALO after A6 PLY, a non-haemolytic mutant with a double deletion of 
the corresponding residues of PLY (Kirkham et al., 2006b). The haemolytic 
activities of mALO and AGmALO were measured to determine whether AGmALO 
was similarly non-haemolytic. mALO was lytic to human erythrocytes but no 
haemolytic activity was detected for the AGmALO mutant on either human or horse 
erythrocytes, even at greater than 10000  fold higher concentration than that 
required to produce pores with mALO.
Members of the cholesterol-dependent cytolysin group typically produce pores on
erythrocyte membranes that can be visualised by transmission electron
microscopy (Sekiya et a!., 1993; Sekiya et a!., 1998). Human erythrocyte
membranes treated with the wild-type and mutant toxins were examined by TEM
to ascertain whether pores produced by ALO were typical of those of other
members of the family of cholesterol-dependent cytolysins, and whether the
AGmALO mutant protein was capable of forming pore structures. Pores were
observed on human erythrocytes treated with mALO and these were similar in
appearance to those produced on membranes treated with PLY and those
produced by other CDCs. The mean inner pore diameter was estimated to be
2G.1nm, which lies within the range of pore sizes described for other CDCs
(Bhakdi et a!., 1985; Mitsui et a!., 1979; Morgan et a/., 1995; Sekiya et a!., 1993;
Sekiya et a/., 1998). Pores were not observed on membranes treated with the
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AGmALO mutant toxin and this agrees with work previously performed using a 
mutant of PLY carrying the same mutation, AGPLY (Kirkham et al., 2006b).
Since AGmALO had been shown to be non-haemolytic and non-pore-forming, a 
binding assay was used to determine whether it was capable of binding to 
erythrocytes. mALO was shown to bind to erythrocytes with two band sizes; one of 
very high molecular weight and one of a lower molecular weight of approximately 
56 kDa, corresponding to the size of monomeric mALO.
It has previously been shown for PFO that pores can maintain their oligomeric 
state after treatment with SDS (Shepard et al., 2000) and the larger species may 
therefore be mALO pores. In work by Bhakdi and colleagues (Bhakdi et al., 1985), 
SLO binding to membranes was detected by SDS-PAGE but the protein ran at the 
size corresponding to the monomeric molecular weight. It is likely that SDS-PAGE 
techniques differed from this work as here samples were only heated to 70°C 
rather than a more typical 95°C to help prevent precipitation of erythrocyte 
membrane proteins, or alternatively this may suggest that the toxin oligomers were 
less stable than those formed by PFO or ALO.
A 56kDa band was obtained for AGmALO indicating that this mutant is capable of 
binding to the cell membrane. No larger molecules were present in the AGmALO 
sample, and this concurs with the electron microscopy in suggesting that AGmALO 
does not form pores.
Page 167
Examination of the lungs of mice lethally challenged with anthrolysin O revealed 
multifocal occlusion of pulmonary vessels by fibrin thrombi in both mice examined. 
Fibrin deposits were not present in pulmonary vessels of a control mouse.
The family of CDCs are produced by an array of Gram-positive pathogenic 
organisms that can cause a wide range of diseases. Vaccination with CDCs or 
their derivatives, including pneumolysin (Paton et al., 1983), pyolysin (Jost et al., 
2003), suilysin (Jacobs et al., 1994) and listeriolysin O (Harty & Bevan, 1992), 
have been shown to protect against diseases caused by the producing organisms.
Anthrolysin O is one of the most recently discovered cholesterol-dependent 
cytolysins and its production by B. anthracis (Shannon et al., 2003) gives rise to 
the possibility that it may play a role in the pathogenesis of anthrax, possibly as a 
mechanism of escape from the phagosomes of macrophages (Wei et al., 2005). 
We were therefore interested to determine whether vaccination with anthrolysin O 
conferred protection against anthrax. On the basis of this hypothesis, we studied 
the capacity of immunisation with mALO, AGmALO and PLY to protect against 
challenge with the mALO toxin and with B. anthracis spores.
As a prelude to vaccination experiments, the toxicity of mALO in vivo was
determined. A dose of 5jig mALO i.v. was immediately lethal to all of the animals
in the group. This dose was therefore used in experiments to detect protection
against challenge with the mALO toxin. The LD50 for listeriolysin O and streptolysin
O have previously been calculated as 3-12pg/kg and 8pg/kg i.v. respectively (Gill,
1982), indicating that these toxins were found to be approximately five-fold more
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potent than mALO. A recent study examined the lethal effect of LLO, ILO, SLO 
and PLY and found that the toxicity of these varied by up to 2.5 fold (Watanabe et 
al., 2006). Since Watanabe et al used survival time rather than percentage survival 
it is difficult to relate the results to those shown here or to those of Park et al. 
Comparison between studies is also hindered as variation may be a result of 
differences in toxin purity or differing susceptibilities of mouse strains.
The first step was to determine whether a toxin-neutralising response could be 
raised in vivo by immunisation with mALO, AGmALO and PLY. Complete 
protection against lethal i.v. challenge with mALO was afforded equally to the 
groups immunised with mALO and AGmALO but not the group immunised with 
PLY. This indicated that despite good homology across the group of cholesterol- 
dependent cytolysins, which typically show 40-97% identity between members, 
neutralising cross-reactivity is not necessarily afforded between members of this 
family.
A previous study on the cross-reactivity of the CDCs used Ouchterlony
immunodiffusion to study cross-reactivity between horse antisera to tetanolysin,
streptolysin O and perfringolysin O with cereolysin O, tetanolysin, streptolysin O
and perfringolysin O (Cowell et al., 1978). In this study, CDCs were found to be
antigenically identical or similar depending on the particular combination of CDCs
tested, however some unexpected results were observed, e.g. anti-tetanolysin
antisera did not appear to precipitate tetanolysin but did precipitate the other CDC.
Cross-reaction of sera appears to require the use of high-titre anti-sera, as can be
obtained from immunisation of horses, (Cowell et al., 1978). Cowell and
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Bernheimer also remark that they have observed that rabbit anti-serum raised 
against cereolysin O neutralises and precipitates cereolysin O itself but not any of 
the other CDCs they tested, although this data is not presented in the paper 
(Cowell et al., 1978). Given the high degree of Identity between cereolysin O and 
anthrolysin O, this data agrees well with the data in this work that suggests there is 
limited cross-reactivity between anthrolysin O and pneumolysin.
For each group, the protective capacity of the sera was mirrored by the anti-mALO 
IgG levels which were high in mALO and AGmALO vaccinated groups but much 
lower in the PLY vaccinated group. Anti-PLY IgG levels were high in the PLY 
vaccinated group, indicating that the low anti-ALO titre was a result of a lack of 
cross-reactivity and not poor immunogenicity of PLY.
The lack of cross-reactivity was not reciprocated, however, as anti-PLY IgG levels 
were also high in mALO-vaccinated animals. Surprisingly, vaccination with 
AGmALO did not give rise to high anti-PLY titres. One explanation for this is that 
the site altered in AGmALO is highly conserved across the CDCs and this may be 
the main cross-reactive epitope between mALO and PLY. This region has 
previously been shown to be one of two highly antigenic sites by epitope scanning 
and was recognised by both convalescent human sera and hyper-immune rabbit 
sera (Salo etal., 1993).
Serum from mALO and PLY immunised animals was found to neutralise the 
activity of the toxin used for vaccination but did not neutralise the activity of the
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other CDC. This lack of cross-neutralisation correlated with the failure of 
vaccination with PLY to protect against challenge with mALO.
Despite the generation of high anti-mALO IgG levels, vaccination with mALO, 
AGmALO and PLY failed to protect against challenge with B. anthracis in the i.p. 
challenge model. The positive control -  immunisation with recombinant protective 
antigen -  conferred full protection.
Anthrolysin O has been shown to be secreted by B. anthracis (Shannon et a!., 
2003) and in this work it has been demonstrated that anthrolysin O causes 
peracute pathology when introduced to the bloodstream of mice. Vaccination with 
mALO or AGmALO was protective against the lethality of i.v. injection with mALO 
but neutralisation of this activity was insufficient to protect against B. anthracis 
infection. Since the role of mALO in the pathogenesis of B. anthracis is currently 
undefined, it may be that the type of response generated was not appropriate to 
neutralise a critical activity of mALO, which may have an intracellular role (Wei et 
al., 2005), or the activity of ALO may not be critical to the virulence of the 
organism. Alternatively, the role of ALO may be specific to a particular event in B. 
anthracis pathogenesis not simulated in this i.p. model, such as translocation of 
the bacterium across the alveolar barrier, so that an opportunity for protection was 
bypassed.
Page 171
Conclusions
• ALO is lytic to both horse and human erythrocytes, and has a specific 
activity similar to that of other CDCs
• The AGmALO deletion mutant of ALO was capable of cell binding but is not 
haemolytic and does not form pore structures on membranes. The effect of 
this mutation therefore mirrors that of the AGPLY mutation.
• mALO forms pores on erythrocytes membranes. These are similar in 
appearance and size to those produced by other members of the CDCs.
• Anthrolysin O is toxic to mice by i.v. challenge with an estimated LD50 of 
35mg kg '\
• Histological examination of mice that succumbed to ALO toxicity showed 
occlusion of the vascular lumen with acellular thrombi.
• Immunisation with a specific CDC does not necessarily confer good cross­
reactivity, cross-protection or cross-neutralisation against other CDCs. 
Addition of the AG mutation to ALO altered the cross-reactivity of the 
antibodies produced.
• Immunisation with mALO and AGmALO was highly protective against 
challenge with mALO but did not protect against i.p. challenge with B. 
anthracis.
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Appendix 1: Sequence Alignment 
of the CDCs
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Appendix 2: Oligonucleotides
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Sequences of oligonucleotide primers
Primer Reference Sequence (S' to 3’)
09Y CGGGATCCGGCAAATAAAGCAGTAAATGACTTT
09Z GACGGAGCTCGACTAGTCATTTTCTACCTTATC
20G GTGAGGCTAGCATGAGTAAAGGAGAAGAAC
20H CCACGCAGATCTTTGTATAGTTCATCC
23B GGTCAATAATGTCGCAATGCAGTATGAAAAAATAACGGCTC
23G GAGGGGTTATTTTTTGATAGTGGATTGGGAGATTATTGAGG
24W GAGTTGTGAGTAGTGGAGTTATGGTGTTGAATGG
24X GGATTGAAGAGGATAAGTGAGAGTAGTGAGAAGTG
26G TAATGTGGGAGGTAGAATGGAATATGAATCTA
26D TTTTTTGATAGTGGATTCTAGGTGGTAGAGGA
26E TGGTGTAGGAGGTAGAATGGAGTATGAAAAAA
26F TAGATTGATATTGGATTGTAGGTGGGAGATTA
26G GAAGTTGGAAAGGAGGAGCAAGAGTAGAAAAG
26H GTTGATGAGTGTTAGTTGTAGTTTGAAATTTC
261 GAAATTTGAAAGTAGAAGTAAGAGTGATGAAG
26J GTTTTGTAGTGTTGGTGGTGGTTTGGAAGTTG
26K GTTGGGGATTTCGTATAGTTGTTTTGTGA
26L GTAAAAAAGAAGTTGTGTAAGAGATTGGTAGA
26M TGTAGGAATGTGTTAGAGAAGTTGTTTTTTAG
26N TGAGAAAAGAAGTAGTATAGGAAATGGGGAAG
260  TGGTTTAAAAGGGAATGTTAGAAAGATTGGGG
26P GAG AGAGATTAGGA AGATTTGGGTTG AAAG GG
260  GGGTTTGAAGGGAAATGTTGGTAATGTGTGTG
26R GGGGAATGTTTGTAAGATTCGGTTTTAAAGGA
26W GGGGATGGGGAAAGACGTAGGAAAGGAAAAGGA
26X GAGGGAGGTGGATTAATGAGTGTTATGTTTGAG
30P CGAGGGAGATGTTATTTGTATAGTTGATGG
31T GTC AG AGTAGTATG AGT AAAGG AG AAGAAC
31U GAAGTATAGAAAGATGGGGAAAGAGGTAGGAAAG
31V GGTAGGTGTTTGGGGATGTTTGTATAGTTGATG
31W GTAAAAGTGATGGTGTAGGAATGGAATATGAATGTATTAGG
31X GGTAATAGATTGATATTGGATTGGTAGAGGATGAGTTTTAG
32G GTAAGGGGAGGCAAGGATTAG
32 H GAAGTGGTGATAGATTGTGGTG
32U GAGGGAGGTGGAGTAGTGATTTTGAAGTTTATGTTGAAAGTGTGG
32V GAGGGAGGTGGATTAATGAGTGTTATGTTTGAGTAGGTTATGGTGTAGGTGAGG
32W GGGGGTTGGGTGGGAAGGTTGGGGTAGGGTTTATG
32X GATAAAGGGTAGGGGAAGGTTGGGAGGGAAGGGGG
32Y GTGGACTAGCTTGGGAGTGGTGGAGAGTGATGTATAG
32Z GTATAGATGAGTGTGGAGGAGTGGGAAGGTAGTGGAG
33A GTAATGTGTGTGTGAAAGTAGTAGGAGGGAGGGGGGTTGCCTGGG
33B GGGAGGGAAGGGGGGTGGGTGGTAGTAGTTTGAGAGAGAGATTAG
33G GAAAGATTGGGGTAAAAATTAGAGAGTGTAGTGGAGTAGGTTGG
33D GGAAGGTAGTGGAGTAGAGTGTGTAATTTTTAGGGGAATGTTTG
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Sequences of oligonucleotide primers
Primer Reference Sequence (S' to 3')
35K GAAACATTAGCATTTGGGGAACAAC
35L GAGCCTTGGAGAACGGTTTATAGGAAGAAC
35M GGTAGTAGTTTTAGAGAGAGGTTTGTAAGATTTG
35N GAAATGTTAGAAAGGTGTGTGTAAAAGTAGTAGG
350 GTTGTTGCTATAAAGGGTTCTGGAAGGGTG
35P GAGAGTGATGTATGAAAAAACGGATGTTGGTTTGG
350 GGAAAGGAAGATGGGTTTTTTGATAGATGAGTGTG
35R GTTGGTTTGGTTGGTAAGGGGAGGATTAGGAGTTG
35S GTTGTTGGGGAAATGGTAATGTTTG
35T GAAGTGGTAATGGTCGGGTTAGGAACGAAAGGAAG
35U GGGAAGAAGGGTTTATGGAGAGTTTGAAG
35 V GTTG A AAGTGTGG ATAAAGG GTTGTTG GG
35W GGTTGATGGAGAGGTAGAAGATAAAGTTG
35X GAAGTTTATGTTCTAGGTGTGGATGAAGG
35Y GAGAGGATGGAAAGAGGTAGGAAAGGAAAGGAAAGGAAAG
35Z TGGAGGGATGGGTTAATGAGTGTTATGTTTGAGTGTTATGTTTGAG
36G GAAGTATAGAAAGATGGGGGAAAAAAAGGTGTGAATG
36D GAGGTTTTTTTGGGGGATGTTTGTATAGTTGATG
38E TGTAAAAGTGATGGTGTACGAAT
40T GGGGACAAGTTTGTAGAAAAAAGGAGGGTTGAGAAAAGTAAGATGGTATAAAG
40U GGGGAGGACTTTGTAGAAGAAAGGTGGGTGTTAATGAGTGTTATGTTTGAG
410  GGGGATGGGATTTTTGTGAATATTAAG
41P GAGGGAGGTGGAGTAATGAGTAATAGTAGGAG
42S GAAGAGATAGGTTAGGTATGGAGTATAGAGAATG
42T GATTGTGTATAGTGGATAGGTAAGGTATGTGTTG
43L CGGTGCGAACGTCATAACAAGTG
43M GTAAATTTGTGGGAAGGTAGAG
43Z GGGGATGGGGAAAGAGAAGGGGGTAATG
45L GGAGGGGAGGTGTTATTTGTATAGTTGATGG
460 GTGGTTTGGTTGGAGAATTGTATGTTTATTG
46R GAATAAAGATAGAATTGTGGAAGGAAAG
46S GAGGGTTGTATGTTAGTTGGGAAGAAGTGGG
46T GGGAGTTGTTGGGAAGTAAGATAGAAGGGTG
46U GATGGGTAGGAAAGTTTGAGTGGTAAGTGTTGGAGTGGAAATG
46V GATTTGGAGTGGAAGAGTTAGGAGTGAAAGTTTGGTAGGGATG
46W GTGGAAATGGCTAGGATTTGGGTGGAGAGTATTG
46X GAATAGTGTGGAGGGAAATGGTAGGGATTTGCAG
46Y GTAGAAGTGTGGGTTTAAAGGGAAATGTTAG
46Z GTAAGATTTCGGTTTAAAGGGAGAGTTGTAG
490  GAAGGTAAGGAAGTGATTCGGTGAAGAGGTTGGGAGAGAAATG
49P GATTTGTGTGGGAAGGTGTTGAGGGAATGAGTTGGTTAGGTTG
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Appendix 3: Buffers and Solutions
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Phosphate Buffered Saline (PBS)
PBS was made using Dulbecco A PBS tablets (Oxoid) according to the 
manufacturer’s recommended protocol. The final composition was:
g/litre
NaCI 8.0
KCI 0.2
Na2HP04 1.15
KH2P04 0.2
pH 7.3
Erythrocyte Medium (ECM)
Dissolve in 2 litres ddH20 then filter sterilise (0.2pM)
140mM NaCI 16.36g
5mM KOI 745mg
20mM Tris/HCI pH = 7.4 6.3g
2mM MgCI2 813mg
0.1 mM EDTA 74.4mg
Dissolved in 2 litres dH20
Terrific Broth
Terrific broth was made up according to the recipe of Tartof and Hobbs (Tartof & 
Hobbs, 1987).
For YTG base, to 900 ml of H2O add: 
12 g bacto-tryptone 
24 g bacto-yeast extract 
4 mL glycerol.
In a separate flask dissolve in 90 mL H2O:
2.31 g KH2PO4 monobasic
12.54 g K2HPO4 dibasic (for trihydrate 16.45 g)
Adjust volume to 100 m l with H2O
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sterilize each separate volume by autoclaving for 20 min at 15 lb/square inch 
liquid cycle. Only add the potassium phosphate solution after the YTG base cools 
to 60°C.
YPAD Medium
Bacto-yeast extract 10 g
Bacto-peptone 20 g
Dextrose 20 g
Adenine sulphate 100 mg
Autoclaved, add distilled water to 1 litre.
ELISA bicarbonate coating buffer (pH 9.6)
1.59g NazCOs 
2.93g NaHCOs 
Dissolved in 1L dHzO
1.0 M Lithium Acetate
Autoclave or filter sterilize
Final pH should be between 8.4 - 8.9
Synthetic Complete (SC) Drop Out Medium
12.0 g Glucose 
Autoclave for 15 min.
Adjust pH to 5.6 with IO N NaOH 
600 ml ddH20
0.50 g Synthetic Complete Drop Out Mix
4.0 g Yeast Nitrogen Base w/o Amino Acids
Synthetic Complete (SC) Drop Out Medium Plates
10.0 g Bacto Agar
Adjust pH to 5.6 with 10 N NaOH 
600 ml ddH20
0.50 g Synthetic Complete Drop Out Mix
12.0 g glucose
Autoclave the solution for 15 min.
4.0 g Yeast Nitrogen Base w/o Amino Acids
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TE buffer
10 mM Ths-HCI, pH 8.0
1.0 mM EDTA
Single-Stranded Carrier DNA
Use 2 mg/ml Deoxyribonucleic acid Sodium Salt Type III from 
Salmon Testes (Sigma). Prior to use, boil an aliquot for at least 5 min 
and quickly cool in an ice water slurry. Disperse the DNA into 
solution by drawing it up and down repeatedly in a 10 ml pipette. Mix 
the solution vigorously on a magnetic stirrer for 2 to 3 hr or until fully 
dissolved. Prepare in TE.
Carrier DNA can be frozen after boiling and used 3 or 4 times.
If transformation efficiencies begin to decrease with a specific aliquot 
of boiled carrier DNA, that aliquot should be boiled again or a new 
aliquot used. Store the aliquots in a -20°C freezer.
Uranyl Formate Negative Stain
Protocol obtained from Dr. Laurence Tetley, University of Glasgow
Use freshly prepared 1% uranyl formate for optimum results.
One millilitre aliquots of 1% uranyl acetate were dispensed into eppendorf tubes. 
0.1 mL of 1.0M NaOH was added, and the tubes were sealed and shaken. The 
precipitate was sedimented by centrifugation, and the supernatant was discarded. 
The pellet was dissolved in IQOpI of 5% formic acid by vigorous mixing and used 
immediately.
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